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1 Latest developments in prostate cancer
surgery and active surveillance
Stacy Loeb
New York University andManhattan Veterans Affairs Medical Center, New
York, New York
Active surveillance is now the recommended management option for
low-risk prostate cancer. In this lecture we will discuss trends in use
of active surveillance worldwide, optimal patient selection and moni-
toring. For men with intermediate- to high-risk localized prostate can-
cer, radical prostatectomy remains a gold standard treatment option.
We will discuss recent trends in the surgical management of localized
prostate cancer.
2 Precise and personalised: Radiation therapy
for prostate cancer in 2019
Sandra L Turner
Radiation Oncology, Crown Princess Mary Cancer Centre, Westmead
Hospital, Sydney, NSW, Australia
Radiation therapy has undergone phenomenal advances over the past
decades. There is now strong evidence that modern radiation ther-
apy provides equivalent (or superior) outcomes to other treatments
in terms of tumour control, side effects and/or quality of life for men
requiring active treatment for prostate cancer. Advances apply in both
the curative and palliative settings. Radiation therapy (including exter-
nal beam and/or brachytherapy) either alone or in combination with
surgical and/or systemic treatments has a central role in prostate can-
cer management.
This presentation will give an overview of some of the numerous ways
in which radiation therapy is now better able to target the cancer,
minimise side effects, enhance patient convenience and generally
lead to improved prostate cancer survival and care. This session will
touch upon clinical, technological, biological, imaging and genomic
research as well as logistical issues that are contributing to radiation
therapy in 2019 beingmore precise and personalised than ever before.
The importance of men, their families and their healthcare teams
fully understanding the radiation therapy options for managing their
prostate cancer will become apparent.
Editorial material and organisation c© 2019 JohnWiley & Sons Australia, Ltd. Copyright of individual abstracts remains with the authors
3 Metastatic hormone-sensitive prostate
cancer: A new era
Arun Azad
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Themanagement of metastatic prostate cancer not previously treated
with androgen deprivation therapy (ADT) has undergone a paradigm
shift in the past 5 years. In addition to commencing ADT, there are
multiple phase 3 clinical trials showing that the addition of docetaxel
chemotherapy or novel hormonal agents (abiraterone acetate, enzalu-
tamide, apalutamide) significantly improves overall survival. Intensifi-
cation of systemic therapy is now the standard of care for newly diag-
nosed metastatic prostate cancer but many challenges remain includ-
ing optimal selection of patients, management of additional toxicity,
and the development of adaptive resistance.
4 Supportive care formenwith prostate cancer
Patsy Yates
Queensland University of Technology, Kelvin Grove, QLD, Australia
Men with prostate cancer have a range of supportive care needs. Cur-
rent evidence indicates that responding effectively to these needs
requires a comprehensive understanding of the man’s responses to
his diagnosis and its treatment, the ability to tailor interventions to
the man’s clinical and personal circumstances and a commitment to
promoting health andwell-being and enabling self-management. Opti-
mal supportive care also requires specialized knowledge and skills to
deal with unique concerns experienced by men with prostate cancer
relating to sexual function and urinary incontinence. In Australia, the
Movember Foundation is trialling the TrueNTHprogram, an innovative
multicomponent supportive care model for men with prostate cancer.
Specialist Prostate Cancer Nurses are now also well established in a
number of treatment centres. This presentation reviews the elements
of existing supportive care models for men with prostate cancer in
Australia and overseas, and examines the system, service and provider
level requirements for effective implementation of suchmodels.
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5 Patient selection and dose prescription for
radiation therapy
Marcus Dreosti
GenesisCare, Adelaide, SA, Australia
The prevalence of muscle invasive bladder cancer increases with age
as does this elderly populations propensity to treatment toxicity, com-
petingmedical comorbidity and geriatric syndromes. This combination
often results in under-treatment, with known worse disease specific
outcomes compared to younger cohorts and increased disease-related
morbidity but equally at times overtreatment and the imposition of
toxicity in the absence of significant benefit arising as a result of poor
patient selection.
Individualisation of treatment decisions for these patients is assisted
by close multidisciplinary discussion and the use of various geriatric
and functional assessment principles and tools in the clinical envi-
ronment. Defining treatment intent and understanding the breadth
of dose/fractionation schedules available for bladder cancer, with
or without systemic therapy, can assist the Radiation Oncologist in
providing optimally tailored radiation therapy to these patients both
in the radical and palliative settings.
6 Patient selection for palliative chemotherapy
Sina Vatandoust1,2
1Medical Oncology, Flinders Medical Centre, Adelaide, SA, Australia
2Flinders University, Adelaide, SA, Australia
Like many other malignancies, the incidence of bladder cancer
increases with age. The older cancer population is heterogeneous with
respect to overall health status. Therefore, the management approach
in older adults with advanced bladder cancer should be individualized.
Here, we review some of the assessment tools that can help evalu-
ate older cancer patients and will discuss the systemic management
approach and the decision-making process in this clinical setting.
7 Renal function estimates vsmeasurements;
implications for chemotherapy dosing
Jenny Casanova
Flinders Medical Centre, Adelaide, SA, Australia
For many years the Cockcroft-Gault equation has been the gold stan-
dard for estimating creatinine clearance, which is used as a surrogate
marker for glomerular filtration rate (GFR) and hence to estimate renal
function. Although Cockcroft-Gault is routinely used to ‘calculate’ GFR
in order to identify requiredmodifications of drug doses, there is some
debate over whether it’s more appropriate to use ideal or actual body
weight, particularly in cancer patients where capping of body surface
area (BSA) for dose calculations is no longer recommended.
When dosing carboplatin, which is 100% renally cleared, the recom-
mendation from COSA and other bodies is to undertake actual mea-
surement of GFR by nuclear medicine scan, as dosing according to
Cockcroft-Gault GFR may underestimate dosing in some patient pop-
ulations and overdose in others. However, NM GFR incurs a cost, and
may not always be accessible in a timely fashion.
Newer formulae are available, including Modified Diet in Renal Dis-
ease (MDRD) and Chronic Kidney Disease-Epidemiology (CKD-EPI).
These were originally designed to alert physicians to gradual changes
inkidney functionality, thereforehavenotbeenvalidated in acute renal
impairment or for use in drug dosing, and do not necessarily take into
account the patient’s BSA. This presentationwill discusswhat it means
when an eGFR, or estimated glomerular filtration rate, is reported by
a pathology system, and what its utility is when calculating doses of
renally cleared cancer therapies, plus those which have the potential
to be nephrotoxic, e.g. cisplatin.
8 Renal-oncology; impacts of these treatments
on renal health
Rob Carroll
South Australian Transplant and Immunogenetics, Australian Redcross
Blood Service, Adelaide, SA, Australia
As the use of biological agents increases in cancer, so too do the renal
side effects. A/Prof Carroll will discuss the management of intersti-
tial nephritis post checkpoint inhibition and also the management of
use of checkpoint inhibitors in renal transplant patientswith urological
cancers.
9 Biopsychosocial screening: The bridge to
engagement, patient experience and partnerships
Matthew Loscalzo
City of Hope, Duarte, California
Based on ∼450 000 completed automated comprehensive biopsy-
chosocial screens and a subset of urological cancer patients, clinical
and programmatic relevant information will be presented that has
the potential to more deeply engage patients and their families.
Additional benefits include higher levels of real-time objective com-
munication among health care providers, enhanced quality of care
and reduced costs. Given increasing Randomized Control Trial evi-
dence for the importance of ongoing communications and support
for quality and extended length of life, screening is emerging as the
sixth Vital Sign internationally. Australian psycho-oncologists have
played a significant role in the development of new knowledge in
biopsychosocial screening. Based on 26 years of first-hand experience
in creating, sustaining and growing such programs, the speaker will
briefly share biopsychosocial screening data illuminating specific
benefits to patients, families and health care providers across settings.
Data will then be shared that are focused on urological cancers and
the impact of age, sex, income and the full range of biopsychosocial
problems and opportunities. Finally, information will be shared relat-
ing to how automated comprehensive screening supports team work,
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clarifies provider functions, saves physician time and creates unique
actionable data sets for enhancements to clinical care, programmatic
development and research.
10 Ten-year quality of life outcomes inmen
with prostate cancer
Nicholas F Ralph1,2,3, Shu KayNg4, Leah Zajdlewicz1, Stephen J
Lepore5, Peter Heathcote6, AndrewKneebone7,8, Jeffrey C
Dunn1,3,9, Suzanne KChambers1,3,10
1Cancer Council Queensland, Brisbane, QLD, Australia
2School of Nursing &Midwifery, University of Southern Queensland,
Darling Heights, QLD, Australia
3Centre for Health Research, University of Southern Queensland, Darling
Heights, QLD, Australia
4Menzies Health Institute Queensland, Griffith University, Southport, QLD,
Australia
5College of Public Health, Temple University, Philadelphia, Pennsylvania,
USA
6Princess Alexandra Hospital, Woolloongabba, QLD, Australia
7University of Sydney, Sydney, NSW, Australia
8Royal North Shore Hospital, St Leonards, NSW, Australia
9Prostate Cancer Foundation of Australia, Sydney, NSW, Australia
10Edith Cowan University, Perth, WA, Australia
Objective: To report physical and mental health-related quality of life
(HRQoL), life satisfaction and symptom burden of men over the ten
years after prostate cancer diagnosis.
Methods: 106 (82.4% response) diagnosed with prostate cancer who
were pre-treatment and close to diagnosis were recruited. Most men
had localised disease (92.1%) at recruitment. Men were assessed over
a ten-yearperiodwith self-reportedHRQoL, life satisfactionand symp-
tom burden using validated questionnaires. Bowel, sexual and urinary
functionwere also assessed. 598men completed the questionnaires at
10-years.
Results: Three trajectory patterns were identified for physical and
mental HRQoL and life satisfaction. Comparedwithmenwho reported
constantly high physical HRQoL,menwith poorer physical healthwere
more likely to receive ADT, have a low income, andmultiple comorbidi-
ties. Poorer mental HRQOL was differentiated by lower income and
multiple comorbidities versus men with high mental HRQoL. Against
menwith ongoing high satisfaction with life, lower life satisfaction was
predicted by younger age, being single, receiving a low income, and
multiple comorbidities. Better urinary, bowel, and sexual functionwere
related to better HRQoL and life satisfaction over time.
Conclusions: Androgen deprivation therapy, comorbidities and
socioeconomic disadvantage are risk indicators for poorer long-term
quality of life after a diagnosis of prostate cancer. Risk indicators
need to be incorporated into survivorship care planning. Survivorship
interventions need to account for these indicators to ensuremenmost
at risk of poorer physical and mental health can access appropriate
care.
11 Emotional care needs of prostate cancer
survivors and their partners:What dowe know?
Peter “Kevin” O’Shaughnessy
University of South Australia, Adelaide, SA, Australia
The initial impact of treatments for men with prostate cancer is well
reported in the literature. Less is known about the emotional needs
of these men as their journey after diagnosis and treatment continues
into the months and years. Previous research by the author investi-
gating provides an insight into the needs of men living with prostate
cancer, and views of partners of prostate cancer survivors. Fear, dis-
tress, loss, regret, anxiety, low self-esteem, depression, changes in sex-
uality, masculinity and relationships were described by both men and
partners as adverse effects of the diagnosis and treatment for prostate
cancer.
A scoping methodology was used to review literature from January
2000 toMarch 2019 to further explore the emotional supportive care
needs of prostate cancer survivors. Although there is some literature
regarding negative emotional experiences such as fear, grief and regret
in prostate cancer survivors, vulnerability, isolation and loneliness are
notwell understood. There is scant literature that investigates the role
of positive emotions such as love, hope and joy and the role they play in
helping men become resilient and cope with prostate cancer. Positive
emotions may help men become more resilient. Preliminary findings
suggest that wives and partners of men with prostate cancer can
provide nurses and healthcare authorities with a powerful and unique
resource in providing supportive care for men who are challenged by
prostate cancer.
12 Survivorship care plans for prostate cancer
survivors – Describing the Australian landscape
Nadia Corsini
University of South Australia, Adelaide, SA, Australia
Over the past two decades, cancer survivorship has received greater
attention among consumers, professional and accrediting bodies,
health care services and policy makers. The structured delivery of
information that includes a summary of the treatment received (treat-
ment summary) and a plan for follow-up care (care plan) has been rec-
ommended to support care coordination and facilitate transition from
regular contact with the treatment team to follow-up care that can
be delivered by other health professionals within and external to the
treatment setting.
Treatment summaries and care plans are related but ‘separate’ docu-
ments, although they are often implemented together as a combined
approach to survivorship care. Various templates have been developed
by different organisations worldwide with several common features.
The treatment summary typically includes clinical and treatment-
related information such as diagnoses, treatment history, key dates
and complications. The care plan is often developed with the patient
and contains specific information on topics such as management of
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persistent treatment effects, supportive care and lifestyle interven-
tions. The purpose of a treatment summary is to ensure that survivors
have an accurate record of their treatment and the purpose of a care
plan is to support specific actions to promote wellness; both may be
shared with other health professionals.
At present, in Australia there are guidelines but no specific mandates
requiring health services to provide treatment summaries and care
plans, and hence their use in practice is patchy. This presentation will
summarise: the history underpinning the focus on survivorship treat-
ment summaries and care plans; intended benefits to patient care and
recovery (and also to the treating team); evidence on effectiveness,
use and implementation of treatment summaries/care plans; current
Australian recommendations and guidelines; and resources and tools
available to assist clinicians who would like to offer care plans and
treatment summaries.
13 Computed tomography-defined sarcopenia
negatively impacts overall survival in patients
with head and neck cancer: Implications for
practice
Merran Findlay1,2,3, Judith Bauer4
1Cancer Services, Royal Prince Alfred Hospital, Sydney, NSW, Australia
2Chris O’Brien Lifehouse, Sydney, NSW, Australia
3Faculty of Medicine and Health, University of Sydney, Sydney, NSW,
Australia
4School of HumanMovement and Nutrition Sciences, University of
Queensland, St Lucia, QLD, Australia
Computed tomography (CT)-defined sarcopenia, or low muscle mass,
is a demonstrated poor prognostic factor for survival in patients with
cancer; however, its impact in patients with head and neck cancer
(HNC) has only recently been established. Sarcopenia may be consid-
ered a nutrition-related condition that can occur in either a primary,
age-related context or secondary to inactivity, malnutrition or a range
of complex pathogeneses including malignancy. This presentation will
provide an overview of CT-defined sarcopenia and the latest research
on the prognostic impact of CT-defined sarcopenia on outcomes for
patients with HNC with a specific focus on survival in those undergo-
ing radiotherapy ± other treatment modality of curative intent. This
presentation will demonstrate that (a) CT-defined sarcopenia impacts
negatively on overall survival in patients with HNC and holds a clini-
cally meaningful prognostic value; (b) consensus regarding sarcopenia
assessment and skeletal muscle index threshold values is warranted;
and (c) future research should focus on implementation of clinically rel-
evant prognostic muscle mass evaluation into routine care.
14 Nutrition and eHealth
Marina Reeves
The University of Queensland, Herston, QLD, Australia
Healthy diet and adequate nutrition play an important role in reduc-
ing risk of cancer, during cancer treatment and to improve survivor-
ship.Nutrition services and interventionshave traditionally beendeliv-
ered face-to-face either one-on-one or group settings. Technological
advancements however have allowed us to disrupt this traditional
model of service delivery. Telehealth and eHealth provide a number
of advantages: increasing reach and access to services, thus providing
an opportunity to address the inequity often experienced by those liv-
ing outside urban areas; they have the potential to increase dose and
duration of ‘intervention’; and, they can be cost-effective. This presen-
tation will summarise the evidence on the delivery of nutrition inter-
ventions via eHealth, including examples of such interventions in can-
cer survivors.
15 Can early and intensive nutrition care
delivered via digital platform or telephone
improve quality of life in patients with upper
gastrointestinal cancer?
Lauren Hanna1,2, Catherine Huggins2, Kate Furness1,3, Mary
Anne Silvers1, June Savva1, Helena Frawley4,3, Daniel Croagh5,
Paul Cashin5, Liang Low5, Judy Bauer6, Helen Truby2, Terrence
Haines3
1Department of Nutrition and Dietetics, Monash Health, Clayton, VIC,
Australia
2School of Clinical Sciences, Department of Nutrition, Dietetics and Food,
Monash University, Clayton, VIC, Australia
3School of Primary and Allied Health Care, Monash University, Frankston,
VIC, Australia
4Centre for Allied Health Research and Education, Cabrini Health, Malvern,
VIC, Australia
5Upper Gastrointestinal and Hepatobiliary Surgery, Monash Health,
Clayton, VIC, Australia
6School of HumanMovement and Nutrition Sciences, The University of
Queensland, St Lucia, QLD, Australia
Background: Malnutrition in patients with upper gastrointestinal can-
cer confers greater risks of morbidity and mortality. Novel cost-
effective approaches that can deliver early, pre-hospital nutrition
intervention before usual hospital dietetic service is commenced are
needed. Linking clinicians and patients via mobile health and wireless
technologies is a contemporary solution not yet tested for delivery of
nutrition therapy to peoplewith cancer. The aimof this study is to com-
mence nutrition intervention earlier than usual care and evaluate the
effects of using the telephoneormHealth for intervention delivery. It is
hypothesised that participants allocated to receive the early and inten-
sive pre-hospital dietetic service will have more quality of life com-
pared with control participants. This study will also demonstrate the
feasibility and effectiveness of eHealth for the nutrition management
of patients at home undergoing cancer treatment.
Methods: This study is a prospective three-group randomised con-
trolled trial, with a concurrent economic evaluation. The 18-week
intervention is provided in addition to usual care and is delivered by
two different modes, via telephone (group 1) or via mHealth (group 2).
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The control group receives usual care alone (group3). The intervention
is an individually tailored, symptom-directed nutritional behavioural
management program led by a dietitian. Participants will have at least
fortnightly reviews. The primary outcome is quality-adjusted life years
lived and secondary outcomes include markers of nutritional status.
Outcomes will bemeasured at 3, 6 and 12months follow-up.
Discussion: The findings will provide evidence of a strategy to imple-
ment early and intensive nutrition intervention outside the hospital
setting that can favourably impact on quality of life and nutritional sta-
tus. This patient-centred approach is relevant to current health service
provision and challenges the current reactive deliverymodel of care.
16 Nutrition and exercise interventions for
prostate cancer
Brenton J. Baguley
School of Exercise and Nutrition Sciences, Deakin University, Melbourne,
VIC, Australia
Obesity, poor diet quality and physical inactivity have been associ-
ated with an increased risk of prostate cancer-specific mortality, all
cause-mortality and treatment-related side effects for prostate can-
cer survivors. It is estimated that approximately 45% of all prostate
cancer survivors are being treated with androgen deprivation therapy
(ADT). However, ADT comeswith significant side effects, including, but
not limited to, unfavourable changes in body composition (reductions
in muscle and bone mass, and increases in fat mass), and increased
risks of cardiovascular disease, insulin resistance and metabolic syn-
drome. The dietary and exercise guidelines for cancer survivors sug-
gest (a) to maintain a healthy body weight, (b) follow a dietary pat-
tern high in fruit, vegetables and whole grains, (c) and engage in at
least 150 min/week of moderate-vigorous aerobic exercise, with two
to three resistance training sessions/week of major muscle groups.
Despite these guidelines, only a few diet interventions with/without
exercise have been published in prostate cancer survivors, or men
treated with ADT. Importantly, the utility of dietary interventions to
improve disease- and treatment-related health outcomes in ADT is yet
to be definitively explored. This presentation will discuss the current
dietary patterns of Australian prostate cancer survivors, and describe
a series of diet interventions with/without exercise in prostate cancer
aiming to counteract the side effects of ADT.
17 Protein SWATH library construction
including recombinant proteins allows
identification and quantification of lower
abundance human plasma cancer biomarkers
Seong BeomAhn1, Karthik ShantharamKamath2, Abidali
Mohamedali3, Zainab Noor3, Dana Pascovici2, JemmaWu2,
Subash Adhikari1, MatthewMcKay2, Mark S. Baker1
1Department of Biomedical Sciences, Macquarie University, North Ryde,
NSW, Australia
2Australian Proteome Analysis Facility (APAF), Macquarie University,
Sydney, NSW, Australia
3Department of Molecular Sciences, Macquarie University, North Ryde,
NSW, Australia
Human plasma is the most informative, accessible biofluid for assess-
ing the status of human health. However, detection and quantifica-
tion of low abundance cancer-related proteins (eg CEA, cytokines and
shed proteins) remains one of the principal challenges in proteomic
biomarker discovery – due to high abundance plasma proteins obscur-
ing biomarkers. Antibody technologies suffer from batch variation
and non-specific detection, therefore, quantitative mass spectrome-
try (MS) techniques such as SWATH-MS and similar DIA methods are
an attractive alternative to assess plasma cancer biomarkers. These
approaches rely on prior library construction using IDA/DDA data and
the challengeofdetecting lowabundancebiomarkers canbehampered
by the same dynamic range issues which limit the proteome discovery
space for plasma proteomics.
Here, we report on the use of a SWATH mini-library comprised of
32 previously reported cancer biomarkers for the quantitative assess-
ment of non-depleted pooled human plasma cohorts from clinically
staged (20 healthy or 20 stages I-IV) colorectal cancer (CRC) patients
by SWATH-MS. To ensure validity, we employed two independent
SWATH analysis software (Skyline and PeakView) to identify quan-
tifiable peptides. Of the 32 cancer biomarkers used to construct the
SWATH mini-library, we reliably identified and quantified 25 proteins
in human plasma of CRC patients. In all cases, a significantly higher
peptide count for each protein allowed better quantification (eg 12 for
CEA and eight for IL-6) compared to prior results. In CRC, CEA expres-
sion was significantly upregulated, recapitulating many prior studies.
Similarly, we recapitulated our observation that plasma ADAMDEC1
is upregulated in early-stage CRC. We propose the use of expanded
recombinant protein SWATH libraries for the discovery of diagnostic,
prognostic and theranostic protein biosignatures for cancers andother
diseases.
18 Analysis of alternative spicing in the
transcriptome of osteosarcoma
Sulev Koks1,2, Xuan D. Ho3, KatreMaasalu3, DavidWood4,
AareMartson3
1Murdoch University, Murdoch,WA, Australia
2The Perron Institute for Neurological and Translational Science, Nedlands,
WA, Australia
3University of Tartu, Tartu, Estonia
4University ofWestern Australia, Nedlands, WA, Australia
Aim: We have assessed the extent of alternative splicing in osteosar-
coma samples and further examined the relationship between alterna-
tive transcripts and gene expression.
Methods: We performed whole transcriptome analysis of osteosar-
coma bone samples and sequenced total RNA from 36 fresh-frozen
samples (18 tumour bone samples and 18 non-tumour paired samples)
in matched pairs for each osteosarcoma patient. Data were analysed
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with Python package HTSeq and R package DEXSeq developed to
analyse differential exon usage in transcriptome data. FDR correction
was used to adjust nominal P-values to obtain genome-wide statistical
significance.
Results: We identified statistically significant (FDR below .05) dif-
ferences in alternative splicing of 4175 transcripts. Several different
alternative transcripts from the same genes were expressed, in the
leptin receptor overlapping transcript, LEPROT; we detected 26
transcripts to be differentially expressed between tumour and normal
tissue. Some transcripts were over-expressed in the tumour and some
transcripts were over-expressed in normal tissue. The function of
LEPROT gene is not fully understood, but it is involved in the regu-
lation of leptin by interacting with the leptin receptor. Also, LEPROT
regulates growth hormone-dependent signalling and activity of the
growth hormone receptor. Most of the differentially expressed genes
were expressed as different alternative forms indicating prevalent and
massive alternative splicing in osteosarcoma.
Conclusions: Alternative splicing is prevalent in osteosarcoma and its
regulation may play a significant role in sarcoma development. This is
a good example of how differential splicing could be involved in the
tumorigenesis and further studies need to consider this as an impor-
tant molecular mechanism.
19 Efficacy of neratinib neoadjuvant therapy in
a pre-clinical model of HER2+ve breast cancer
brainmetastasis
Aadya Nagpal1, Rick P. Redvers1, Scott Ayton2, Robin
Anderson1, Sherene Loi3, Normand Pouliot1
1Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
2Florey Institute of Neuroscience andMental Health, Parkville, VIC,
Australia
3Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
HER2-targeted therapies such as trastuzumab effectively control
systemic disease but resistance to treatment is common and up to
50% of patients progress to incurable brain metastases. Tyrosine
kinase inhibitors (TKIs) are increasingly used as second line therapy
but the best clinical setting for these inhibitors and whether they
have a place in the clinic for the treatment of breast cancer brain
metastasis remains unclear. Progress on that front has been hindered
by the lack of clinically relevant models of HER2 breast cancer brain
metastasis.
Aim: To develop and characterise a robust mouse model of spon-
taneous HER2 breast cancer brain metastasis for evaluation of TKI
efficacy.
Methods: We selected and characterised clonal variants from a mam-
mary tumour that developed spontaneously in an immune-competent
Balb/c mouse. The efficacy of a panel of TKIs was tested in vitro and
neratinibwas selected for further evaluation in vivo. Resistant variants
were developed by long-term exposure to neratinib.
Results: We identified a clonal variant (TBCP-1) that naturally
expresses high levels of HER2 and aggressively metastasises from the
mammary gland to the brain in immune-competent mice. Evaluation
of TKIs against human and mouse tumour lines in vitro identified
neratinib as the most potent TKI. Neratinib’s superior efficacy was
associated with its unique ability to induce cell death by ferroptosis,
a mechanism distinct from apoptosis. Neratinib as a first line neoad-
juvant therapy potently inhibited tumour growth and spontaneous
metastasis to brain and other organs. Neratinib-resistant TBCP-1
variants acquired a mesenchymal phenotype and showed altered
expression of integrin receptors and cross-resistance to other TKIs
but could be resensitised by treatment with integrin inhibitors.
Conclusions: TBCP-1 is the only model that aggressively recapitulates
the spontaneous spread ofHER2breast cancer to the brain in immune-
competent mice. Further evaluation of neoadjuvant neratinib alone or
in combination with integrin inhibitors is warranted.
20 Change in frailty index following a
12-monthweight loss intervention in Australian
breast cancer survivors
Natasha Reid, Ruth E. Hubbard, Nancye Peel, Marina Reeves
The University of Queensland, Runcorn, QLD, Australia
Aim: To investigate change in the frailty index (FI) following a12-month
intervention targeting diet and physical activity in Australian breast
cancer survivors diagnosedwith stage I-III breast cancer.
Methods: The Living Well after Breast Cancer study was a two-arm
pragmatically designed randomised controlled trial of a 12-month
telephone-delivered weight loss intervention versus usual care in
women (aged 18-75 years; body mass index [BMI]: 25-45 kg/m2) fol-
lowing treatment for early-stage (I-III) breast cancer. Intervention tar-
gets included: modest weight loss (5-10%), 500 kcal/day reduction
in energy intake and increasing diet quality, and increasing physical
activity to 210 min/week and resistance exercise to 2-3 times/week.
Regression analyses, adjusted for baseline FI, age, smoking status,mar-
ital status and time since diagnosis were used to assess the interven-
tion effects on change in FI.
Results: Data for participants with complete data (n= 127) were anal-
ysed (age [mean± SD]: 56.4± 9.0 years; BMI: 31.5± 5.1 kg/m2). Mean
weight losswas significantly higher (P< .001) in the intervention group
(−4.2 ± 5.4 kg) compared to the usual care group (−0.01 ± 4.2 kg).
Mean FI at baseline was 0.19± 0.09. Mean FI improved significantly in
both groups (intervention: −0.018 [95% CI, −0.027 to −0.009]; usual
care: −0.010 [95% CI, −0.019 to −0.000]), although the between-
group difference was not statistically significant (intervention minus
usual care: –0.008 [95%CI,−0.021 to 0.005]).
Conclusion: Intervention participants experienced a larger mean
reduction in their FI compared to the usual care group, although this
was not statistically significant. This is one of the first studies to inves-
tigate the impact of a weight loss intervention on the FI. In addition to
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the intervention targets in this study, future interventions should aim
to target more health factors that contribute to the FI, such as social,
cognitive and mental health, and medication use. Factors associated
with the improvement of the FI in the usual care group also warrant
further exploration.
21 The “Ick” factor: An unrecognised affective
predictor of symptoms during chemotherapy
LisaM. Reynolds, Dev Vinayak, Nathan S. Consedine
University of Auckland, Auckland, New Zealand
Aim: The emotion of disgust is associated with gastrointestinal symp-
toms and aversion to certain foods. Given the frequency with which
symptoms of this kind are seen in chemotherapy patients, it would
appear to have particular relevance. However, disgust’s role during
cancer treatment has been overlooked. The aims of this research were
to investigate whether disgust (a) predicted physical symptoms during
chemotherapy (particularly, taste- and smell-related changes) and (b)
compare its predictive utility against the most commonly used affec-
tive predictor, that is, psychological distress.
Methods: The target sample of this prospective, observational study
was 58 participants. Over recruitment ensured that analytical power
would not be compromised. Better thanexpected retentionmeant that
63 cancer patients completed questionnaires at both baseline (imme-
diately prior to commencing chemotherapy) and follow-up (6 weeks
later). Predictors (distress, disgust sensitivity and propensity) were
assessed at baseline and outcomes (physical symptoms and food sen-
sory processing) at both baseline and follow-up.
Results: Contrary to expectations, psychological distress did not pre-
dict any of the outcomes. However, disgust sensitivity (𝛽 = .53; 95%
CI, 0.27-1.29; P = .003) and propensity (𝛽 = −.56; 95% CI, −1.20 to
−0.29; P = .002) both predicted food sensory processing changes,
whereas disgust sensitivity predicted marginally greater symptoms
during chemotherapy (𝛽 = .34; 95% CI, −0.04 to 1.90; P = .060).
Broadly, findings were consistent with expectation insofar as disgust
was a better predictor of symptoms than distress.
Conclusions: The study represents the first prospective investiga-
tion of disgust’s ability to predict symptoms experienced during
chemotherapy. It demonstrates (a) a robust association between dis-
gust and the food sensory processing changes common in chemother-
apy and (b) disgust as potentially being amore useful predictor of food-
and digestion-related symptoms than psychological distress. In doing
so, it identified hitherto unstudied vulnerabilities and opens newdoors
for better care during cancer treatment.
22 Inhibition of vitamin D catabolism and its
effects on chemotherapy-induced
gastrointestinal mucositis
Cyan L. Sylvester, Paul H. Anderson, AndreaM. Stringer
University of South Australia, Adelaide, SA, Australia
Aim: 5-Fluorouracil (5FU) is a chemotherapy agent known to cause
gastrointestinal mucositis (GM), a side effect of cancer treatment,
for which there is currently no effective treatment. Vitamin D has
beenwidely shown to have immunomodulatory and anti-inflammatory
effects in the intestine, and therefore may reduce severity of GM.
Because the use of vitamin D and vitamin D analogues have an asso-
ciated risk of hypercalcaemia, we considered whether competitive
vitamin D catabolism inhibitor (VDCI) could be used for reducing
5FU-induced GM, without causing hypercalcaemia.
Methods: C57Bl6mice (n=36) received a single intra-peritoneal injec-
tion of 450 mg/kg 5-fluorouracil (5FU) or saline (vehicle control), and
subcutaneous 500 ng/kg VDCI or saline (vehicle control) daily for 5
days prior and 2 days following 5FU administration, before being euth-
anized at 48 h following 5FU administration. Routine H&E, RT-PCR
and immunohistochemistry was carried out on duodenum sections.
NDP.view 2was used to quantify villi and crypt parameters. Serum cal-
cium levels were measured via KONE analysis. One-way ANOVA, with
Tukey’s test, was used for statistical analysis.
Results: Calcium levels were unaltered in the presence of VDCI. 5FU
significantly reduced villous height (VH; P = .0002) and villous area
(VA; P = .0006) in the duodenum, compared to saline. 5FU+ VDCI sig-
nificantly increasedVHcompared to5FU (P= .043), andwasnot signif-
icantly different to saline. 5FU treatment decreases transient receptor
potential cation channel subfamily v member 6 (TRPV6) RNA expres-
sion, whereas VDCI/5-FU does not upregulate TRPV6 in duodenum,
suggesting amechanism for normocalcemia.
Conclusions: Inhibition of vitamin D catabolism alleviates intestinal
damage in 5FU-treatedmice without causing hypercalcaemia andmay
provide a promising new avenue for anti-mucotoxic therapy.
23 Patterns of surgery and outcomes: A guide
to best practice for bladder cancer patients
following radical cystectomy inQueensland
Geoffrey Coughlin1,2,3, Philippa Youl4, Shoni Philpot4, David E.
Theile5, JulieMoore4
1TheWesley Hospital, Brisbane, QLD, Australia
2The Royal Brisbane andWomen’s Hospital, Queensland Health, Brisbane,
QLD, Australia
3Urology Sub-Committee, Queensland Cancer Control Safety and Quality
Partnership, Queensland Health, Brisbane, QLD, Australia
4Queensland Cancer Control Analysis Team, Queensland Health, Brisbane,
QLD, Australia
5Queensland Cancer Control Safety and Quality Partnership, Queensland
Health, Brisbane, QLD, Australia
Aim: Radical cystectomy (RC) is a relatively uncommon surgical pro-
cedure and the management of patients undergoing this surgery is
complex. We conducted a review of bladder cancer patients who
underwent a RC to understand patterns of surgery and outcomes in
Queensland.
Methods: This review includes patients diagnosed with bladder can-
cer who underwent RC from 2002 to 2016. Data were obtained
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from the Queensland Oncology Repository (QOR). A review of pathol-
ogy reports was conducted. Hospitals were categorised as high (>7
RCs/year) and low (≤7 RCs/year). Multivariate analysis and 2-year
overall survival was conducted. Follow-up time was to 31 December
2018.
Results: In the 15-year period, 7403 patients were diagnosed with
bladder cancer, of these 1230 underwent RC. Overall 77% were male
and the median age was 67 years. One-third (33.5%) were T-stage 3
& 4 at diagnosis. Of the cohort, 71% of (n = 871) had a lymph node
dissection and the median number of nodes removed was 7 (range 1-
73). Positivity rate was 22.8% and this was similar across hospital vol-
umes. Patients residing in middle and disadvantaged areas were less
likely to have had lymph node dissection (OR= 0.46, 95%CI, 0.28-0.75
and OR = 0.44, 95% CI, 0.23-0.84). Lymph node dissection was more
likely for public compared to private patients (OR= 2.69, 95%CI, 2.10-
3.44). Surgical marginswere involved in 9.7% of patients. Surgical mar-
gin involvement was higher in low-volume hospitals (10.9% vs 7.1%,
respectively, P= .03). Stage (P< .001), positive lymph nodes (P≤ .001),
no lymph node dissection (P = .003) and involvement of surgical mar-
gins (P < .001) were all significantly associated with poorer overall
survival.
Conclusions: This review has identified some subgroups of patients
experience poorer post-operative outcomes. Later stage, positive
lymph nodes, no lymph node dissection and surgical margin involve-
ment were all predictors of poorer survival.
24 Cost-effective analysis of supervised
exercise training inmenwith prostate cancer
previously treatedwith androgen deprivation
therapy and radiation
Kim Edmunds1, Penny Reeves2, Haitham Tuffaha1, Daniel
Galvao3, RobNewton3, Nigel Spry4, James Denham5, Dennis
R. Taaffe3, David Joseph4, David S. Lamb6, Suzanne K.
Chambers7, Paul Scuffham8
1Centre for Applied Health Economics, Griffith University, Nathan, QLD,
Australia
2Health Research Economics, Hunter Medical Research Institute, New
Lambton Heights, NSW, Australia
3Exercise Medicine Research Institute, Edith Cowan University, Joondalup,
WA, Australia
4Department of Radiation Oncology, Sir Charles Gairdner Hospital,
Nedlands, WA, Australia
5Radiation Oncology, Mater Hospital, Newcastle, NSW, Australia
6University of Otago,Wellington, New Zealand
7Faculty of Health, University of Technology, Sydney, NSW, Australia
8Menzies Health Institute, Gold Coast, QLD, Australia
Aim: Exercise for prostate cancer (PC) survivors has been shown to
be effective in addressing metabolic function and associated comor-
bidities (eg, diabetes, cardiovascular disease, etc), as well as sarcope-
nia and significant functional impairment resulting from long-term
androgen deprivation. The aim of this study is to determine the cost-
effectiveness of a supervised exercise intervention for long-term PC
survivors who received radiation therapy and androgen deprivation
therapy.
Method: We conducted a cost-effectiveness analysis of a multi-
centre randomised controlled trial (RCT) of supervised exercise train-
ing (resistance and aerobic) in long-term PC survivors (>5 years
post-diagnosis) alongside theTrans-TasmanRadiationOncologyGroup
(TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy
(RADAR) trial.
Results: In comparison to usual care, the total cost of the intervention
was $546 from a health care payer perspective. The incremental cost
per QALY gain was $65 050 (2018 AUD).
Conclusions: This is the first cost-effectiveness analysis of a super-
vised exercise intervention for long-term PC survivors after curative
radiotherapy and adjuvant ADT. The results indicate the interven-
tion is effective, but not cost-effective at a generally accepted WTP
of $50 000. Evidence to support cost savings from post-intervention
outcomes would potentially reveal greater benefits such as reduced
health service utilisation, chronic disease, falls and fractures and con-
tribute to a more comprehensive analysis and more favourable cost-
effectiveness outcome. Future research should address these deficits
via a larger trial with longer follow up.
25 Prognostic performance of qSOFA in cancer
patients admitted to the emergency department
with suspected infection
Tze TL Koh1, Emmanuel EC Canet2, Sobia SA Amjad3, Rinaldo
RB Bellomo4, David DT Taylor5, Hui HGGan6, Nada NM
Marhoon6, AndrewAL Lim6, Vivek VKKrishnan7, Richard RK
Khor1
1Radiation Oncology, Olivia Newton John Cancer Research andWellness
Centre, Heidelberg, VIC, Australia
2Medical ICU, Hôtel-Dieu, University Hospital, Nantes, Loire-Atlantique,
France
3University of Melbourne, Parkville, VIC, Australia
4ICU, Austin Health, Heidelberg, VIC, Australia
5Emergency Department, Austin Health, Heidelberg, VIC, Australia
6Medical oncology, Olivia Newton John Cancer Research andWellness
Centre, Heidelberg, VIC, Australia
7MKMHealth, South Yarra, VIC, Australia
Aim: We aimed to test the performance of the quick Sequential Organ
Failure Assessment (qSOFA) score for predicting adverse outcomes in
cancer patients admitted to the emergency department (ED) with sus-
pected infection.
Methods: Retrospective cohort analysis of all ED patients with sus-
pected infection admitted between 01 December 2014 and 01 June
2017 at a tertiary hospital. Cancer patients were identified by cross-
linking the electronic health records of the ED and oncology depart-
ment. The primary outcome was in-hospital mortality and/or ICU stay
≥3 days.
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Results: Among 165 912 patients admitted to the ED, 11 205 (6.8%)
had suspected infection, of whom 1655 (14.8%) had cancer. Solid
tumours accounted for 1267 (76.5%) patients and 388 (23.5%) had
haematological malignancies. Chemotherapy or radiotherapy were
administered within 6 months before ED admission in 560 (33.8%)
patients and 167 (10.1%) had neutropenia at ED admission. A total
of 371 (22.4%) patients were qSOFA positive (+). qSOFA+ patients
were older, more prone to respiratory infections, and more likely to be
admitted to ICU or require mechanical ventilation. In-hospital mortal-
ity or ICU stay≥3 dayswere 17.3% and 21%, respectively, for qSOFA+
patients versus4.7%and6.9% for qSOFAnegative patients (P< .0001).
For prediction of in-hospital mortality, a positive qSOFA had a positive
predictive value (PPV) of 17% and a negative predictive value (NPV) of
95%. For prediction of in-hospital mortality or ICU stay ≥3 days, the
PPV andNPV of a positive qSOFAwere 21% and 93%, respectively.
Conclusions: Among cancer patients admitted to the ED with sus-
pected infection, a positive qSOFAwas associatedwith amuch greater
risk of ICU admission and hospital mortality. Its absence helped iden-
tify patients with low risk of such adverse outcomes.
26 Alignment with indices of a care pathway is
associatedwith improved survival: An
observational population-based study in colon
cancer patients
Luc teMarvelde1, PeterMcNair2, KathrynWhitfield3, Philippe
Autier4, Peter Boyle4, Richard Sullivan5, Robert J. S. Thomas6
1CCV/DHHS, Melbourne, VIC, Australia
2Victorian Agency for Health Information, Melbourne, VIC, Australia
3Cancer Strategy & Development, Department of Health and Human
Services, Melbourne, VIC, Australia
4International Prevention Research Institute (iPRI), Lyon, France
5Institute of Cancer Policy, King’s College London, London, UK
6University of Melbourne, Melbourne, VIC, Australia
Introduction: Causes of variations in outcomes from cancer care in
developed countries are often unclear. Australia has developed health
system pathways describing consensus standards of optimal cancer
care across the phases of prevention through to follow-up or end-
of-life. These optimal care pathways (OCP) were introduced from
2013 to 2014.We investigated whether care consistent with the OCP
improved outcomes for colon cancer patients.
Methods: Colon patients diagnosed from 2008 to 2014 were identi-
fied from the Australian State of Victoria Cancer Registry (VCR) and
cases linked with State and Federal health data sets. Surrogate vari-
ables describeOCP alignment in our cohort, across three phases of the
pathway: prevention, diagnosis and initial treatment and end-of-life.
We assessed the impact of alignment on (1) stage of disease at diag-
nosis and (2) overall survival.
Results: Alignment with the prevention phase of the OCP occurred
for 88% of 13 539 individuals and was associated with lower disease
stage at diagnosis (OR = 0.33, 95% CI, 0.24-0.42), improved crude 3-
year survival (69.2% vs 62.2%; P < .001) and reduced likelihood of
emergency surgery (17.7% vs 25.6%, P < .001). For patients treated
first with surgery (n = 10 807), care aligned with the diagnostic and
treatment phase indicators (44% of patients) was associated with a
survival benefit (risk-adjusted HRnon-aligned vs aligned = 1.23, 95% CI,
1.13-1.35), better perioperative outcomes and higher alignment with
follow-up and end-of-life care. The survival benefit persists adjusting
for potential confounding factors, including age, sex, disease stage and
comorbidity.
Conclusion: This population-based study shows that care aligned to
a pathway based on best principles of cancer care is associated with
improved outcomes for patients with colon cancer.
27 Value formoney of putting precision into
practice: Germline genetic testing to guide
olaparib treatment in HER2-negativemetastatic
breast cancer
Haitham Tuffaha, Paul Scuffham
Menzies Health Institute Queensland, Gold Coast, QLD, Australia
Aim: Genetic testing for germline BRCA mutation in women with
HER2-negative metastatic breast cancer (MBC) can guide targeted
treatment with poly-ADP-ribose polymerase (PARP) inhibitors (eg
olaparib) and inform cancer prevention strategies (eg risk-reducing
surgery) for family members of women who test positive. This study
aimed to evaluate the cost-effectiveness of BRCA testing in women
with MBC to inform olaparib treatment and cascade testing of family
members.
Methods: A cost-effectiveness analysis was conducted using a deci-
sion analytic model from an Australian health-payer perspective. Two
scenarios were evaluated compared with no testing and standard
chemotherapy: (a) BRCA testing of women with MBC followed by ola-
parib if the test is positive; and (b) BRCA testing of women with MBC
followed by olaparib and cascade testing of first- and second-degree
family members if the test is positive. For each scenario, the incre-
mental costwas comparedwith the quality-adjusted life-years (QALYs)
gained to estimate the incremental cost-effectiveness ratio (ICER).
Decision uncertainty was characterised using probabilistic sensitivity
analysis.
Results: Scenario 1 resulted in an incremental cost of AU$11 607
and 0.04 QALYs gained (ICER = AU$277 000/QALY), whereas Sce-
nario 2 resulted in an incremental cost of AU$12 575 and 0.12
QALYs gained (ICER = AU$105 000/QALY). At a willingness-to-pay
threshold of AU$100 000/QALY and at the listed price of olaparib,
none of the scenarios were cost-effective. Probability of being cost-
effective was 0% and 40% for Scenario 1 and Scenario 2, respec-
tively. Nevertheless, if olaparib price is significantly reduced by
60%, the two scenarios would become cost-effective, with Scenario
2 offering an additional AU$1100 in mean monetary benefit over
Scenario 1.
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Conclusions: Genetic testing for BRCA germline mutation to guide
olaparib treatment in women with MBC is not cost-effective unless
the price of olaparib is significantly reduced. Extending BRCA test-
ing to cover family members of mutation carriers would pro-
vide additional benefits compared with testing affected women
only.
28 Factors associatedwith treatment type for
prostate cancer patients in the 45 andUp Study,
NSW
Mei Ling Yap1,2,3,4,5, DianneO’Connell4,5,6, David Goldsbury4,
MarianneWeber4,5, David P. Smith4,5, Michael Barton7,2
1Collaboration for Cancer Outcomes, Research and Evaluation (CCORE),
Ingham Institute for AppliedMedical Research, UNSW Sydney, Liverpool,
NSW, Australia
2Liverpool andMacarthur Cancer Therapy Centres, Liverpool, NSW,
Australia
3School of Medicine, Western Sydney University, Campbelltown, NSW,
Australia
4Cancer Research Division, Cancer Council NSW, Kings Cross, NSW,
Australia
5School of Public Health, the University of Sydney, Camperdown, NSW,
Australia
6School of Medicine and Public Health, University of Newcastle, Newcastle,
NSW, Australia
7Collaboration for Cancer Outcomes, Research and Evaluation (CCORE),
Campbelltown, NSW, Australia
Aim: We aimed to describe the patterns of care for prostate cancer
patients in the 45 and Up Study and ascertain factors associated with
type of treatment received.
Methods: There were 267 153 individuals aged ≥45 years in the Sax
Institute’s 45 and Up Study, a population-based cohort study in New
South Wales (NSW). Participants completed a baseline questionnaire
during 2006-2009, which included items on sociodemographic fac-
tors and was linked to administrative health datasets by the Centre
for Health Record Linkage. Incident prostate cancer cases were iden-
tified from the NSW Cancer Registry to December 2010. Receipt of
radical prostatectomy (RP), external beam radiotherapy (EBRT) and/or
androgen deprivation therapy (ADT) were identified in the NSW
Admitted Patient Data Collection (to June 2014) and/or the Medi-
care Benefits Schedule and/or the Pharmaceutical Benefits Scheme
(both provided by the Department of Human Services to December
2014). Multivariable logistic regression was used to examine variation
in treatment types by sociodemographic characteristics.
Results: A total of 2432 men had a new diagnosis of prostate cancer
(median age: 69, range: 45-98; median follow-up 5.5 years, range: 4.0-
8.9). The first treatment received was 40% RP (n = 979), 22% EBRT
(n = 537) and 10% (n = 232) ADT alone. Of RP patients, 124 (13%)
had a radiation oncology consultation recorded prior to surgery. From
multivariable analysis, RP was associated with younger age (P < .001),
regional stage (P < .001), being partnered (P = .023), having better
performance status (P = .003) and having private health insurance
(P < .001). EBRT receipt was associated with older age (P = < .001),
higher stage (P < .001), living <100 km from a radiotherapy centre
(P = .007), fewer co-morbidities (P = .047) and not having private
health insurance (P< .001).
Conclusions: Prostate cancer patients were twice more likely to
receive RP than EBRT. Very few RP patients saw a radiation oncologist
prior to surgery. Type of treatment received varied by both health fac-
tors and sociodemographic characteristics.
29 Cancer care 2040 –Meeting the global
demand
Michael Barton1,2
1UNSW Sydney, Sydney, NSW, Australia
2SouthWestern Sydney Local Health District, Liverpool, NSW, Australia
Thepaceof investment in cancer treatmenthasnot followed theneeds.
Coverage is still poor and in some cases worsening, in parts of the
world. By 2040, there will be 26 million new cases of cancer every
year. About half of these caseswill need radiotherapy, similarly half will
need chemotherapy and about 55% will require surgery. Nearly 70%
of cases will occur in low and middle income countries (LMIC) where
increasing wealth will lengthen life expectancy and the ability to pro-
vide cancer treatments. Investment in cancer treatment will save lives
and increase productivity. We estimate that it will cost $184 billion to
scale up radiotherapy access in LMIC so that all patients can get access
by 2035. This will save nearly 1 million lives per year and create a net
benefit of $365 billion. For chemotherapy, the demand for cancer clin-
icians will increase from 65 000 worldwide to 100 000 by 2040. There
are many barriers to the sustainable development of cancer services.
Cancer control does not happen in isolation and requires functional
government, health services, pathology and diagnostics. Small island
states are poorly suited to the traditional models of service delivery
because their small and dispersed populations.
1. ML Yap, E Zubizarreta, J Ferlay, F Bray, M Barton. Global access
to radiotherapy services: have we made progress over the last
decade? Journal of Global OncologyMarch 16, 2016 2:4, 207–215,
https://doi.org/10.1200/JGO.2015.001545
2. Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B,
Hanna TP, Knaul FM, Lievens Y, Lui TYM,MilosevicM, O’Sullivan B,
Rodin DL, Rosenblatt E, Van Dyk J, Yap ML, Zubizarreta E, Gospo-
darowiczM. Expanding global access to radiotherapy. LancetOncol
2015; 16: 1153–86
3. BE Wilson, S Jacob, MLYap, J Ferlay, F Bray, MB Barton. An Esti-
mate of Global Chemotherapy Demands and Corresponding Physi-
cianWorkforce Requirements in 2018 and 2040. Lancet Oncol doi:
https://doi.org/0.1016/S1470-2045(19)30163-9.
4. CJ Logeman, J Flanigan, S Foliaki, F Bray, M Barton and F Sitas.
Cancer in small states – no small matter. Cancer Epidemiology 50
(2017) 173-175.
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30 Cancer and equality – The global view
Lena Sharp
Regional Cancer Centre Stockholm-Gotland, Sweden and European
Oncology Nursing Society, Stockholm, Sweden
There are increasing evidence of unmotivated differences between
groups of cancer patients, related to diagnosis, treatment, care and
outcomes. The impact of socioeconomic inequalities in both cancer
survival and other outcomes has been frequently reported during the
last decades, even in countries whose cancer care system provide care
without cost at the point of delivery. Availability to cancer screening
and vaccinations, but also awareness among the general public are fac-
tors that will heavily impact the level of equality. Well-organised can-
cer preventionwork and supportive care strategies could reduce these
differences.
During this session, an overview of existing evidence will be presented
and discussed. Experiences from primary and secondary cancer pre-
vention programs and population-based research from the Stockholm-
Gotland area of Sweden will be presented. The session will focus on
interventions and what cancer care professionals can do to reduce
inequalities in cancer prevention and care.
31 Impact of environmental changes on cancer
Hubertus Jersmann
University of Adelaide, Adelaide, SA, Australia
Professor Jersmann will summarise the current state of Climate
Change, it’s main drivers and the general impacts on our planet includ-
ing Human Health. Specific effects on certain cancers, such as skin,
breast and lung and possible mechanisms for this effect of Climate
Change will be highlighted. The wider implications of destabilisations
of societies/economies and the effect of this on the future of cancer
therapy in general will be discussed. To enable oncologists to do some-
thing about Climate Change several options for mitigation will be out-
lined.
32 Maximising curewhileminimising
treatment in testicular cancer
AndrewWeickhardt
Olivia Newton-John Cancer andWellness Centre, Austin Hospital,
Heidelberg, VIC, Australia
Metastatic testicular cancer is a curable malignancy with cisplatin-
based chemotherapy. However, some men develop platinum resis-
tance, and despite high-dose chemotherapy die from their disease.
Over the last 5 years, increased knowledge of the biology behind this
phenomenon has led to opportunities for enhancing treatment inten-
sity for this subgroup. On the other hand, population-based research
has shed light on the ability to place many patients on simple surveil-
lance after orchidectomy and sparing them chemotherapy-related side
effects. The evidence behind these developments will be reviewed.
33 What are the psychosocial challenges facing
testicular cancer survivors and how can
technology help to address them?
Ben Smith
Ingham Institute for AppliedMedical Research and University of New
SouthWales, Liverpool, NSW, Australia
Testicular cancer (TC) is themost common formof cancer in youngmen
(18-39). More than 95% of men survive TC, but psychosocial seque-
lae are common. Clinically significant anxiety (approximately one in
five) and to a lesser extent distress (approximately one in seven), but
not depression, are more prevalent in TC survivors than the general
population. Approximately one in three TC survivors experience ele-
vated fear of cancer recurrence (FCR). Up to two-thirds of TC survivors
report unmet needs for help adjusting after TC, particularly regard-
ing existential, relationship/sexual and financial/insurance issues.
Poorer outcomes are more common in men who are single, younger,
unemployed/low socioeconomic status, suffering from co-morbidities,
experiencing worse symptoms/side effects and using passive coping
strategies.
Men may be reluctant or unable to seek face-to-face help due to bar-
riers including stigma, distance and cost. Innovative approaches to
providing support are needed. TC survivors report positive attitudes
towards eHealth and TC survivors with more unmet needs are more
likely to engage in online TC communities. TrueNTH TC (Movember;
truenth-tc.org) and e-TC 2.0 (PoCoG/ANZUP; e-TC.org) are two online
resources designed to support men from testicular cancer diagnosis
through to survivorship. TrueNTH TC aims to reduce anxiety and iso-
lation by providing information and connections with TC survivors and
clinicians. Testing of TrueNTH TC is ongoing. e-TC 2.0 is an interactive
web-based self-management intervention that aims to reduce anxiety,
depression and FCR in TC survivors reporting elevated psychological
distress. A single arm phase I trial of e-TC 2.0 in 44 TC survivors found
high (>8/10) self-reported acceptability of e-TC 2.0 and pre- to post-
intervention reductions in borderline/clinical anxiety (79% vs 30%),
distress (59% vs 44%) and FCR (39% vs 8%). However, the feasibility
of e-TC 2.0 as a scalable tool to reduce psychological distress in TC sur-
vivors may be constrained by limited website usage.
34 Endocrine consequences of treatment:
Hypogonadism
Ada Cheung
1Department of Endocrinology, Austin Health, Heidelberg, VIC, Australia
2Department of Medicine (Austin Health), The University of Melbourne,
Heidelberg, VIC, Australia
Testicular cancer is the most common solid tumour in men of repro-
ductive age and as the 10 year survival rate exceeds 97%, long-term
complications need to be considered. Primary hypogonadism, defined
as low total testosterone levels with elevated luteinising hormone
(LH) occurs in up to 20% of testicular cancer survivors and has been
associated with increased risk of metabolic syndrome. In addition to
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hypogonadism, impaired fertilitymay occur, often related to treatment
intensity (particularly with chemotherapy). Independent of treatment,
underlying risk factors for testicular germ cell tumours such as cryp-
torchidismmay also be risk factors for hypogonadism or infertility.
Delineating symptoms attributable to hypogonadism are challeng-
ing, as many symptoms such as fatigue, decreased libido and mood
disturbance are non-specific. Untreated hypogonadism may con-
tribute to long-term osteoporosis and metabolic syndrome which pre-
disposes to cardiovascular disease.
A decision to initiate testosterone replacement, which is often given
lifelong, should be individualised. Benefits and potential risks should
be carefully weighed and there is insufficient evidence to show that
testosterone replacement is of benefit onmetabolic syndrome. Studies
in older men without cancer with mild hypogonadism have suggested
that testosterone replacementmay be associatedwith increased coro-
nary atherosclerosis. Furthermore, as testosterone is a contraceptive,
it should not be initiated in men seeking fertility without discussion
with a fertility specialist. Nonetheless, men who have biochemical
hypogonadism and clear symptoms should be considered for a trial of
testosterone therapy and treatment should be ceased if no demonstra-
ble benefit is achieved.
35 Surgical advances: Robotic retro peritoneal
lymph node dissection
Nari Ahmadi
Chris O’Brien Lifehouse, Camperdown, NSW, Australia
Introduction & Objectives: Robotic RPLND (R-RPLND) has been
shown to be a viable alternative to open RPLND with lower periop-
erative morbidities, while maintaining the same oncological outcomes.
Herein, we report our initial experience with R-RPLND at a single ter-
tiary referral centre.
Methods: Retrospective review of our prospectively collected
database was performed of all patient undergoing R-RPLND at our
institution from May 2018 till September 2019. Demographic data,
operative parameters, oncological and perioperative outcomes were
examined. Intraoperative as well as 30 & 90 day post-operative
complications were recorded using Clavien-Dindo classifications.
Results: Overall, 11 patients underwent R-RPLND during the study
period. Primary pathology was NSGCT in 9 (82%), Seminoma and
paratesticular embryonal rhabdomyosarcoma in 1 (9%) each. 9 (82%)
of patients underwent prior chemotherapy with BEP and other 2
patients underwent primary RPLND. Preoperative staging was as fol-
lowing: IIA 2 (18%), IIB 5 (45%), IIC 4(36%). Nine (82%) patients under-
wentmodified unilateral template resection and two (18%) underwent
bilateral template resection.
Median age was 31 (14-39) and Median nodal count was 38 (28-65).
Median operative time was 300 min (240-360) and Mean estimated
blood loss was 100mls (30-1500) with no cases of blood transfusion.
One patient required conversion to open surgery due to difficulty in
resectionandbleeding from IMA.Pathology results indicated teratoma
in 5 (45%); necrosis in 4 (36%), Choriocarcinoma in 1 and embryonal
rhabdomyosarcoma in 1.
Median return of bowel function was 1 day(1-2) and mean length of
stay was 2 days(2-4). There were no early or late (30 & 90 day) post-
operative complications. With median follow up of 9 months (1-18),
there were no recurrences.
Conclusions: R-RPLND is technically a challenging procedure requir-
ing advanced skills, however it is safe and feasible in selected patients
and in a dedicated tertiary centres. The robotic approach offers
promising early result with lower perioperative morbidity and length
of stay. Larger cohorts and longer follow up is required to demonstrate
safety and oncological equivalence to open RPLND.
36 50/50 – ComedianMichael Shafar’s
reflections on being diagnosedwith testicular
cancer
Michael N. Shafar
Michael Shafar, Melbourne, VIC, Australia
After five rounds of surgery and 24 weeks of chemotherapy, he was
finally declared to be in remission. He has since toured his show 50/50
around Australia, which chronicles the entire experience.
37 The patient perspective
Shona Edwards
Content not available at time of publishing
38 Exercise and nutrition to treat adverse
musculoskeletal effects of hormone therapy
in prostate cancer
Steve Fraser
Institute for Physical Activity and Nutrition, Deakin University, Burwood,
VIC, Australia
Androgen deprivation therapy (ADT) is a commonly prescribed ‘hor-
mone’ treatment for advanced or metastatic prostate cancer that has
been shown to improve overall survival. However, treatment-induced
hypogonadism is associated with a range of adverse effects, includ-
ing an accelerated decline in muscle mass and strength, bone density
and an increased fracture risk. Although exercise training is recom-
mended to ameliorate some of these effects, the benefits on skele-
tal health are inconsistent and no known studies have examined the
combined effects of exercise training with a nutritional supplement on
skeletal health outcomes. Therefore, we conducted a 12-month ran-
domised controlled trial investigating whether resistance training and
weight-bearing exercise combinedwith a nutritional supplement could
optimizemusculoskeletal health in ADT-treatedmen.
We randomised 70 ADT-treated men (mean age: 71.3 ± 6.2 years)
to exercise + supplementation (ExSuppl, n = 34) or usual care (CON,
n = 36). The daily nutritional supplement included 25 g whey protein,
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1200 mg calcium carbonate and 1000 IU vitamin D. Key outcomes
included: DXA areal hip and spine bone mineral density (aBMD) and
total body leanmass and fatmass; pQCTcortical and/or trabecular vol-
umetric BMD, bone structure and strength at the distal (4%) and prox-
imal (66%) tibia and radius; andmuscle strength (leg press, chest press
and seated row).
ExSuppl resulted in an 11% greater increase in leg press muscle
strength compared to CON (P < .05), but had no effect on lean or
fat mass, DXA aBMD or any pQCT bone outcomes. At 12-months,
both groups experienced similar and significant losses of total hip and
femoral neck aBMD (1.1-2.0%), distal radius trabecular vBMD (2.7-
2.9%) and proximal tibia and radius cortical bone area (1.4-2.3%) and
strength (2.1-3.5%). In conclusion, ADT-treated men who completed a
12-month multicomponent exercise program with daily consumption
of a protein, calcium and vitamin D-enriched drink improved muscle
strength, but not bone andmuscle loss.
39 The cardio-oncology burden is ever-present,
so how canwe affordably and feasibly assess
cardiorespiratory fitness in every patient
DavidMizrahi
Prince ofWales Clinical School, University of New SouthWales, Sydney,
NSW, Australia
The cardio-oncology field has become an increasing focus among the
management of cancer survivors. Despite the survival rate of most
cancers increasing, cancer survivors experience an increased rate
of cardiovascular diseases (CVD) such as ischaemic heart disease,
heart failure and stroke compared with the general population. This is
generally attributed to treatments such as chest radiotherapy, anthra-
cyclines and methotrexate causing short- and long-term effects. With
known potential cardiovascular risks from treatment, an important
clinical focus is to prevent the development of CVD after treatment.
Supportive care such as increasing physical activity is becoming
increasingly supported in oncology clinics, with the Clinical Oncology
Society of Australia recently releasing their first statement supporting
exercise. Despite this increasing support, receiving individualised
physical activity advice and assessing cardiorespiratory fitness are not
standard-of-care in Australian cancer hospitals.
Having higher physical activity and cardiorespiratory fitness levels has
been shown to reduce the risk of CVD in the general population, as
well as improving many physical and psychological factors impaired
by cancer treatment. There are multiple methods of assessing car-
diovascular fitness, a modifiable CVD risk factor. The gold standard,
Cardiopulmonary Exercise Test, requires maximal patient exertion,
trained staff, a calibrated gas analysis system and a cycle ergometer
or treadmill. Cardiorespiratory fitness can also be estimated, which
reduces sensitivity but becomes more practical when large patients
volumes are seen and resources are limited. Patients can be objectively
monitored over time using submaximal exercise assessments including
the 6-min walk test, 3-min step test and a submaximal cycle test.
Further, patients can generally accurately self-perceive if they have
high or low fitness. This information should be used to identify patients
with low fitness to motivate them (and refer if necessary) to become
more physically active and thus decrease their CVD risk.
40 It’s not all face to face: Digital delivery of
exercise oncology
MichaelMarthick
Chris O’Brien Lifehouse, Camperdown, NSW, Australia
For individuals with cancer, the disease and treatment can result in
impairments that limit physical, psychosocial and cognitive function-
ing, interferingwithpatients’ quality of life andability toperformwork-
related functions.
Clinical trials published since 1983 have demonstrated that super-
vised exercise training prescribed during and/or after the completion
of cancer treatments is safe and can counteract treatment-related side
effects, and elicit many other physiological, functional and psychologi-
cal benefits.
There are currently limited supportive care programs and services
available for cancer patients and survivors in Australia, with recent
research indicating that less than 1% of patients with cancer are cur-
rently accessing comprehensive, multidisciplinary rehabilitation pro-
gram within hospitals. Further, the few existing programs rely largely
on face-to-face delivery of services, reducing options for those who
may be unable to attend due to location or time constraints. A large
component of these programs is exercise therapy.
Clearly defined, integrated and patient-centred models of care will be
required to deliver exercise services to a growing number of cancer
patients; otherwise, such services may continue to remain peripheral
to standard care and underutilised. Delivery and availability of exer-
cise oncology services enabled by digital technology may offer consid-
erable potential for improved reach, cost savings and improved health
outcomes. Such services can be broadly characterised under Shaw et
al’s conceptual model, consisting of three core domains:
(1) Health in our hands: using digital technologies to monitor, track,
and inform health, for example smartphones, tablets, clinical
devices, mobile sensors and wearables, Apps, social media, and
online information.
(2) Interacting for health: using digital technologies to enable health
communication among practitioners and between health profes-
sionals and clients or patients, for example traditionally dom-
inated by teleconferencing and videoconferencing, this domain
increasingly includes a range of synchronous and asynchronous
tools, such as SMSandpushnotifications frommobile applications,
dedicated portals, social media platforms and virtual or simulated
therapy tools.
(3) Data enabling health: collecting, managing and using digital health
data, for example technologies that providedexpandedknowledge
and insights about the health and wellness of an individual, com-
munity or population.
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41 International volunteering through ASCO–
aVietnam experience
David Goldstein
Prince ofWales Hospital, Randwick, NSW, Australia
The International Cancer Corps [ICC] is one of the American Society
of Clinical Oncology International Programs. ASCO supports Health
VolunteersOverseas (HVO), to operationalise this programof partner-
ing with low andmiddle income countries to strengthen cancer care in
medical centres.
ASCO also has a range of Workshops with Volunteer International
Faculty which pair with either individual hospitals or national Cancer
Organisations. Topics include Multidisciplinary Cancer Management,
International Clinical Trials, International Palliative Care, Cancer Con-
trol in Primary Care.
HVO/ASCOhas current programs inNepal, Bhutan,Honduras, Uganda
and Vietnam. I have previously led the Hue program as well as joined
multidisciplinary cancer workshops in Vietnam and the Philippines.
The Hue program had over 88 volunteers visit over five years. The
average of four groups per year would over a 2-week period cover a
particular organ cancer and its management. To achieve the goal of
enhancing multidisciplinary care the stated goal of our hosts, we
had a core of at least one medical, radiation and surgical oncologist
and senior nurse practitioner/team. Often supplemented with pallia-
tive care, pharmacy, anatomical pathology and on one occasion each,
psych-oncology and radiation therapy. The format included didactic
lectures, participation in tumour boards, individual clinician visits to
their clinics or theatre or radiation planning, daily ward rounds and
demonstrationmultidisciplinary tumour boards involving local and vis-
iting faculty with local cases prepared and presented.
Planning and implementation issues and the ongoing process of mea-
suring outcomes are key issues. Of paramount importance is a joint
approach to identifying realistic goals, in partnership with the host
organisation and ensuring broad internal support and Champions
within the local leadership in each targeted speciality. Cultural aware-
ness is a key issue to be sensitive to in planning. The relative benefits
of single craft group andmultidisciplinary teams and development of a
core faculty will be discussed. As will opportunities to link these pro-
gramswithmentorship and career and research development of junior
faculty, and new program directors from visiting volunteers.
The joys of interacting with an international multidisciplinary faculty
are immense as is the delight of learning from our colleagues in other
countries and understanding the challenges they face and overcome
is both humbling and rewarding. Joining is easy, new volunteers are
always welcome.
42 DevelopingOncology Services in Johannes
Hospital, Kupang,West Timor
Chris Karapetis
Flinders Centre for Innovation in Cancer, Bedford Park, SA, Australia
West Timor is a western province of Indonesia. The Flinders Overseas
Health Group (FOHG) is a not-for-profit organisation that has sup-
ported medical services in West Timor for over a decade. Recently,
FOHG initiatedefforts todevelop cancer services at the JohannesHos-
pital in Kupang, the capital city of West Timor. The program involved
training and supportingmedical and nursing staff of the JohannesHos-
pital through sponsored training programs conducted at the Flinders
MedicalCentre. In2015and2017,medical oncology, nursing andphar-
macy representatives of FOHG traveled in West Timor. Local services
were evaluated and areas of need were identified. Prioritisation of
resources were considered, and sustainable system changes were rec-
ommend and supported. The promote change, FOHG advocated on
issues of policy and process through hospital administration and local
government. FOHG representatives also met with the Governor of
West Timor in an effort to support the commencement of radiother-
apy services in the region.
The initiatives of FOHG have promoted the following cancer service
changes and improvements at the Johannes Hospital inWest Timor;
– reorganisation of ward structure, creating palliative care area
– developing ordering system for chemotherapy drugs (communica-
tion between day unit and pharmacy)
– organised patient chemotherapy times in the day infusion centre,
matching established ‘cyclical’ protocols.
– developing pharmacy impress and ordering system
– commencingmultidisciplinary teammeetings for case discussion
– supplying pathology diagnostic equipment
– training in transfusionmedicine
– biomedical hazardous waste removal
A guide to optimising medical oncology services in under-resourced
regions is being developed by FOHG.
43 The APROSIG-National Cancer Centre
Collaboration: Expanding access to radiation
therapy in Cambodia
Mei Ling Yap1,2,3,4, IWard5
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The incidence of cancer is rising rapidly, with a global projection of
26 million cases annually by 2040; 70% of these will arise in low- and
middle-income countries (LMICs).1 Radiotherapy is a core component
of cancer care and has been shown to be cost-effective.2 However,
there remains a huge deficit in radiotherapy services in LMICs, with
the provision of resources inversely proportional to Gross National
Income.3 By geographic region, the Asia-Pacific has been demon-
strated to have the highest absolute deficit in radiotherapy services4
and the largest investments required to meet those needs. The Global
Task Force in Radiotherapy for Cancer Control Lancet Commission
demonstrated that in addition to the need for radiotherapy equipment,
there is an urgent need for human resources.2 At present, there is a
shortage of in-country training pathways for radiotherapy profession-
als in many LMICs in the Asia-Pacific.
One such country facing a shortage of radiotherapy resources is Cam-
bodia, which has one linear accelerator for a population of 16 million
people. An exciting development has been a recently-built comprehen-
sive cancer centre in Phnom Penh, the National Cancer Centre (NCC),
which includes modern radiotherapy services. A major challenge for
NCC has beenworkforce, given the specialized skills required and lack
of formal training programswithin Cambodia.
The Asia-Pacific Radiation Oncology Special Interest Group
(APROSIG) of the Royal Australian and New Zealand College of
Radiologists (RANZCR) has partnered with NCC, primarily in aiding
with education and training of radiation oncology staff. APROSIG is a
volunteer group which aims to support the safe and effective delivery
of radiotherapy in neighbouring LMICs. Initiatives have included the
organization of in-country Australian radiation therapist trainers in
Cambodia for 6-15 months’ duration and an observership program for
Cambodian cancer professionals in Sydney; both programs supported
by the Australian government.
1. Ferlay JEM, Lam F, Colombet M, et al. Cancer tomorrow.
http://gco.iarc.fr/tomorrow (accessed Sept 4th, 2019)
2. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to
radiotherapy. Lancet Oncol 2015;16(10):1153–86.
3. Levin V, Tatsuzaki H. Radiotherapy services in countries in transi-
tion: gross national income per capita as a significant factor. Radio-
ther Oncol. 2002;63(2):147–50.
4. Zubizarreta E, Van Dyk J, Lievens Y. Analysis of Global Radiother-
apy Needs and Costs by Geographic Region and Income Level. Clin
Oncol 2017;29(2):84–92
44 DFAT pacific islands program: Building
capacity and capability of an oncology unit in the
Solomon Islands
Desmond Yip
The Canberra Hospital, Garran, ACT, Australia
The Solomon Islands is a low income nation in the South Pacific
with significant challenges in health care resourcing. The National
Referral Hospital (NRH) in Honiara is the country’s only tertiary
referral hospital. There is limited availability of pathology and medical
imaging services. There is only a small range of cytotoxics on the
formulary. A scoping visit was carried out in 2016 funded by the
John James Foundation with recommendations made to assist in the
development of coordinated cancer services and to establish amedical
oncology unit. This was followed by an observership visit to Canberra
by an NRH doctor in 2017 supported by the Foundation. Following
a request from the Solomon Islands Ministry of Health, the Aus-
tralian Government Department of Foreign Affairs and Trade (DFAT)
arranged a mission under the Royal Australasian College of Surgeons
(RACS) Pacific Islands Programme (PIP) to the NRH with a team con-
sisting of a medical oncologist, haematologist, oncology clinical nurse
consultant and oncology pharmacist to help in the commissioning
of the NRH Medical Oncology Unit in September 2018. The aims
were to (a) create protocols and guidelines for procurement, storing,
mixing, administration and disposal of chemotherapy agents suitable
to NRH context; (b) to conduct training for health staff assigned to
the new department on their respective responsibilities. The team
with the assistance of an Australian Volunteers International (AVI)
Pharmacist has helped the NRH staff to develop localised Solomon
Islands Oncology Guidelines. Donated equipment and supplies have
helped with the establishment of the service. Another DFATOncology
mission visit was made in 2019 followed by two NRH oncology nurses
coming to Canberra on observership. These collaborative initiatives
have contributed to building the capacity and capability of the NRH
Medical Oncology Unit to treat cancer patients.
45 Developing amodel for safe cytotoxic
administration in the Solomon Islands
Wendy Spencer
The Canberra Hospital, Garran, ACT, Australia
The National Referral Hospital in Honiara is seeking to establish an
oncology unit as part of a project to deliver cancer services in the
Solomon Islands.
The cancer treatment room, like the rest of the hospital, suffers from a
lack of maintenance. It has louvredwindows, no air conditioning, badly
rusted fans and the holes in the floor mean that the room is subject to
flooding in themonsoon season. Theworking environment is cluttered
with boxes stacked on trolleys and the floor due to there being no stor-
age cupboards.
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There are no basic temperature or blood pressure machines to check
observations prior to giving treatment andweight scales are borrowed
from theMedicalWard on an ad hoc basis. Imaging and pathology ser-
vices are limited. Treatment can only be given via a peripheral cannula.
Cannulas differ depending on which country provided them and there
arenobifurcated lines. Intravenous saline and5%glucose arenot avail-
able in the volumes normally used for cancer treatment and there are
nopumpsor giving sets. Not all drugs are available, thereby limiting the
protocols that can be used.
The treatment room is staffed by only one registrar and two nurses,
none of whom have been given any specialised training in the delivery
of cancer treatment. There is no cover if the doctor or oneof the nurses
is absent for any reason. Providing training and advice and support to
the staff remotely is hampered by the patchy availability of internet
services.
This presentation describes the approach to developing a model for
the safe administration of cytotoxic drugs. The model will use proto-
cols that have been adapted to make best use of the equipment, sup-
plies anddrugs available,whileminimisingwastage. Themodelwill also
address staff training and succession planning.
46 Thewhat, when and how of stereotactic
ablative body radiotherapy for oligometastatic
prostate cancer
Marcus Dreosti
GenesisCare, Adelaide, SA, Australia
Oligometastatic prostate is a hot topic and an area of growing inter-
est in daily urological oncology practice, mandating a multidisciplinary
team approach. It is however variably defined and high-quality evi-
dence guiding optimal management is limited. The initial question
is how best to define this state, as prognosis will be dependent on
the imaging modality used (conventional vs functional), the tissues
involved (nodal vs bone vs visceral), the tempo of disease and the num-
ber of lesions detected (1 vs 3 vs 5 vs more). Timing is also critical,
given that the oligometastatic state can be detected either at diagno-
sis (synchronous) or following local treatment (metachronous). There
are options regarding the integration of local treatments with sys-
temic therapy and consideration must be given to defining relevant
endpoints. There are also technical challenges associated with deliv-
ering ablative or potentially immuno-stimulatory radiotherapy to such
lesions. Here, wewill explore the biology, technology and ongoing clin-
ical trial activity around the use of stereotactic ablative body radiation
(SABR) techniques in the oligometastatic state of prostate cancer.
47 Prostate SBRT: Is it ready for prime time?
Mark Sidhom1,2
1University of NSW, Randwick, NSW, Australia
2Liverpool Cancer Therapy Centre, Liverpool, NSW, Australia
Stereotactic body radiation therapy (SBRT) involves extremehypofrac-
tionation whereby a high dose per fraction, and an overall lower num-
ber of fractions than conventional radiotherapy, is used for treatment.
Advanced treatment delivery platforms, incorporation of MRI into
target localization, motionmanagement and real-time image guidance,
is required for optimal prostate SBRT delivery. Large published series
report long-term data of SBRT regimens giving four to five radiother-
apy fractions for low and intermediate risk prostate cancer patients.
These data support prostate SBRT having similar efficacy and toxicity
to conventionally fractionated radiotherapy. One recent randomised
study comparing conventional fractionation with prostate SBRT
reported equivalent tumour control, as well as acute and late toxicity,
whereas several other randomised studies are currently underway
exploring similar stereotactic regimens. In response to this growing
body of evidence, international guidelines have incorporated prostate
SBRT monotherapy as a treatment option for centres experienced in
this technique for low and intermediate risk prostate cancer patients.
However, the role of SBRT in the management of high risk prostate
cancer remains to be determined, including questions of efficacy in
this patient cohort, the role of dose escalation, optimal fractionation
regimens and the tolerability and efficacy of whole pelvis radiotherapy
incorporated in SBRT courses. The next decade will see a major shift
toward extreme hypofractionation in the management of prostate
cancer.
48 Evolvingmolecular imaging and
radionuclide therapies in prostate cancer
Nat Lenzo2,1
1Medicine and Pharmacology, University ofWestern Australia, Perth, WA,
Australia
2GenesisCare, Alexandria, NSW, Australia
The last decade has seen the development and implementation of
molecular imaging techniques that are changing the management
paradigms of prostate cancer. Despite widespread clinical acceptance
in countries such as Australia and Germany, these imaging agents have
yet to obtain formal regulatory approval in most countries and also
their role in various clinical scenarios has yet to be fully determined.
These new targeted imaging agents have also directly lead to the
development of targeted therapeutic agents using beta emitters such
as Lutetium-177 and now alpha emitters such as Actinium-225. This
dual imaging-therapy paradigm is known colloquially as Theranostics,
though the principles of this branch of medicine date back to Iodine-
131 therapy used for imaging and treating thyroid cancer since 1943.
In this symposium, wewill explore the development and emerging role
of molecular imaging in the management of prostate cancer and also
the growing body of data on the use and potential role of targeted
radionuclide therapies, such as Lu-177PSMAandAc-225PSMA, in the
management of advanced (and not so advanced) prostate cancer.
Learning Objectives: To better understand the role of the new molec-
ular imaging agents (Ga-PSMA, F-PSMA and similar analogues) in the
management of prostate cancer patients.
To consider the role of targeted radionuclide imaging and therapy in
current and futuremanagement of prostate cancer.
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To update on the new advances in this area (eg Ac-225 PSMAand com-
bination therapy) and ongoing clinical trials in this space.
1. Review of Gallium-68 PSMA PET/CT Imaging in the Management
of Prostate CancerNat P. Lenzo, DanielleMeyrick, J. Harvey Turner
Diagnostics (Basel) 2018Mar; 8(1): 16.
2. Wester HJ, Schottelius M. PSMA-Targeted Radiopharmaceuticals
for Imaging and Therapy. Semin Nucl Med. 2019 Jul;49(4):302–
312.
3. Farolfi A, FendlerW, Iravani A, Haberkorn U, Hicks R, Herrmann K,
Walz J, Fanti S. Theranostics for Advanced Prostate Cancer: Cur-
rent Indications and Future Developments. Eur Urol Oncol. 2019
Mar;2(2):152–162.
49 International experiencewith lutetium- and
actinium-based radionuclide therapies in prostate
cancer: Current state of clinical practice and
future directions
Aviral Singh1,2
1Theranostics Center for Molecular Radiotherapy andMolecular Imaging,
Zentralklinik Bad Berka GmbH, Bad Berka, Germany
2GROW - School for Oncology and Developmental Biology, Maastricht
University, Maastricht, The Netherlands
Prostate-specificmembrane antigen (PSMA) is expressed in poorly dif-
ferentiatedprostate cancers andcanbe identifiedbyPSMA-ligandPET
imaging with subsequent PSMA-based radioligand therapy (PRLT) fol-
lowing the principle of Theranostics.
Retrospective observational data report favourably on the efficacy
and safety of PRLT with beta-emitting Lutetium-177 (177Lu). Results
fromaprospective phase-II clinical trial (LuPSMA)have confirmedhigh
response rates, low toxicity, symptomatic pain relief and improvement
in the quality of life of patients with metastatic castration-resistant
prostate cancer and treatment-refractory progressive disease. Com-
passionate use based observational studies and meta-analyses have
reported the efficacy of 177Lu-PRLT with a biochemical response (PSA
decline >50%) in more than half of the patients, and imaging-derived
partial response in about one-third of patients. Presence of visceral
metastases and serum alkaline phosphatase ≥220 U/L is associated
with poor outcome.
Reports of safety analysis following 177Lu-PRLT demonstrated grade
3-4 hematotoxicity in less than 10% of patients. Other clinical symp-
toms observed include fatigue, xerostomia, nausea and exacerbation
of pain syndrome due to ‘flare phenomenon’.
Actinium-225 (225Ac)-based PSMA alpha radioligand therapy (PSMA-
ART) utilizes the shorter tissue penetration range of the higher energy
alpha particles. It is performed in patients with extensive lymph node,
visceral or bone and bone marrow metastases, and sometimes as an
escalation therapy in case of disease progression under 177Lu-PRLT.
TANDEM (177Lu/225Ac) PRLT is the approach of administering frac-
tionated activities of both beta- and alpha-emitting radiation dur-
ing the same cycle in order to maintain the therapeutic effect while
attempting to avoid severe and treatment-limiting xerostomia, which
could result as an adverse effect of ARTwith 225Ac.
Future developments are aimed at reducing side effects caused
by radioligand therapy, combination therapies, dosimetry studies,
application of novel radioligands and radioisotopes as well as novel
imaging hardware and software, and most importantly, randomised
controlled studies.
1. Kulkarni HR, Singh A, Langbein T, Schuchardt C, Mueller D, Zhang
J, Lehmann C, Baum RP. Theranostics of prostate cancer: from
molecular imaging to precision molecular radiotherapy target-
ing the prostate specific membrane antigen. Br J Radiol. 2018
Nov;91(1091):20180308.
2. Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP.
ClinicalOutcomes of (177)Lu-PSMARadioligand Therapy in Earlier
and Later Phases ofMetastatic Castration-Resistant Prostate Can-
cer Grouped by Previous Taxane Chemotherapy. J Nucl Med. 2019
Jul;60(7):955–962.
3. Edler von Eyben F, Singh A, Zhang J, Niepsch K, Meyrick D,
Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni
HR, Baum RP. (177)Lu-PSMA radioligand therapy of predominant
lymph node metastatic prostate cancer. Oncotarget. 2019 Mar
29;10(25):2451–2461.
4. SathekgeM,Bruchertseifer F,VorsterM, Lawal I, KnoesenO,Maha-
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cer patients receiving (225)Ac-PSMA-617 radioligand therapy. J
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50 Feasibility of collecting patient-reported
outcomes (PROs) fromCALD populations:
Experience of Arabic immigrants with cancer
Ivana Durcinoska1, RoyaMerie2, Geoff P. Delaney1,2,3, Afaf
Girgis1,3
1Centre for Oncology Education and Research Translation (CONCERT),
Ingham Institute for AppliedMedical Research, UNSW Sydney, Sydney,
NSW, Australia
2Liverpool Cancer Therapy Centre, Liverpool Hospital, Sydney, NSW,
Australia
3SouthWestern Sydney Clinical School, UNSW Sydney, Sydney, NSW,
Australia
Background: Systematic monitoring of patient-reported outcomes
(PROs) is increasingly important in patient-centred care. However,
widespread collection and integration into clinical practice remains
a challenge, particularly among culturally and linguistically diverse
(CALD) patients with limited English proficiency. This is the first study
to compare the feasibility and acceptability of ePRO screening as part
of routine clinical care among Arabic versus English-speaking patients
diagnosedwith cancer.
Methods: Patients receiving care at Liverpool andWollongong Hospi-
tals were recruited in clinic and invited to complete PRO assessments
ORAL ABSTRACTS 73
(Distress Thermometer and Problem List [DT], Edmonton Symptom
Assessment Scale [ESAS-r]) in their preferred language on two occa-
sions, 4 weeks apart, followed by an evaluation survey. Assessment #1
was completed on a tablet in-clinic, with option for completing Assess-
ment #2 on a tablet or paper. A mixed method approach was used to
evaluate feasibility and acceptability.
Results: Overall, 55 patients (36%Arabic, 64% English speaking, mean
age 62 years, 67% female) completed 105 PRO assessments and 46
evaluation surveys. Satisfactionwith the PROassessment items varied
between groups (50% Arabic, 75% English). Arabic speaking patients
had difficulty understanding survey instructions (50%) and using the
tablet (60%), with 95% requiring assistance to complete Assessment
#1. Arabic patients expressed greater concern about privacy (22% vs
0%; P = .02) and who would access and view responses (33% vs 4%;
P = .01). The majority (73%) of Arabic-speaking patients elected to
complete Assessment #2 on paper, with 95% (19/20) indicating lack of
regular access to or use of email to complete assessments outside of
the clinic.
Conclusions: Sustainable implementation of PROs in clinical care is
challenging. Although acceptability and feasibility of implementing
PRO screening was high among English-speaking patients, screening
among Arabic-speaking patients presented several challenges. Devel-
opment and evaluation of targeted strategies to better support CALD
populations overcome these linguistic and cultural barriers is needed.
51 Barriers and facilitators of implementing a
web-based infertility risk prediction tool
(FoRECAsT) for young breast cancer patients into
clinical practice
Zobaida Edib1,2, Yasmin Jayasinghe1,2,3, Martha Hickey1,2,
Alexandra Gorelik4,5, Christobel Saunders6, Shanton Chang7,
Patrick Pang7, Kate Stern8,9, Michelle Peate1,2
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Parkville, VIC, Australia
2University of Melbourne, Parkville, VICT, Australia
3The Royal Children’s Hospital, Parkville, VIC, Australia
4Department of Medicine, The Royal Melbourne Hospital, University of
Melbourne, Parkville, VIC, Australia
5School of Behavioural & Health Sciences, Australian Catholic University,
Melbourne, VIC, Australia
6Faculty of Health andMedical Sciences, Surgery, University ofWestern
Australia, WA, Australia
7School of Computing and Information Systems, University of Melbourne,
Parkville, VIC, Australia
8Melbourne IVF, Melbourne, VIC, Australia
9Fertility Preservation Service, The RoyalWomen’s Hospital, Parkville, VIC,
Australia
Aim: Current tools to predict fertility outcomes after breast cancer
treatments are imprecise and do not offer individualised predictions.
To address the gap,we are developing a novelweb-based infertility risk
prediction tool (FoRECAsT) for young breast cancer patients. The aim
of this study is to identify the barriers and facilitators for patients and
health care providers in implementing the FoRECAsT tool into clinical
practice
Methods: A purposive sample of 12 breast cancer patients, six breast
surgeons, nine medical oncologists, nine fertility specialists, 12 breast
care nurses and two fertility preservation nurses participated in semi-
structured in-depth telephone interviews. A constant comparison the-
matic approachwas used to analyse the interviews.
Results: Datawere categorized into fivemain themes: interest in using
the FoRECAsT tool; user attributes; access and confidentiality; impact
on consultation; and anticipated fertility-related outcomes. A total of
14 sub-themes emerged. Patients identified a need for information
regarding post-treatment fertility outcomes. Clinicians and patients
both indicated that a comprehensive web-based tool that provided an
accurate prognostication about the risk of future infertilitywould facil-
itate the use of the tool in clinical practice and result in bettermanage-
ment of expectations. The clinical use of the tool would ultimately help
patients to make a good quality fertility preservation decisions and be
supportive in principle. Barriers included the challenges in inputting
clinical data thatwould be collected at a different time in the treatment
process, the responsibilities of clinicians and patients in using the tool,
andwhere andwhen the toolmight beused in the treatment trajectory.
Conclusion: Designing the FoRECAsT tool in consultation with
patients and clinicians increases the likelihood that it will be used in
clinical practice. Design considerations include taking into account the
facilitators and barriers identified in this study.
52 How can digital health be used to improve
outcomes in pancreatic ductal adenocarcinoma
(PDAC)? Examining the potential of the PURPLE
translational pancreatic cancer platform
Belinda Lee1,2,3,4, Julia Shapiro5,6, Benjamin Thomson1,7,8,
Sumitra Ananda1,8,9, Lara Lipton1,5,8, Sue-AnneMcLachlan10,
RachelWong11,12, Prasad Cooray13, Matthew Burge14, Kate
Clarke15, Sharon Pattison16,17, MehrdadNikfarjam7,18, Niall
Tebbutt18, Marion Harris19, Daniel Croagh19, David
Goldstein20, AdnanNagrial21, Rob Zielinski22,23,24, Amitesh
Roy25, Cheng Ean Chee26, Tracy Putoczki2, Frederic
Hollande27,28, Oliver Hofmann27,28, Joep Vissers28, Sean
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Background: The PURPLE translational registry supports analysis of
large amounts of structured clinical and molecular data from rou-
tine clinical practice, into a single collaborative data repository. We
explored whether, by utilising digital health technology, we could
potentially enable big data insights into PDAC.
Methods: ThePURPLE translational pancreatic cancer registry is a col-
laborative effort among 27 institutes, employing an electronic web-
based platform for entry of key clinicopathological and outcome data
on consecutive patientswith PDAC. This federated platformallows de-
identified data to be combined and analysed for research purposes,
whilst maintaining privacy, confidentiality and data security, with the
goal of supporting clinical, genomic and translational research.
Results: Between January 2016 and June 2019, 1279 PDAC patients
with >400 matched biospecimens, 369 resections and 486 biopsy
specimens have been entered in PURPLE. Median age at diagnosis
was 69 (range 20-94 years), and 681 of 1279 (53%) were male. Over-
all 754 of 1279 (59%) patients presented with localised disease; 350
of 1279 (27%) were deemed resectable, 148 of 1279(12%) border-
line resectable and 247 of 1279 (20%) unresectable. A further 445 of
1279 (35%) were metastatic and 80 (6%) were not fully staged. Tar-
geted molecular sequencing performed in 143 PDAC patients identi-
fied mutations in KRAS in 131 (92%), BRAF in 1 (1%), TP53 in 72 (71%),
CDKN2A in 41 (41%) and PIK3CA in two (2%). BRCA/BRCA-like signa-
tures were identified in five of 75 cases undergoing Genome Sequenc-
ing (WGS). Since September2019, 20WGScaseswere reviewedby the
Molecular Tumour Board and Precision Oncology Program at the Vic-
torian Comprehensive Cancer Centre. Research in circulating tumour
DNA, biomarkers and organoid models is also being supported by the
PURPLE translational pancreatic cancer platform.
Conclusion: The comprehensive data collected in the PURPLE reg-
istry support a broad range of research focused on precision oncology,
including linking molecular data that can help identify candidates for
targeted interventions.
53 The Patient-reported Experience (Cancer)
Questionnaire: Development, validation,
reliability testing…. and on to system-wide
digitisation
AlexandraMcCarthy1,2,3, Carol Reid1,4, Leanne Stone1, Lee
Jones5, Danette Langbecker2, Monkia Janda2, Bobbi Laing3,
Ron Tenenbaum3, Koray Atalag3
1Princess Alexandra Hospital, Brisbane, QLD, Australia
2University of Queensland, Brisbane, QLD, Australia
3University of Auckland, Auckland, New Zealand
4Nursing, Griffith University, Brisbane, QLD, Australia
5Queensland University of Technology, Brisbane, QLD, Australia
Background: Patient-reported experience measures in cancer care
ideally capture hospital performance in six domains advocated by the
Institute ofMedicine (IOM):
1. Respect for patient needs and preferences
2. Care coordination
3. Information and education provision
4. Physical support
5. Emotional comfort
6. Involvement of significant others.
The Patient-Reported Experience-Cancer (PRE-C) instrument was
developed to capture these variables and inform responsive cancer
service delivery.
Aim: To determinePRE-C reliability (𝛼≥ .7); to establishPRE-C conver-
gent and divergent validity.
Method: ThePRE-Cwas developedwith cancer patients and clinicians.
Face and content validity were tested with 30 patients and 10 clini-
cians. Items were revised according to their feedback until a 28-item
questionnairewas ready for psychometric testing. A sample size of 280
was needed to determine reliability.
Exploratory factor analysis (EFA) examined the PRE-C’s dimensional-
ity. Maximum likelihood was used for extraction, with direct oblimin
rotation examining correlation between constructs.
Results: A total of 414 consecutively recruited ambulatory chemother-
apy patients from a single tertiary hospital participated. EFA indicated
that six of the 28 items were problematic – some fitted better in other
domains and some did not measure as intended. Particularly problem-
atic were items that explored respect for cultural preferences and the
financial impacts of treatment. Removing these items and re-running
the EFA indicated reliability (𝛼 in the six domains ranging from .73
to .81).
Discussion: The revised PRE-C instrument reliably and accurately cap-
tured all IOM constructs. It is also important that the PRE-C cap-
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tures the financial and cultural experiences of cancer patients. To this
end, we have revised the problematic items and are currently test-
ing the PRE-C with ambulatory patients in three large health services,
anticipating N > 280 for a new EFA and >300 for subsequent confir-
matory factor analysis.Weare also preparing the instrument for digital
embedment to enable routine, responsive data capture.
54 Impact of age on drug utilization and
survival outcomes in advanced colorectal cancer
MadisonMOOrr
The University of Sydney, Newtown, NSW, Australia
Introduction: Forty per cent of newly diagnosed colorectal cancer
(CRC) patients are aged over 75 years. However, often elderly patients
are underrepresented in clinical trials; resulting in limited evidence-
based data to assist clinicians inmaking clinical decisions. Investigating
drug deliverance in real world populations is vital in the extrapolation
of clinical trial data to the diverse CRC real world population.
Aim: This study aimed to investigate the effect of patient age on qual-
ity use of medicine and outcomes using a linked data set of real world
stage IV CRC patients.
Methods: Records from Queensland’s CHARM oncology prescribing
databasewere linked to externalQLDhealthdata collections from four
hospital sites between 2009 and 2018. Statistical analysis was used
to investigate relationships between patient age and the prediction of
drug utilisation and survival.
Results: Overall 25% of the 589 mCRC patients were aged ≥75 years.
Elderly patients recorded a comparable overall survival (OS) when
compared with young counterparts (17.9 vs 22.3 months, P = .292).
Patients aged ≥75 years were less likely to receive beneficial triplet
therapy as first line therapy when compared to younger patients
(16% vs 38%, P < .0001). Elderly patients were also more likely to
be dose reduced at the initiation of first line treatment compared to
younger counterparts (65% vs 31%, P < .0001). Within the elderly
cohort, such dose-reduced patients and those dosed appropriately
reported comparable OS outcomes (18.1 vs 15.9 months, P = .796).
Dose-reduced elderly patientswere however significantly less likely to
experience therapy de-escalation (13%vs 29%, P= .036) and less likely
to experience a dose reducing toxicity event throughout their first line
of therapy (29% vs 57%, P= .002).
Discussion: Although age appeared to influence treatment selec-
tion and decision making, survival outcomes were found comparable
between elderly and younger mCRC patients.
55 The Australasian tele-trial model – Access
to clinical trials closer to home using tele-health
Sabe Sabesan1, Andrew Bowskill2, Gardiner Vicki2, Chantal
Gebbie3, Larissa Karpish2, Peter Komocki2, MarieMalica3,
Clare Scott4, Richard Vines5, John Zalcberg6
1Townsville Hospital, Douglas, QLD, Australia
2Medicines Australia, Deakin, ACT, Australia
3Clinical Oncology Society of Australia, Sydney, NSW, Australia
4Walter and Eliza Hall Institute of Medical Research, Parkville, VIC,
Australia
5Rare Cancers Australia, Bowral, NSW, Australia
6Monash University, Melbourne, VIC, Australia
Background/Objectives: The Australasian tele-trial model (ATM)
developed by the Clinical Oncology Society of Australia (COSA) uses
existing literature on tele-oncology to articulate a comprehensive
framework for the use of tele-health to enable clinicians from larger
centres (primary sites) to enrol, consent and treat patients on clinical
trials at regional and rural centres (satellite sites).1 The benefits are
not limited to regional areas, with the same model having the poten-
tial to connect larger centres (even within the same city) and improve
the rate of recruitment to highly specialised trials such as those for rare
cancers.
Methods: COSA is leading a project to pilot the model in New South
Wales, Victoria and Queensland at regional, rural and metropolitan
sites. Five primary sites have received funding through the project to
implement the model and the project has supported state-wide imple-
mentation of the ATM inQueensland.
Results: Currently three tele-trials are open in New South Wales, one
in Victoria and three in Queensland and more than 50 patients have
been recruited to tele-trials. Trials are sponsored by industry, cooper-
ative trials groups and investigators. No ethical or safety issues have
been raised. Eight new staff have received GCP training and staff have
welcomed the inter-site collaboration.
Tele-trial SOPs, supervision plans and subcontracts have been devel-
oped and submitted for National Mutual Acceptance. In Queensland,
a Health Service Directive will incorporate the ATM into Queensland
Health policy.
Conclusion(s): The ATM has been successfully piloted within New
South Wales, Victoria and Queensland enabling improved access to
clinical trials for regional and rural patients. Increased accessibility to
clinical trials and greater participant recruitment also improve collabo-
ration and networking among regional, rural andmetropolitan centres,
enhance workforce development and improve adherence with guide-
line recommended care through greater engagement in research activ-
ity. This may lead to reduced disparity in cancer outcomes for geo-
graphically dispersed populations.
1. COSA. Australasian tele-trial model: access to clinical trials closer
to home using tele-health. Sydney, Australia: COSA; 2016.
56 My health record and beyond: Harnessing
themodern information revolution
Angela Ryan
Australian Digital Health Agency, Sydney, NSW, Australia
Digital information is the bedrock of high-quality healthcare. The ben-
efits for patients are significant and compelling: hospital admissions
avoided, fewer adverse drug events, reduced duplication of tests,
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better coordination of care for people with chronic and complex con-
ditions, and better-informed treatment decisions. Digital health can
help save and improve lives. This session will describe recent advances
in Australia’s national digital infrastructure, including the My Health
Record system, in the context of cancer care.
57 If PROswere a drug, the public would
demand immediate implementation! The case for
PROs reducing costs and variations in care
Afaf Girgis1,2
1Centre for Oncology Education and Research Translation (CONCERT),
Ingham Institute for AppliedMedical Research, UNSW Sydney, Liverpool,
NSW, Australia
2SouthWestern Sydney Clinical School, UNSW Sydney, Liverpool, NSW,
Australia
Routine assessment and clinical utilisation of patient-reported out-
comes (PRO) is acceptable to patients and care providers, and signif-
icant impacts on patient and survival outcomes, and reduced emer-
gency department (ED) presentations in specific patient populations
have also been demonstrated. Despite these effects, PRO collection
and use has not been systematically adopted as part of routine care in
Australia.
The PROMPT-Care eHealth system was initially developed in 2013
to facilitate PRO data capture from cancer patients, data linkage
and retrieval to support clinical decisions, patient self-management
and shared care. Research has demonstrated the system to be
acceptable, feasible and effective in reducing ED presentation
in subgroups of patients. However, to date, the patients utilising
the PROMPT-Care system have largely been compliant, health-
literate, motivated and able to complete the assessment in English.
Furthermore, although PROMPT-Care achieved full integration
into the electronic medical record, lack of such integrated sys-
tems could be a barrier for widespread adoption of systems like
PROMPT-Care.
Despite the challenges, the potential benefits of well-implemented
PRO systems are significant and cost to the patient and health sys-
tem, having clear, evidence-based, care pathways and actionable rec-
ommendations in response to above-threshold PRO scores, which not
only facilitate PRO integration into the clinical workflow, but can also
reduce variations in care. Identifying and addressing patient needs in
a systematic, timely manner can reduce the overall burden and cost to
the patient and to the health care system.
The PROMPT-Care program was funded by Cancer Institute NSW,
Bupa Health Foundation, SouthWestern Sydney Local Health District,
Wollondilly Health Alliance
The PROMPT-Care team also includes: Geoff P. Delaney, Ivana Dur-
cinoska, Anthony Arnold, Nasreen Kaadan, Andrew Miller, Joseph
Descallar, Orlando Rincones, Sandra Avery, Martin Carolan, Stephen
Della-Fiorentina, KennethMasters,Weng Ng, Tiffany Sandell, Thomas
T. Tran, andMartha Gerges.
58 How canmobilization of health data and
application of AI inform decisionmaking in cancer
care?
Tim Shaw
The University of Sydney, Sydney, NSW, Australia
There are increasingly large volumes of data being collected within
electronic health records and other repositories that include increas-
ingly large volumesof data regarding thedelivery andoutcomesof can-
cer care. The potential to mobilise this data to impact on care delivery
andpatient outcomes is considerable but yet to be fully realised. Key to
this realisation is the engagement of clinical teams and organisations
in the co-creation of systems of clinical engagement including tools
and resources. This presentation will explore key issues that underlie
the successful development of data mobilisation programs. This will
include a presentation of results and findings from the application of
data resources inWestern Sydney LHD including dashboards for clini-
cal teams, linking of data to clinical reasoning in medical oncology and
the use of electronic health data to trigger just in time learning.
59 Issues and limitations that arise with digital
health
TrishWilliams
Flinders University, Adelaide, SA, Australia
Digital health transformationhas thepotential to revolutionisehowwe
deliver healthcare, facilitating improved value-based, patient-centric
care. But, should we be concerned about the impact of digital health
on clinical oncology? What will be the impact of digital health on the
safety and quality? Howmuch disruption will we be able to tolerate?
60 Introduction: End of life care is aboutmore
than euthanasia
Peter Allcroft
Flinders Medical Centre Southern Adelaide Palliative Services, Bedford
Park, SA, Australia
Content not available at time of print.
61 Organisational readiness for legislated
VAD –Reflections on the lessons learnt and
experience gained
Mark Boughey
St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
A dynamic, changing and evolving health care system will always be
influenced and affected by government’s legislated changes. How-
ever, legislation that fundamentally changes clinical practice and chal-
lenges the moral framing of health care professionals’ personal and
professional ways of working and intentions of care brings consid-
erable organisational pressures, challenges and anxieties. At St Vin-
ORAL ABSTRACTS 77
cent’s Hospital Melbourne, at the five months mark since the enact-
ment of the Voluntary Assisted Dying legislation in Victoria, organi-
sational readiness, has proven to be the backbone of working in such
change, helping to contain and work with the stress points, allow
clinical staff to feel supported and help our services navigate these
unchartedwaters. In this presentation I will explorewith you the expe-
riences gained and reflect on lessons learnt that may indeed provide
ideas and understandings for those whose states and territories are
focussing on similar challenges.
62 Voluntary assisted dying: How does
palliative care respond?
HelenWalker
Salhn, Norwood, SA, Australia
How to respond to Victoria’s legislation and other developmental leg-
islative activity in WA, Qld and South Australia has presented chal-
lenges for the palliative care sector. In determining its position, the
Board of PCA has embarked upon a comprehensive process including
an international literature review, international study tour, publishing
of reflections and learnings from this tour, guiding principle develop-
ment and finally the launch of a new position statement on euthanasia
and voluntary assisted dying.
Helen will, as part of this panel, outline this journey the palliative care
sector has been on to inform its position.
63 Experience implementing VAD in Victoria
Speaker TBC
Affiliation, to be confirmed
Content not available at time of publishing
64 Medicines in paediatric oncology – A family
matter
Hayley Vasileff
Women’s and Children’s Hospital, North Adelaide, SA, Australia
Background: Erwinia asparaginase is a chemotherapy medication for
the treatment of patients with Acute Lymphoblastic Leukaemia who
have previously had a hypersensitivity reaction to E. coli-derived
asparaginase. There is little published information regarding the eme-
togenicity of erwinia asparaginase and it is not included in current
international antiemetic guidelines.
Aim and Method: This study retrospectively assessed and compared
the incidence of nausea and vomiting in paediatric patients receiv-
ing intravenous and intramuscular erwinia asparaginase from 2008 to
2017 in a tertiary hospital. Case notes were reviewed for the first
course of erwinia asparaginase for each patient and the data collected
included the dose, infusion time, concurrent chemotherapy medica-
tions, use of anti-emetics, and the incidence and severity of nausea and
vomiting.
Results: Fourteen patients received erwinia asparaginase intra-
venously and 19 patients intramuscularly. Vomiting occurred with 1
or more doses in 57% of patients administered erwinia asparaginase
intravenously compared with only 16% of patients who had intramus-
cular administration. More than 1 antiemetic was administered for
26% and 4% of total doses of intravenous and intramuscular erwinia
asparaginase respectively. There was no correlation between nausea
with or without vomiting and other chemotherapy agents adminis-
tered concurrently for all patients.
Conclusions: In our cohort, nausea and vomiting was a common
side effect of erwinia asparaginase with multiple antiemetics often
required. Erwinia asparaginase administered intravenously had a
much higher incidence of emesis than when administered intramus-
cularly. The incidence of vomiting in these patients suggests that
erwinia asparaginase administered intravenously may be classified as
at least moderately emetogenic, whereas intramuscular doses may be
classified as having low emetogenic potential. These findings should
be validated in other centres and/or prospectively to allow guidelines
to be updated to include recommendations for antiemetics for erwinia
asparaginase.
65 Engaging adolescent and young adult (AYA)
cancer patients: Challenges or opportunities?
Alexandre Chan
1National University of Singapore, Singapore, Singapore
The adolescent and young adult (AYA) population comprises patients
who are at major milestones of their lives with multiple familial and
societal responsibilities and roles, and least expect themselves to be
ill, much less burdened with cancer. In the literature, studies have
highlighted numerous areas that have significant impact on AYA’s
health-related quality of life, including symptom burden, issues of
employment and education, sexual identity and social isolation from
peers. The physical and psychosocial toxicities of disease and treat-
ment are made more challenging by the significant changes and life
events attendant to AYAs. Hence, there is a clear need for dedicated
programs that are designed to address AYA cancer patients’ health
concerns. At National Cancer Centre Singapore which is the largest
ambulatory cancer centre in Singapore, an orientation program that is
designed to target AYA cancer patients has been initiated since 2017.
In this talk, we will discuss the role that an oncology pharmacist plays
in this program, as well as the challenges and opportunities that an
oncology pharmacist faces from this program and what we can learn
from engaging AYA cancer patients.
66 Medicine(s) matter(s) in the older patient:
Understanding, counselling and health literacy
Jenny Casanova
Flinders Medical Centre, Adelaide, SA, Australia
Patients who are older than ever before are now being given
chemotherapy – which was once restricted to under-60s- or
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immunotherapy. Many have challenges relating to cognitive impair-
ment (e.g. delirium and early dementia), and the burden of medication-
related problems renders these issues more complex. Some patients
display little interest in receiving further information about their con-
dition, possibly because they are overwhelmed. Other patients may
have well-meaning family and friends who perform an internet search
but don’t fully comprehend the information they have retrieved.
Numerous papers regarding patient health literacy and comprehen-
sion of medical/pharmaceutical information have been published over
the years, demonstrating that up to 80%of information provided is not
retained by patients and assessing their comprehension of that which
is retained is not straightforward.
This interactive presentation will discuss challenges facing the phar-
macist counselling anolder patientwho is receiving cancer therapy and
associated supportive care medications. Various educative and recall
strategies will be discussed. A ‘triage’ approach can determine the
information patients have already received from other sources and
their retention of this. Consideration may be given to deprescribing
non-essential medications in order to minimise pill burden, but this
needs to be donewith sensitivity.
67 Mastering patient education
LisaMcLean
eviQ, Eveleigh, NSW, Australia
Cancer patients and their carer’s education needs are high. Educa-
tion may be less effective in patients who experience high anxiety
levels secondary to a cancer diagnosis. Lower health literacy adds to
confusion and this cohort of people is vulnerable to inappropriate
information.
A total of 59% of the Australian population aged 15-74 are considered
to have low health literacy levels.1
Low levels of health literacy and health knowledge in patients are asso-
ciated with increased rates of hospitalisation and use of emergency
care, reduced ability to interpret labels and takemedications properly,
reduced ability to interpret health messages and poorer knowledge
about own disease or condition.2
Changing the way health professionals deliver patient information to
respond to differences in patient health literacy levels can lead to pos-
itive change in behaviours, improved health status, reduced anxiety
and improved self-management of treatment-related side effects and
complications.
Simple, practical education strategies such as practicing universal
health literacy precautions, personalising information and the incorpo-
rating the teach-back method are effective in supporting the informa-
tion needs of patients and are easily embedded in clinical practice.
1. Australian Bureau of Statistics.Health literacy, Australia. Belconnen,
Australia: Australian Bureau of Statistics; 2006.
2. AustralianCommissiononSafety andQuality inHealthCare.Health
literacy: taking action to improve safety and quality. Sydney, Aus-
tralia: AustralianCommission on Safety andQuality inHealth Care;
2014.
68 The promise and peril of social media for
clinicians, researchers and patients
Stacy Loeb
New York University andManhattan Veterans Affairs Medical Center, New
York, New York
The use of social media in medicine has rapidly increased. Social net-
works are used by clinicians for many purposes, including clinical case
discussions, professional networking, advertising their practice, and
patient education. Researchers are using social media for recruitment
and dissemination of research, and as a source of data. Patients are
also using social media as a source of information on health conditions,
although there is a significant amount of misinformation. In this lec-
ture, wewill discuss the pros and cons of social media use by clinicians,
researchers and patients.
69 Implementing digital health for assessing
and responding to clinical anxiety and depression
(ADAPT)
Phyllis Butow1, Heather Shepherd1, Joanne Shaw1, Lindy
Masya1, Liebeth Geerligs1, Nicole Rankin2, Jessica Cuddy1,
Fiona Davies1, Haryana Dhillon1
1Psycho-Oncology Co-operative Research Group (PoCoG), The University
of Sydney, Sydney, NSW, Australia
2Research in Implementation Science and e-Health (RISe), Faculty of
Health Sciences, The University of Sydney, Sydney, NSW, Australia
Introduction: Digital health promises to facilitate delivery of clinical
pathways (CPs) through use of automatic processes to minimise staff
burden. The ADAPT Program uses a digital health solution, an online
portal, to implement a CP for anxiety and depression (A/D) in can-
cer patients in 12 NSW Oncology services, tailored to accommodate
local resources, preferences and workflow. This analysis explored the
strategies staff reported using to successfully implement the CP.
Methods: Within a cluster randomised trial where sites implement
ADAPT for 12 months, we gathered quantitative and qualitative data
from all staff prior to ADAPT going live, and at 6 and 12 months, and
interviewed psychosocial staff about iCanADAPT. After eight engage-
ment sessions with each site to tailor the CP and clarify staff respon-
sibilities, staff attend training using the portal. Online education in
screening and assessingA/Dandmaking psychosocial referrals is avail-
able to all staff. An online cognitive behavioural therapy program
(iCanADAPT) was available to patients with mild to moderate A/D.
Local data on ADAPT screening results and processes are made avail-
able to each site.
Results: To date (July 2019), 1305 screening events have been com-
pleted (653 first and 652 repeat screens). Five of six sites who have
completed the study elected to continue using ADAPT in routine care.
Uptake of online training has been low (due to lack of dedicated time)
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as patient referrals to iCanADAPT (due to unfamiliarity with and mis-
trust of online therapy). Staff needed tailored trainingon theportal. Lit-
tle technical support has been required. Staff interviews revealed the
importance of addressing (a) evidence (staff perceptions), (b) context
(culture and staff support) and (c) facilitation (intervention fit, familiari-
sation, engagement and burden).
Discussion: Tailoring and flexibility of intervention content and pro-
cess, and of implementation strategies, are essential to ensure suc-
cessful implementation and long-term sustainability of digital inter-
ventions.
70 Using digital behaviour change tools to help
cancer survivors adopt andmaintain regular
exercise
Camille Short
Faculty of Medicine, Dentistry, and Health Sciences, University of
Melbourne, Melbourne, VIC, Australia
Providing exercise support to cancer survivors is now recommended
as a key cancer recovery strategy. This is reflected in the 2018 position
statement of the Clinical Oncology Society of Australia, which states
that best practice cancer care includes referral to experienced exercise
physiologist or physiotherapist with oncology expertise.
Unfortunately, Australia is currently unable to implement this recom-
mendation equitably at a population level. For many people, access to
exercise physiology and physiotherapy is limited by geographical isola-
tion, limited services and/or inability to pay.
Digital health interventions delivered via apps, websites and wearable
sensors have the potential to improve the scale and scope of exercise
oncology services in Australia. However, innovative research is needed
to embed tailored exercise prescription and supervision options into
digital models of care, and to encourage sustained participation in the
prescribed exercises. This will require multi-disciplinary input, draw-
ing on evidence and theory fromboth exercise and behavioural science
and the lived experience of cancer survivors.
This presentation will showcase several digitally based intervention
models that could be utilised in practice to increase access to multi-
disciplinary exercise support across the cancer care continuum.
71 Web-based psychological interventions for
cancer-related distress
Lisa Beatty
Flinders University, Adelaide, SA, Australia
Aim: Clinically significant psychological distress is prevalent among
30-40% of patients after cancer diagnosis, and impacts on medical,
quality of life and health service outcomes. However, numerous access
barriers to uptake exist, including workforce shortfalls, geography for
those residing rurally and personal preferences/stigma. Online deliv-
ery of cognitive behaviour therapy (CBT) holds promise for overcom-
ing some of the access barriers to conventional therapist-administered
psychosocial interventions in cancer. We conducted a multiphase pro-
gram of research to develop and evaluate a 6-module/6-week online
program (‘FindingMyWay’).
Methods: The programofwork comprised a phase I pre-post feasibility
trial (n = 12); a phase II single site pilot RCT (n = 60); and a phase III
multisite RCT of heterogeneous cancer patients treated with curative
intent (n=191) recruitedbetweenOctober2013andNovember2015,
and randomised to receive either the intervention or attention control.
We then subsequently implemented the program into routine clinical
andcommunitypractice, andcollecteduptakeandadherencedataover
amatched timeframe to the clinical trial.
Results: Phases I and II outcomes supported the feasibility and
potential efficacy of the program. The phase III RCT demonstrated an
uptake rate of 41%, moderate-to-high adherence and high satisfaction
rates (82%). Finding My Way led to reduced health service utilisation
at post-treatment, and improved emotional functioning at 3-month
follow-up. Ongoing implementation has had similar uptake, but lower
adherence than during the clinical trial. FMW is currently being piloted
for feasibility amongwomen receiving endocrine therapy in theUnited
States (n = 12), with data to date suggesting high usage and resulting
improvements in depression symptoms. Our group has recently
developed FindingMyWay-Advanced – an adaptation for womenwith
metastatic breast cancer – which is currently undergoing usability
testing. Updated results of these latest trials will be presented.
Conclusion: This research program demonstrates the promise of web-
based CBT for increasing the reach of psychological therapies after
cancer, but also highlights the current challenges this field faces
regarding ongoing implementation and dissemination.
72 Using virtual reality as a clinical tool
Belinda Lange
Flinders University, Bedford Park, SA, Australia
Virtual Reality involves the use of computer hardware and software
to create a simulated environment that places the user inside a virtual
experience. Virtual reality has potential to be used in a range of clin-
ical areas, offering new opportunities to support and/or enhance cur-
rent assessment and interventionmethods. A brief overview of a range
of clinical virtual reality applications will be presented and discussed.
These examples will demonstrate different ways in which virtual real-
ity technology can be used and encourage clinicians to think about how
technologymay be explored in other settings.
73 Active surveillance (AS) for low and
intermediate risk prostate cancer (PCa): Patterns
of care from theNSWprostate clinical cancer
registry (PCCR)
Chau Bui1, Andrew Brooks2, Claire Cooke-Yarborough1,
Warick Delprado3,4,5, AndrewKneebone6, Manish Patel5,6,7,
David Smith8, Serina Teuss9
1NSWCancer Registry, Cancer Institute NSW, Sydney, NSW, Australia
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2SydneyWest Local Area Health Network, Sydney, NSW, Australia
3Douglass Hanly Moir Pathology, Sydney, NSW, Australia
4University of Notre Dame, Sydney, NSW, Australia
5Macquarie University Hospital, Sydney, NSW, Australia
6University of Sydney, Sydney, NSW, Australia
7Westmead Private Hospital, Sydney, NSW, Australia
8Cancer Council NSW, Sydney, NSW, Australia
9NSWProstate Clinical Cancer Registry, Sydney, NSW, Australia
Introduction: Active surveillance (AS) is an established management
option for low-risk (LR) PCa and is increasing in intermediate-risk (IR)
men, although data on outcomes are limited.1,2 Our data report on pat-
terns of care for LR and IR PCa in NSW.
Methods: Data were obtained for 4833men participating in the PCCR
diagnosed with localised PCa by biopsy, from 2015 to 2018. Partic-
ipation by specialists and hospitals is voluntary. Primary treatments
are recorded for all participants and follow-up data collected where
available. The D’Amico classification (cT-stage omitted due to incom-
plete data) was used to classify LR and IR groups. IR with grade group
(GG) 1-2 were sub-classified as favourable-IR and those with GG 3 as
unfavourable IR. Advanced pathology (AP) was defined as an upgrade
of GG or stage (extraprostatic disease).
Results: Overall, 3343 cases were classified as either LR or IR. Of 942
LRmen, 735 (78.0%)wereprimarilymanagedbyASand140 (14.9%)by
radical prostatectomy (RP). Of those managed by AS, 86 (11.7%) pro-
gressed to active treatment within 2 years. For those whose primary
treatment was RP, 104 (74.3%) had AP. Of 1567 favourable-IR men,
890 (56.8%) had a primary RP – 466 (52.4%) of these cases had AP.
Of the 279 (17.8%) managed by AS, 47 (16.8%) progressed to active
treatment. Of the 834 unfavourable-IRmen, 518 (62.1%)were primar-
ilymanagedbyRP–323 (62.4%)of these caseshadAP.Of the37 (4.4%)
managed by AS, three (8.1%) progressed to active treatment.
Conclusion: Overall, most LR men were managed by AS. The propor-
tion of AS cases progressing to intervention is low in both LR and
favourable-IR groups and negligible for unfavourable-IR men. Where
the primary treatment was RP, AP was seen in the prostate specimen
in themajority of LRmen and half of the favourable-IRmen.
1. Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P, Defining inter-
mediate risk prostate cancer suitable for active surveillance. J Urol
2019; 201(2):292–299.
2. Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw
KW,Nguyen PL,Muralidhar V, Use and earlymortality outcomes of
active surveillance in patients with intermediate-risk prostate can-
cer. Cancer 2019; https://doi.org/10.1002/cncr.32202.
74 Implementation of a lifestyle-based clinical
pathway in daily clinical practice inmen
undergoing androgen deprivation therapy for
prostate cancer
Renée Bultijnck1,2, Anniek Bruggeman3, Barbara Van
Ruymbeke3, StefanieMortier4, Anneleen Raes4, Elke
Rammant1, Martine DeMuynck3, Benedicte Deforche5,6,
Valérie Fonteyne1, Karel Decastecker1, Nicolaas Lumen1, Piet
Ost1,2
1Department of Human Structure and Repair, Ghent University, Ghent,
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Aim: To assess the effect of a lifestyle-based prostate cancer path-
way, incorporated in daily practice, to increase the implementation of
evidence-based strategies tomanage ADT-induced side effects.
Methods: PCa patients receiving ADT for >6 months were referred
to the pathway (ie as standard practice), through a central coordina-
tor. The pathway consisted of a medical screening (ie bone and car-
diometabolic screening) and a rehabilitation program with a super-
vised exercise program (3 months) and referrals to a dietician and a
psychologist. Anthropometric parameters and physical performance
were measured at baseline and after 3 months. Primary endpoint was
physical performance evaluated with the 400-m walk test. Planned
referral target was set at 200 to accomplish a sample size of 120
patients following the exercise program. Ameaningful clinically impor-
tant difference of the 400-m testwas defined as 17 s improvement and
P< .05 was considered statistically significant.
Results: Between January 2015 and June 2018, 200 patients were
referred to the pathway, of which 177 were enrolled (median age 69,
IQR 63-74). The majority (84%) had a good functional status (Karnof-
sky Performance ≥90) at baseline. The indication for ADT was cura-
tive in combination with local therapy for locally advanced PCa in 67%
and palliative for (non)metastatic PCa in 33% of patients. In total, 124
followed the complete pathway. Medical screening indicated a lower
bone mineral density in 51% of the patients and 25% had metabolic
syndrome. After initial referral, 43% choose to receive diet advice and
64% psycho-education. A clinically meaningful performance improve-
ment was observed in patients following the exercise program (282 to
253 s; P < .001). Compliance rate of the exercise program was high
(83%). A total of 10% dropped-out due to medical reasons. After the
3-month exercise program, 81% voluntary continued.
Conclusion: Physical performance improved after following a lifestyle-
based clinical pathway for prostate cancer patients in daily practice.
75 Radiotherapy underutilization in prostate
cancer and its impact on overall survival and local
control, NSW, Australia
Gabriel Gabriel, Michael Barton, Jesmin Shafiq, Geoff Delaney
UNSW, CCORE, Ingham Institute for AppliedMedical Research, Liverpool,
NSW, Australia
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Background: Evidence-based modelling estimates show that 52%
of prostate cancer patients would benefit from radiotherapy at
diagnosis.1-3 Itwasestimated that5-yearoverall survival (OS) and local
control (LC) shortfall due to not receiving RT were 1.1% and 12.4%,4,5
respectively.
Aim: to calculate actual RT utilization rate, estimate shortfall inOS and
irreplaceable LC and identify factors affecting RTU.
Methods: NSWCCR data for prostate cancer patients diagnosed from
2009 to 2011 were linked to radiotherapy, admitted patients, clinical
cancer registry and death datasets. Patients located near State border
where their closest RT facility was outside NSW (cross borders) were
excluded from the analysis. Irreplaceable benefit of RT counted only
where there was no guideline-recommended alternative treatment5.
Results: There were 19 816 prostate cancer patients during study
period. Median age was 67 years, 65% had localized disease, 4% had
distant disease and 30%had unknown stage. Of patientswith localized
disease, 18% received RT, 37% had radical prostatectomy (RP) and 4%
had both RP and RT. A total of 28% of patients had RP alone, 3% had
RP and RT, 20% had RT alone and 49% had neither RP nor RT. Overall,
23% of all prostate cancer patients received RT within 1 year of diag-
nosis. OS and irreplaceable LC person-shortfall were 124 and 1398,
respectively.Univariate andmultivariate analysis showed that younger
patients with loco-regional disease, living in least-disadvantaged areas
and living >100 km of RT facility were predictors for RT underutiliza-
tion. Patients living in least-disadvantaged areas were 33%more likely
to have RP than patients living in most-disadvantaged areas.
Implications: Prostate cancer constituted to 18% of patients diag-
nosed with cancer during study period. Underutilization of RT
increases disease burden on health system due higher risks of local
failure and OS shortfall. Giving RT according to evidence-based
guidelines would probably have prevented 41 early deaths and 466
local failures annually.
76 A comparison of treatment for prostate
cancer between patients diagnosed in public and
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GrahamG. Giles1, JeremyMillar3, Ian Haines4,5
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Aim: To compare prostate cancer treatment for Victorian men diag-
nosed with prostate cancer in public versus private Victorian health
care facilities.
Design: Retrospective study utilising state-wideVictorianCancerReg-
istry data linked to various administrative datasets.
Setting/Participants: Victorian men diagnosed with prostate cancer
between 2011 and 2017 eligible for inclusion (n= 29 813).
Main Outcome Measures: Utilization of prostatectomy (±radiation
therapy) and radiation therapy alone within the first year following
cancer diagnosis.
Results: Comparedwithmendiagnosed in public health services, those
diagnosed in private health services were younger, had fewer comor-
bidities, lived in areas of higher socioeconomic position andweremore
likely to live in major cities. They were alsomore likely to be diagnosed
with lower risk prostate cancer. After adjusting age and the presence
of comorbidities, men diagnosed in private hospitals were more likely
to receive a radical prostatectomy than those diagnosed in public hos-
pitals (44%vs 28%; odds ratio= 2.29; 95%CI, 2.15-2.45) and less likely
to receive radiation therapy alone (11%vs. 20%; odds ratio=0.50; 95%
CI, 0.46-0.54). These differences were consistent across each of the
Gleason score-defined subsets. Although patterns have changed over
time, stark differences remain.
Conclusion: Prostate cancer treatment patterns differ substantially
between men diagnosed in public health services compared with pri-
vate health services in Victoria.
77 Mixedmethods to develop and evaluate a
patient-reported symptom index for usewith
non-muscle invasive bladder cancer patients
Claudia Rutherford1,2, Margaret-Ann Tait1, Daniel S. J.
Costa3,4, Madeleine T. King1, David P. Smith5,6,7, Shomik
Sengupta8,9, Manish Patel10,11
1Faculty of Science, School of Psychology, University of Sydney, Sydney,
NSW, Australia
2Sydney Nursing School, Cancer Nursing Research Unit (CNRU), The
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3PainManagement Research Institute, Royal North Shore Hospital, St
Leonards, NSW, Australia
4SydneyMedical School, Central Clinical School, University of Sydney,
Sydney, NSW, Australia
5Cancer Research Division, Cancer Council New SouthWales, Sydney,
NSW, Australia
6Sydney School of Public Health, University of Sydney, Sydney, NSW,
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7Menzies Health Institute Queensland, Griffith University, Brisbane, QLD,
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Aim: Non-muscle invasive bladder cancer (NMIBC) is a chronic
condition requiring frequent follow-up, endoscopic examinations,
tumour resections, and intravesical treatments. In this clinical context,
patient-reported outcomes (PROs) have enormous potential to inform
treatment assessment and recommendations for NMIBC; however,
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current PRO measures are inadequate for NMIBC because they
lack key NMIBC-specific symptoms and side-effects associated with
contemporary treatments. This study aimed to develop and evaluate
a patient-reported NMIBC Symptom Index (NMIBC-SI) that is accept-
able to patients; reliable, valid, and responsive to treatment effects;
and fit-for-purpose as an endpoint in clinical trials.
Methods:Wedevelopedadraft 104-itemNMIBC-SI througha system-
atic review and interviews with 26 patients and 20 clinicians, and pre-
testedusing cognitive interviews.We thenadministered theNMIBC-SI
to patients on active treatment from nine Australian sites. NMIBC-SI
item responseswere analysed and flagged for exclusion if they had low
prevalence, were conceptually similar, or highly correlated (≥0.50).
Nine urologists reviewed the results and final items for inclusion.
Results: Planned target accrual, n= 220, was reached (178male, mean
age 69.3) representing all risk groups (low 27.7%; intermediate 13.2%;
high 50.9%). More than 80% of participants did not experience 21
items, seven items were highly correlated, and four excluded as >50%
of urologists rated them not directly related to NMIBC treatment
(eg ‘have you had a cough?’). The final 56-item NMIBC-SI includes a
23-item symptom burden scale, two treatment-specific modules, and
three optional function scales.
Conclusions: The NMIBC-SI allows comprehensive assessment of
patients’ self-reported symptom burden and functioning impairment.
A validation studywas commenced in July 2018, recruiting newly diag-
nosed NMIBC patients from 15 centres across four countries. It will
assess key PROs across treatments, disease trajectory (acute to 1-year
survivorship), and patient risk categories. The NMIBC-SI will be suit-
able for use in clinical practice and future clinical trials of treatments
for NMIBC.
78 Treatment decisions among regional
Victorians with urological cancer: A consumer
perspective
Ilana Solo, Yachna Shethia, Michael Leach
LoddonMallee Integrated Cancer Service (LMICS), Bendigo, VIC, Australia
Aim: People with urological tumours such as prostate, kidney and
bladder cancer have many management options, including surgery,
radiotherapy, chemotherapy, active surveillance, watchful waiting and
hormonal therapy. It is recommended that men with prostate cancer
see multiple specialists for information about available management
options.1 This study aimed to assess variation in treatment decisions
between people with urological and non-urological cancers.
Methods: The Victorian Department of Health and Human Service’s
(DHHS’) validated Patient Experience of Cancer Care Survey (PECCS)
was administered at five hospitals2 in the Loddon Mallee region
(LMR). Patients treated with chemotherapy or surgery in 2016-2017
were identified through the Victorian Admitted Episodes Dataset and
assessed against DHHS’ inclusion/exclusion criteria.2 Overall, 1096
surveys were posted to eligible patients, with one reminder sent to
non-responders. In the PECCS section ‘Deciding on Treatment’, the
number (%) of all responders was calculated for each question cate-
gory. Resultswere stratified bywhether patients hadurological cancer,
with inter-group comparisons performed using the chi-square test for
independence. A P-value< .05 was considered statistically significant.
Results: Overall 439 people treated across five LMR hospitals
responded to the PECCS section ‘Deciding on Treatment’ (response
rate = 40%). There were significant differences among cancer types in
the proportions of patients who responded ‘yes’ to the question ‘Were
you involved as much as you wanted to be in decisions about your care
and treatment?’1 (urological: 87% of 71 respondents; non-urological:
75% of 364 respondents) and ‘yes’ to the question ‘Did the health
professionals encourage you to ask questions about your treatment
options?’1 (urological: 89% of 64 respondents; non-urological: 77% of
345 respondents).
Conclusions: More regional Victorian patients with urological than
non-urological cancers were involved in treatment decisions and
encouraged to ask questions about treatment options. Thismay reflect
the relatively wide range of management options available to urologi-
cal cancer patients.
1. Cancer Council Victoria. Optimal care pathway for men with
prostate cancer, 2015. Available online: https://www.cancervic.
org.au/downloads/health-professionals/optimal-care-pathways/
Optimal_care_pathway_for_men_with_prostate_cancer.pdf
2. Department of Health and Human Services. Victorian Cancer
Patient Experience Survey Tool Project, 2018. Available online:
https://www2.health.vic.gov.au/about/health-strategies/cancer-
care/cancer-projects/victorian-cancer-patient-experience-survey-
tool-project
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Background: Ovarian cancer has a5-year survival rate of<45%.Better
overall survival has been shown for women who are able to complete
a greater proportion of their planned chemotherapy. Physical activ-
ity during chemotherapy may reduce treatment-related side-effects
enabling patients to better tolerate chemotherapy and avoid dose
delays or reductions. We aimed to evaluate if physical activity during
chemotherapy or changes in physical activity from pre-to-post diagno-
sis were associated with improved chemotherapy completion rates.
Methods: Women in the Ovarian cancer Prognosis And Lifestyle
(OPAL) Study who received more than three cycles of carboplatin and
paclitaxel first-line chemotherapy and completed the Active Australia
Survey during chemotherapy were included in this analysis (n = 334).
Planned chemotherapy, and dose reductions or delayswere abstracted
from clinical records. Women were asked about time spent in various
types of physical activity in the years before their cancer diagnosis (at
baseline) and in the past week (during chemotherapy). We classified
physical activity during chemotherapy into tertiles of metabolic equiv-
alent of task (MET)minutes and change frompre-diagnosis into largest
decrease (n = 107), smaller decrease (n = 107) and no change (±90
MET-min/week) or increase (n=84). The associations of physical activ-
itywith chemotherapy completion (relative dose intensity [RDI]≥85%)
were assessed using logistic regression, withminimal sufficient adjust-
ment informed by a directed acyclic graph.
Results: Overall 44% of women received ≥85% RDI. We found no
association between level of physical activity during chemotherapy
and chemotherapy completion (odds ratio [OR] = 1.1; 95% CI, 0.6-
1.8 for highest vs lowest tertile). However, compared to women with
the largest decrease from pre-diagnosis, women who maintained or
increased their physical activity were significantly more likely to com-
plete chemotherapy (RDI≥85%; OR= 2.2; 95%CI, 1.2-4.0).
Conclusions: Supporting women to maintain their pre-existing level of
physical activity during chemotherapy for ovarian cancermay improve
chemotherapy completion and in turn overall survival.
80 Development and validation of a
immunotherapy prognostic score (IPS) for
patients with advanced lung cancer treatedwith
immune checkpoint inhibitors
AshleyM. Hopkins1, Ganessan Kichenadasse1,2, Chris S.
Karapetis1,2, Andrew Rowland1, Michael J. Sorich1
1Flinders University, Adelaide, SA, Australia
2Department of Medical Oncology, Flinders Medical Centre, Adelaide, SA,
Australia
Aim: Immune checkpoint inhibitors (ICI) are a significant advance
to the treatment arsenal for advanced non-small cell lung cancer
(NSCLC); however, there initiation is still associated with significant
heterogeneity in survival outcomes. This study aimed to develop
and validate a pre-treatment prognostic tool of survival outcomes in
advanced NSCLC patients treated with ICIs.
Methods: Time-to-eventmodelling techniques including decision-tree,
Cox proportional hazard and random forest analysis were evaluated
to determine the optimal pre-treatment prognostic model using com-
monly available clinicopathological data.Model developmentdata con-
sistedof advancedNSCLCpatients treatedwith atezolizumab fromthe
randomised clinical trials OAK and POPLAR (n = 751). Data from the
single-arm atezolizumab trials BIRCH and FIR (n = 797) were used for
external validation.Overall survival (OS)was the primary outcome and
progression-free survival (PFS) was assessed as a secondary outcome.
Results: Based upon pre-treatment C-reactive protein, lactate dehy-
drogenase, derived neutrophil-to-lymphocyte ratio, albumin, PDL1
expression, performance status, time since metastatic diagnosis and
metastatic sites count, an optimal prognostic tool was defined. The
tool allows the calculation of a personalised Immunotherapy Prog-
nostic Score (IPS). The OS discriminative performance of the IPS was
consistent with a well-performing model in both the development and
validation cohorts (c-index >0.73). The IPS discriminated significantly
different OS probabilities (P < .001), with median OS ranging from
3.4 to greater than 24 months for the upper and lower 15th risk
percentiles, from the OAK and POPLAR trials. Similar findings were
identified for PFS (P < .001), with median PFS ranging from 1.4 to 4.7
months for the upper and lower 15th risk percentiles.
Conclusions: A pre-treatment prognostic tool was developed and val-
idated to identify patient groups with distinctly different survival
probabilities following the initiation of atezolizumab treatment for
advancedNSCLC.
81 Prostate cancer risk factors in the New
SouthWales 45 andUp Study: Family history,
lower urinary tracts symptoms (LUTS) and
diabetes are associatedwith risk of prostate
cancer diagnosis
Visalini Nair-Shalliker1,2, Albert Bang2, Sam Egger2, Karen
Chiam2, XueQin Yu1,2, Manish Patel1, Dianne L. O’Connell2,
Bruce Armstrong1, David P. Smith2
1The University of Sydney, Sydney, NSW
2Cancer Council NSW,Woolloomolloo, NSW, Australia
Aim: The aetiology of prostate cancer (PC) is unclear, with the
few known risk factors being non-modifiable. We examined the
relationships between confirmed and potential risk factors of PC diag-
nosis in the New SouthWales (NSW) 45 and Up Study (n= 267 153).
Methods: Participants were 123 732 men aged ≥45 years recruited
between 2006 and 2009. Data from the 45 and Up Study were
probabilistically linked with (a) NSW Cancer Registry (1994-2013)
by the Centre for Health Record Linkage and (ii) Medicare Benefits
Schedule and Pharmaceutical Benefits Scheme by the Sax Institute
using a unique identifier provided to the Department of Human
Services to identify reimbursements for Prostate Specific Antigen
(PSA) tests and prescriptions for diabetes and urological issues. Men
with history of PC and radical prostatectomy were excluded. We
used multivariable Cox regression analysis, with age as the underlying
variable, to estimate adjusted hazard ratios (HRs), and multivariable
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Joint Cox regression to examine each association by disease spread at
diagnosis.
Results: Of the 91 859 eligible men, 3701 PC cases were diagnosed
between recruitment and 2013. Factors associated with PC diagnosis
included family history of PC (vs none; HR = 1.26; 95% CI, 1.11-1.42),
with analmost twofold increased risk formenwith a father andbrother
with PC diagnosis (vs none; HR = 1.91; 95% CI, 1.35-2.70), LUTS (vs
none; HR = 1.75; 95% CI, 1.50-2.03), benign prostatic hyperplasia (vs
none; HR = 1.45; 95% CI, 1.34-1.57), vasectomy (vs none; HR = 1.11;
95% CI, 1.03-1.20), and erectile dysfunction (vs none; HR = 1.10; 95%
CI, 1.01-1.19). There were associations between PC diagnosis and
treatments for diabetes (vs none; HR = 0.73; 95% CI, 0.67-0.80) and
urinary complications (vs none; HR= 0.84; 95%CI, 0.75-0.94), with no
variation in associations by disease spread at diagnosis.
Conclusion: These results support family history, urinary factors and
diabetes as factors associated with PC diagnosis. The conflicting
associations observed between self-reported urinary issues and pre-
scriptions commonly used to treat these conditions warrant further
investigation.
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Aim: There is uncertainty on the relationship between multivitamin
supplementation use and prostate cancer (PC) diagnosis. For example
the SELECT study found an increased risk of PC in men who regularly
took vitamin E supplements. We explored the relationship between
self-reported supplementation use andPCdiagnosis inmen participat-
ing in the New SouthWales 45 and Up Study.
Methods: Participants were males enrolled in the Sax Institute’s 45
and Up Study between 2006 and 2009 aged ≥45 years at recruit-
ment (n = 123 732/267 153). Data from the 45 and Up Study were
probabilistically linked with NSW Cancer Registry data (1994-2013)
and the Admitted Patient Data Collection by the Centre for Health
Record Linkage, and deterministically linked to Medicare data pro-
vided by the Department of Human Services to obtain Prostate Spe-
cific Antigen (PSA) tests andGPvisits.Menwith a history of PCprior to
recruitment or a radical prostatectomy were excluded. Multivariable
Cox regression analysis with age as the underlying variable was used
to estimate adjusted hazard ratios (HRs) for the associations between
self-reported supplement use and PC diagnosis. We used multivari-
able jointCox regression to examine this association bydisease spread,
adjusting for sociodemographic factors, BMI, physical activity, comor-
bidities and frequencies of PSA tests and GP visits.
Results: A total 91 859 men were eligible for this analysis and of
these 3701were subsequently diagnosedwith PC up to 7.8 years after
recruitment. Overall 45% of the entire cohort of men reported use of
supplements ormultivitamins. Therewas no association between vita-
min and supplement use and PC diagnosis (vs no use; HR = 1.05; 95%
CI, 0.98-1.12). Joint Cox analysis showed no association by disease
spread.
Conclusion: The use of multivitamins in the community is widespread.
There is no evidence for a relationship between supplement intake and
PC diagnosis in this Australian cohort.
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ClaireM. Vajdic1, Oscar Perez-Concha1, Joel Rhee2, Timothy
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Introduction: Little is known about the risk factors for cancer of
unknown primary site (CUP), a high-burdenmalignancy.
Aim: We examined the association among demographic, social and
lifestyle factors, comorbid disease, health service use and risk of can-
cer registry-notified CUP in a prospective cohort of 266 724 people
aged 45 years and over in New SouthWales, Australia.
Methods: A total of 45 and Up Study baseline questionnaire data
were linked by the CHeReL to the NSW Cancer Registry, the NSW
Registry of Births, Deaths and Marriages, and health service records
(NSW Admitted Patients Data Collection, NSW Emergency Depart-
ment Data Collection and Medicare Benefits Schedule, the latter sup-
plied by the Department of Human Services) 4-27 months prior to
diagnosis. Using anested case-control design,we compared individuals
with incident cancer registry-notified CUP (n = 327) to controls ran-
domly selected (3:1) from the general cohort population (n= 981).We
used conditional logistic regression to estimate adjusted odds ratios
(ORs) and 95% confidence intervals (CIs).
Results: In the fully adjustedmodel, risk ofCUP increasedwith increas-
ing age (OR = 1.10, 95% CI, 1.08-1.12 per year), current (OR = 3.42,
95% CI, 1.81-6.47) and former (OR = 1.95, 95% CI, 1.33-2.86) smok-
ing, low educational attainment (OR = 1.69, 95% CI, 1.08-2.64), poor
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compared to excellent self-rated overall health (OR = 6.22, 95% CI,
1.35-28.6), and a personal history of diabetes (OR=1.89, 95%CI, 1.15-
3.10) or cancer (OR = 1.62, 95% CI, 1.03-2.57). Risk of CUP decreased
in those with a personal history of anxiety (OR = 0.28, 95% CI, 0.12-
0.63). Neither tertiary nor community-based health service use inde-
pendently predicted CUP.
Conclusions: Risk of CUP appears increased in people who are older,
more unwell and less well-educated. Several novel associations are
worthy of further investigation to elucidate modifiable risk factors. Of
interest is the implied associationwith low health literacy andwith low
self-rated overall health, whichwarrants exploration to identify oppor-
tunities for earlier cancer diagnosis.
84 Socioeconomic disparities in colon and
rectal cancer survival: Contributions of
prognostic factors in a large Australian cohort
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Aim: To quantify the contributions of various prognostic factors to
socioeconomic disparities in survival for colorectal cancer in a large
Australian cohort.
Methods: The study cohort were participants (267 153) in the 45 and
Up Study (recruited 2006-2009) who were subsequently diagnosed
with colorectal cancer. Socioeconomic status (SES) was defined using
the individual’s educational attainment and a neighbourhood measure
based on place of residence. Study data were linked by the CHeReL
with the NSW Cancer Registry, NSW Admitted Patient Data Collec-
tion, NSW Emergency Department Data Collection and death data
(to 31 December 2015). Treatment information was obtained through
record linkage with hospitals, and Medicare Benefits Schedule and
Pharmaceutical Benefits Scheme claims supplied by the Department
of Human Services. Hazard ratios (HRs) for colorectal cancer-specific
mortality were estimated from Cox proportional hazards regression
and proportions of socioeconomic differences explained by prognostic
factors were quantified.
Results: A total of 1720 participants were diagnosed between recruit-
ment and 31 December 2013: 1174 (68%) colon and 546 rectal can-
cers. Significant colon cancer survival differences were only observed
for neighbourhood SES (P = .033): 95% being explained by disease-
related factors.
Differences in rectal cancer survival were greater with the highest
risk of death for those with lowest SES compared with the highest
(HR = 3.72; 95% CI, 1.86-7.43; P = .0013 for neighbourhood SES;
HR=2.36; 95%CI, 1.44-3.54;P= .0009 for individual SES).Neighbour-
hood SES differenceswere explained by patients’ characteristics (36%)
anddisease-related factors (28%). Patients’ characteristics, treatment-
and disease-related factors explained 33%, 41%and 30%, respectively,
of survival differences by individual SES. Inclusion of all significant
prognostic factors explained 35% and 65% of the survival differences
in neighbourhood- and individual-level SES, respectively, but signifi-
cant disparities remained.
Conclusions: Disease-related factors explained most of the socioeco-
nomic survival disparities in colon cancer. However, substantial differ-
ences remained for rectal cancer after accounting for patients’ charac-
teristics, treatment- and disease-related factors.
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Cancer significantly contributes to the burden of disease in adoles-
cents and young adults (AYA) and has notable implications in terms of
their health care engagement and psychosocial well-being. Added to
this, large numbers of AYA oncology patients in Australia are treated
within adult hospitals, occupying an at-times uninviting landscapewith
the potential for unsatisfactory care experiences and poorer health
outcomes. The emergence of AYA oncology as a specialised field
seeks to redress this historical ‘no man’s land’, championing the cause
for developmentally informed and multidisciplinary clinical services
within age-appropriate treatment environments.
Notwithstanding the progress of recent decades, for a number of AYA
sub-populations cancer care is far from equitable. Over the past 18
months, work undertaken by the Victorian Adolescent & Young Adult
Cancer Service suggests that this is pertinent for the AYA with cancer
who identifies as sexually and/or gender diverse.
This session will outline how the intersection of cancer (and its asso-
ciated treatment and interventions) to an already complex period
of evolving sexuality and gender diversity can result in unique chal-
lenges and risks for the young LGBTI cancer patient. It is relevant
to all health care professionals involved in cancer care, from allied
health clinician to consultant oncologist, and particularly those whose
well-intentioned response may be ‘But I don’t have any LGBTI cancer
patients’. Indeed, consciousor not, this patient cohort are accessingour
oncology clinics, hospital wards, radiotherapy beds and surgical suites,
and it is imperative that we understand and respond to their unique
care needs appropriately.
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Topics include:
• Current knowledge of cancer in AYAs who identify as LGBTI: out-
comes from literature and systematic reviews (updated to August
2019).
• The case for LGBTI + AYA + Cancer = a medically underserved
patient cohort. What we know from the care experiences of similar
patient populations.
• Moving toward an equitable and LGBTI-inclusive model of care:
from clinical governance and physical space to staff education and
training needs.
• Challenges in implementing LGBTI-inclusive principles: reflections
informed from the outcomes and barriers experienced by the Victo-
rian Adolescent & Young Adult Cancer Service
• Development of the first resource for LGBTI young peoplewith can-
cer: an exercise in meaningful consumer engagement and evidence-
informed practice.
• Call to action: next steps in building the evidence base.
86 Cancer and gender-affirming hormone
therapy in transgender individuals
Ada Cheung
1Department of Endocrinology, Austin Health, Heidelberg, VIC, Australia
2Department of Medicine (Austin Health), The University of Melbourne,
Heidelberg, VIC, Australia
Transgender (trans) or gender diverse (TGD) people are estimated to
comprise approximately 0.1%–2% of the population. Likemany human
traits, gender is diverse and has a biological basis. Many TGD people
undergo masculinising or feminising gender-affirming hormone ther-
apyand/or surgery to align their physical characteristicswith their gen-
der identity. Many cancers are known to be sex hormone-dependent
yet uptake of screening by TGDpeople can be challenging. This is often
related to fear of mistreatment in healthcare settings as well as dis-
tress or dysphoria towards secondary sexual characteristics such as
the cervix in trans men.
There are no well-designed studies of sufficient duration to suggest
that gender-affirming hormone therapy increases the risk of hormone-
dependent cancers. Further studies are required. Until then, cancer-
screening guidelines should be no different from the general popula-
tion, based on the presence of organs in TGD people and not based on
gender identity or hormonal therapy status. Trans women can develop
prostate cancer and transmen can develop gynaecological cancers.
In TGDpeoplewho have been diagnosedwith cancer, interactionswith
hospitals and health care professionals can be traumatic. This is under-
standable given that 28% of TGD Australians have experienced dis-
crimination in healthcare settings and many have been refused care.
Respect and sensitivity towards TGD people are required, including
the use of inclusive language in interactions, use of preferred names
(which may differ from hospital identity labels) and use of pronouns
(i.e she/he/they), whilst acknowledging the presence of organs which
may not be in keeping with one’s gender identity. Many breast cancer
or prostate cancer resources, support groups and health services are
not only highly gendered, butmay not be inclusive of LGBTIQ+ individ-
ualswhichneeds tobe considered to ensure all people canbenefit from
healthcare services and cancer organisations.
87 Unmet needs of gender and sexually diverse
people with cancer
Micah Peters
UniSA, Adelaide, SA, Australia
People who are gender and sexually diverse (GSD) experience dis-
proportionate cancer burden in comparison to mainstream popula-
tions. Risk factors, social determinants of health, engagement with
healthcare services, real and anticipated discrimination,maltreatment,
assumptions and poorer health and well-being outcomes mean that
although inclusion ofGSDpeople is growing in someparts of theworld,
true equity is far from achieved.
There is growing awareness of the importance of sexual issues for peo-
ple affected by cancer and an increasing appreciation of the need for
equality in terms of gender and sexuality, but how cancer impacts GSD
people, and how sexuality and gender relates to experiences of cancer
and healthcare are less understood.
Every person should receive the best possible care and treatment
delivered in a way that meets their personal, individual needs. It is
the health professional’s responsibility to ensure that each person is
informed and able to participate and make decisions that are right for
them in relation to that care.
Underpinning effective, safe, appropriate and meaningful healthcare
is communication between staff within healthcare contexts and the
people who they engage with including patients and their significant
others.
GSD people are themselves a diverse group with special, unique needs
in relation to healthcare. Understanding how GSD people’s needs
may not be met in the context of cancer care as well as the ways
which healthcare professionals can address these deficiencies is vital
to improving the care experiences and outcomes of GSD people.
88 Improving outcomes for rural cancer
survivors: Reflections from a Churchill Fellowship
KateM. Gunn1,2
1University of South Australia Cancer Research Institute, Adelaide, SA,
Australia
2Department of Rural Health, University of South Australia, Adelaide, SA,
Australia
To address rural Australians’ inferior cancer survival, more needs to be
known about what drives this disadvantage, and effective strategies
that assist rural people to access optimal cancer treatment and adopt
healthier lifestyles during and after cancer treatment (so that they can
bettermanage side effects and reduce their risk of cancer reoccurring)
are likely to be required.
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As part of a body ofmulti-disciplinary behavioural research focused on
addressing this, and building upon her clinical experience from work-
ing as a Clinical Psychologist with people affected by cancer, as well
as from lived experience from growing up in a remote community, in
April-June 2018 Dr Kate Gunn undertook a Churchill Fellowship to
ascertain pertinent research questions that are likely to translate into
improved understanding of, and better outcomes for, this disadvan-
taged group of cancer survivors. Information was gathered from the
World Rural Health Conference in New Delhi, as well as visits to
Macmillan Cancer Support in London and over 30 universities, cancer
control organisations, treatment centres and non-government organi-
sations across the Netherlands, Canada and the United States, includ-
ing the National Cancer Institute and American Cancer Society, and a
follow-up trip to Scotland in July 2019.
Insights and strategies that have successfully improved rural cancer
outcomes in other contexts will be outlined (eg lay and nurse-led
rural patient navigation, delivery of supportive care interventions via
the internet and telehealth networks), with the view to generating
research interest and new collaborations in Australia, to help progress
this work. Although understanding and addressing rural-urban cancer
disparities using culturally appropriate methods is currently receiving
much attention in the United States, rural Australians affected by can-
cerwould benefit frommore funding andeffort being directed towards
multi-disciplinary, translational research in this field.
89 Implementation of teleoncologymodels
of carewithin health systems
Sabe Sabesan
Department of Medical Oncology, Townsville Cancer Centre, Townsville
Hospital and Health Services, Townsville, QLD, Australia
Teleoncology models have been established as safe, cost-effective
and acceptable way of enhancing rural and regional access to can-
cer care closer to home. They enable clinical consultations, delivery
of chemotherapy under direct supervision (Tele-chemotherapy) and
recently conduct of clinical trials (Tele-trials).1,2 By shifting special-
ist services to rural and regional areas, these models enhance rural
and regional service delivery capabilities. All levels of governments
have made significant investments to embed telehealth/teleoncology
as routine practice. Although uptake has exponentially increased over
the last 5 years, we as a country could do better given that the dispar-
ity in access and outcome for rural, regional and Indigenous patients
remain wide. At local level, frontline clinicians and managers need to
use implementation science principles to ensure all aspects of imple-
mentation including stakeholder engagement are covered. Atmanage-
ment levels, appropriate key performance indictors need to be applied
for accountability and adequate resources need to be allocated for
sustainability.3 Clinicians and clinical managers may gain extra confi-
dence to navigate the health systems by familiarizing themselves with
negotiation skills and ‘clinician levers’.
1. Sabesan et al, Enhancing chemotherapy capabilities in rural hos-
pitals: implementation of a tele-chemotherapy model (QReCS)
in North Queensland, Australia, Journal of Oncology Practice
2018,14(7): e429–e437 (https://doi.org/10.1200/JOP.18.00110)
2. Australasian Teletrial model: A national guide for implementation,
Clinical Oncology Society of Australia, Sydney, 2016.
3. Sabesan S and Kelly J, Perspective: Benefits of telehealth are
many: It is time to implement as core business, Med J Aust
2015;202(5),231–232.
90 Delivering the best andmost
technologically advanced treatment for cancer
patients regardless of their address
Michael Penniment
Royal Adelaide Hospital, Adelaide, SA, Australia
Establishing a facility to provide radiation therapy is expensive. Rural
and suburban patients should expect cancer care equal to the best
treatment in theworld. For radiation therapy this treatmentwill always
be based in a centrewith aminimumof $5million equipment andmany
cancer care professionals to staff the facility and provide care. There is
a trade off of distance to travel for such care versus the need to focus
expertise in centres of excellence.
Proton therapy is the extreme end of this equation.
The Australian Bragg Centre (ABC) has commenced construction in
Adelaide. The cost of the centre is more than $100 million and the
expertise required to deliver the care draws upon expertise developed
internationally over many years.
Howdowe integrate the comprehensive care of a cancer patient, deliv-
ering excellence throughout the country yet making low volume high
cost treatments accessible.
“Accessible” is more than the PATS for transport costs, it is training
all health care providers to recognize options, perhaps to participate
actively in planning the care and certainly the follow up.
We have 2 years to develop a coordinated scheme to make the Bragg
centre a truly national facility for everyone.
The COSA members are invited to contribute to planning care path-
ways and all aspects of care delivery, training needs and opportunities,
linkages to provide care to our region and research opportunities in
medicine and science. There will also be need to define which patients
will benefit most from particle therapy and the role of national guide-
lines, and to advocate for research in areas where the role of particle
therapy is yet to be defined.
Guidance in the ABCwork in each of these areas will be presented.
91 Contemporary cancer care coordination:
Better rural patient outcomes
Peggy Briggs
WACountry Health Service, Gosnells, WA, Australia
Western Australia Country Health Service (WACHS) comprises seven
regionswith five of themhaving aRegional CancerCentre (RCC). RCCs
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provide a comprehensive range of treatments close to home; however,
country people still need to travel to Perth to access complex and spe-
cialised cancer diagnostic and/or treatment services. The tyranny of
vast distances WA people have to travel adds to the complexity of
ensuring they get the right treatment, in the right place, at the right
time. Country people have an increased risk of falling through the
gaps and get lost navigating the large and fragmented tertiary health
systems. The Rural Cancer Nurse Coordinator bridges these gaps by
being an available point of contact that facilitates timely and appropri-
ate access to care for cancer patients across Western Australia. Case
studies describe how Cancer Care Coordination supports rural people
in Western Australia access equitable, evidence-based cancer care as
close to home as possible.
92 Why a roadmap is needed for digital health
in cancer care – A consumer perspective
Chris Christensen
Cancer Voices South Australia, Adelaide, SA, Australia
Communication and easy to access information, support and resources
are critical components of living with and self-managing a cancer
diagnosis. The world of digital applications offers great potential for
improving current approaches and supporting cancer survivors as they
monitor and self-manage their illness in partnership with health pro-
fessionals. With a growing demand for digital applications, consumers
and health professionals need to be confident that such applications
are credible and effective. A roadmap with underlying fundamental
principles is needed to ensure that the applications can be assessed,
amongst other elements, for their quality, evidence base, fit for pur-
pose and security so that consumers living with cancer can have confi-
dence in using digital technology to monitor progress and self-manage
their cancer and be assured this will be of benefit.
This presentation aims to set the scene for development of the Aus-
tralian Digital Health in Cancer Care Roadmap by introducing issues
for the implementation of digital health in cancer care and the need
for a digital health roadmap, from the perspective of a consumer living
with cancer.
93 Finding the evidence: Do stakeholder views
reflect literature priorities for digital health?
EmmaKemp1, Joshua Trigg2, Patricia A. H.Williams3, Lisa
Beatty1,4,2, Haryana Dhillon5, AnthonyMaeder3, Chris
Christensen6, VinceMcCauley7, Bogda Koczwara1,4
1College of Medicine and Public Health, Flinders University, Adelaide, SA,
Australia
2Cancer Council SA, Adelaide, SA, Australia
3Flinders Digital Health Research Centre, Flinders University, Adelaide, SA,
Australia
4Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders
Medical Centre, Adelaide, SA, Australia
5School of Psychology, University of Sydney, Sydney, NSW, Australia
6Cancer Voices South Australia, Adelaide, SA, Australia
7Telstra Health, Sydney, NSW, Australia
Aim: Despite strong consumer advocacy in cancer, little is knownabout
consumer preferences regarding implementation of digital health
technologies in cancer care. This study aimed to compare issues for
implementationof digital health in cancer care identified by consumers
and other stakeholders with issues identified through a systematic
meta-review of international literature, in order to inform the priority-
setting process for developing the Australian Digital Health in Cancer
Care Roadmap.
Methods: A systematic meta-review of international literature (Jan-
uary 2013-July 2018) was conducted with data extracted by two inde-
pendent reviewers on barriers, enablers, needs and opportunities for
implementation of digital health in cancer care. Concurrently, consul-
tation on implementation of digital health in cancer care was held
via focus groups and interviews with stakeholders to identify barri-
ers, enablers, needs and opportunities specific to the Australian con-
text. Consultation emphasised consumers (people with a history of
cancer/cancer caregiving, and health care professionals using digi-
tal health). Review and consultation data were thematically analysed
(framework analysis).
Results: Analysis of 93 reviews of digital health in cancer care
and consultation with 51 stakeholders, including people with a
history of cancer/cancer caregiving (14), health care professionals
(nine), researchers (six), developers (six), non-government cancer care
organisation representatives (six) and government/policy represen-
tatives (10), indicated 20 themes. Although literature focused on
websites, online interventions and mHealth, stakeholders often dis-
cussed electronic health/medical records. Compared with literature,
stakeholders were less focused on evidence and theory, and more
often raised issues of ease of use/integration, coordination, dispar-
ities, access, privacy/security and confidentiality and participatory
design.
Conclusions: Althoughvalidity, credibility and safetyof digital health in
cancer care are important to Australian stakeholders, issues for imple-
mentation raised in consultation centred on practical issues of ‘how to’
implement in ways that improve access and efficiency of cancer care.
94 Developing a roadmap for digital health
in cancer in Australia
Bogda Koczwara1, EmmaKemp1, Joshua Trigg2, Lisa Beatty1,
Haryanna Dhillon3, AnthonyMaeder4, Chris Christensen5,
VincentMcCauley6, Patricia A. H.Williams1
1Flinders University of South Australia, Adelaide, SA, Australia
2The Cancer Council of South Australia, Adelaide, SA, Australia
3University of Sydney, Camperdown, NSW, Australia
4Flinders University of South Australia, Adelaide, SA, Australia
5Cancer Voices SA, Adelaide, SA, Australia
6Telstra Health, Telstra, Adelaide, SA, Australia
Aim: As digital technologies are increasingly adopted in cancer care,
there is a need for a systematic approach to development and
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application tomaximise benefits andensure equity of access.However,
strategic frameworks for implementation of digital health in Australia
are not cancer specific. Additionally, there is a need for any cancer-
specific framework to reflect consumer-driven priorities. This study
aimed to identify stakeholder (including consumer) priorities to inform
the Australian Digital Health in Cancer Care Roadmap.
Methods: Priority action items were developed through meta-review
and stakeholder consultation, across five categories: (a) design and
development; (b) adoption and integration; (c) governance and evalu-
ation; (d) specific digital interventions; and (e) research gaps. Following
expert panel review, stakeholders including consumers and other end-
users of digital health applications responded to two rounds of Delphi
consensus survey, indicating (a) level of priority for each item and (b)
appropriate time frames for achieving each item. Data were analysed
using frequencies, mean ranks and Kendall’s Concordance Coefficient.
Results: A total of 29 stakeholders responded to Round 1 and 23 to
Round 2.Most highly ranked priorities included: end-user involvement
in design and development; increased quality and usability of digital
technologies;monitoring access to, engagementwith, anduseof digital
technologies; facilitating two-way communication between patients
and health professionals; developing a research strategy to identify
and address research gaps and reflecting consumer-identified priori-
ties in research. Stakeholders identified the appropriate time frame for
achievingmost priorities to be short term (up to 2 years).
Conclusions: Stakeholder-identified priorities reflected in the Aus-
tralian Digital Health in Cancer Care Roadmap indicate consumer and
other end-user preferences for increasedquality/valueof digital health
technologies and increased involvement and engagement in develop-
ment and use of digital technologies in cancer care. The Roadmap pro-
vides strategic directions for and implementation of digital health in
Australian cancer care.
95 National digital health strategy for every
cancer patient – Connecting the dots
Angela Ryan
Australian Digital Health Agency, Sydney, NSW, Australia
Digital information is the bedrock of high-quality healthcare. The ben-
efits for patients are significant and compelling: hospital admissions
avoided, fewer adverse drug events, reduced duplication of tests, bet-
ter coordination of care for people with chronic and complex condi-
tions and better-informed treatment decisions. Digital health can help
save and improve lives.1
Safe, Seamless and Secure, Australia’s National Digital Health Strategy,
was developed following a national consultation with consumers, clin-
icians, government, researchers and industry. Throughout the consul-
tation, the Australian community was clear about what it expects from
healthcare services, today and in the future. Australians want a health
systemwhich puts people first – givingmore choice, control and trans-
parency. They want better access to mobile digital health services for
the whole community – not just those who are experienced users of
new technology. They want their health information to be confidential
and secure, protected from cyber criminals and from any unauthorised
access2.
The strategy identified seven strategic priority outcomes to be
achieved by 2022:
1. Health information that is available whenever and wherever it is
needed;
2. Health information that can be exchanged securely;
3. High-quality data with a commonly understood meaning that can
be usedwith confidence;
4. Better availability and access to prescriptions and medicines infor-
mation;
5. Digitally enabled models of care that drive improved accessibility,
quality, safety and efficiency;
6. Aworkforce confidently using digital health technologies to deliver
health and care; and
7. A thriving digital health industry delivering world-class innovation.
The symposium will be an opportunity to discuss these priorities in
more detail, Australia’s progress against these priorities and specifi-
cally how they relate to cancer care – in particular, how they relate to
the Australian Digital Health in Cancer Care Roadmap.
1. https://conversation.digitalhealth.gov.au/sites/default/files/adha-
strategy-doc-2ndaug_0_1.pdf
2. Ibid
96 A comprehensive approach to high-quality
patient educationmaterials: The beyond five
experience
Joe Jabbour1, Haryana Dhillon2, Heather Shepherd2, Puma
Sundaresan3, ChrisMilross4, Jonathan Clark5
1The University of Sydney, Camperdown, NSW, Australia
2Psycho-Oncology Cooperative Research Group (POCOG), The University
of Sydney, Camperdown, NSW, Australia
3Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead,
NSW, Australia
4Department of Radiation Oncology andMedical Services, Chris O’Brien
Lifehouse, Camperdown, NSW, Australia
5Sydney Head and Neck Cancer Institute, Chris O’Brien Lifehouse,
Camperdown, NSW, Australia
Background: Information available for patient use is complex, pep-
pered with medical jargon and requires a high reading ability to
understand.
Aim:Our aim is todescribe a comprehensive,methodological approach
to developing patient-centred education materials using the Beyond
Five website as an exemplar.
Methods: The following stepped approach was taken in developing
a comprehensive information site for head and neck cancer (HNC)
patients:
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1. Identification of existing information sources
2. Gap analysis to determine unmet information needs of patients and
health care providers (HCP)
3. Development of content which involved adaption of existing mate-
rials and newmaterials to address gaps
4. Content expert review of material
5. Health literacy expert review of material
6. Website interface development and testing with experts and
patient advocates
7. Iterative revisions to content, user interface and information gaps
8. Usability testing of specific disease information by patients
9. Recommendations for revision
Results: A total of 597 HNC patients and 112 HCP were surveyed
demonstrating need for information in coping with psychological dis-
tress, sexual health and availability of support groups. Development
of content for 10 HNCs was completed with an expert panel includ-
ing clinicians and health literacy experts. Information about preven-
tion, diagnosis, treatment, side effects and recovery into survivorship
was incorporated. Development testing identified the need to layer
information and provide it in downloadable, printable factsheet for-
mats. Website usability analysis in 18 patients demonstrated a pref-
erence for video content, particularly patient stories. Most patients
found the website informative and could navigate to complete specific
tasks; however, simplificationof theuser interface andnavigationwere
required. All patients would revisit the website for accurate informa-
tion about their HNC.
Conclusion: A structured comprehensive approach to developing
patient educationmaterials delivers improved information support for
patients, caregivers and HCP. Maintaining information and ensuring it
is evidence based remains an ongoing challenge.
97 Facilitating effective family carer
engagement in cancer care: Development of the
eTRIO educationmodules
Ilona Juraskova1, Phyllis Butow1,2, Rachael Keast1, Frances
Boyle3,4, Daniel Costa5, Michael Jefford6, Judy Kay7, Bogda
Koczwara8, AnnieMiller9, RachaelMorton10, Christobel
Saunders11, Penelope Schofield12,6, Sandra Turner13, Kate
White14, Patsy Yates15, Rebekah Laidsaar-Powell1
1Centre for Medical Psychology and Evidence-based Decision-making
(CeMPED), The School of Psychology, The University of Sydney, Sydney,
NSW, Australia
2Psycho-oncology Co-operative Research Group (PoCoG), The University of
Sydney, Sydney, NSW, Australia
3School of Medicine, The University of Sydney, Sydney, NSW, Australia
4Patricia Ritchie Centre for Cancer Care & Research, Mater Hospital,
Sydney, NSW, Australia
5PainManagement Research Institute, The University of Sydney, Sydney,
NSW, Australia
6Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
7School of Computer Science, The University of Sydney, Sydney, NSW,
Australia
8Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, SA,
Australia
9Cancer Council NSW, Sydney, NSW, Australia
10NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW,
Australia
11UWAMedical School, University ofWestern Australia, Perth, WA,
Australia
12Department of Psychology, School of Health Sciences, Faculty of Health,
Arts and Design, Swinburne University, Melbourne, VIC, Australia
13Westmead Clinical School, The University of Sydney, Sydney, NSW,
Australia
14Cancer Nursing Research Unit, The University of Sydney, Sydney, NSW,
Australia
15Queensland University of Technology, Brisbane, QLD, Australia
Aim: Family carers play an important role in cancer care. However,
many carers report feeling disempowered and ill-equipped to support
patients. Our group published the evidence-based ‘TRIOGuidelines’ to
improve clinician’s engagement with carers and management of chal-
lenging situations in the cancer setting. To facilitate implementation
of these guidelines into clinical practice, we have developed two novel
online education modules: for oncology clinicians (eTRIO) and for can-
cer patients and carers (eTRIO-pc).
Methods: The eTRIOmodules were based on extensive prior research
by our group (systematic reviews, qualitative interviews, consulta-
tion analyses and Delphi consensus guidelines). Draft module content
was iteratively reviewed by an expert advisory group involving aca-
demic/clinical experts (n= 13) and consumers (n= 5). User experience
testing of the modules was completed by clinicians (n = 5), patients
(n= 5) and carers (n= 5).
Results: Both programs utilise interactive web-technology to pro-
mote learners’ engagement and uptake of key skills. The clini-
cian module includes nine professionally produced short films (with
embedded trigger activities) modelling effective clinician behaviours.
Reflective practice is encouraged via self-assessments and clinical sce-
narios. The patient-carer module includes three professionally pro-
duced films which model key carer skills (such as advocating for
a patient’s unmet needs), as well as experiential content provided
via video messages from consumers and clinicians. Interactive activ-
ities such as a consultation question list builder are also included.
A national RCT is currently evaluating the effectiveness of the com-
bined modules in improving: (a) carer involvement in consultations, (b)
stakeholders’ self-efficacy in clinician-patient-family communication,
(c) patient/carer psychosocial outcomes and (d) healthcare costs.
Conclusions: The eTRIO programs have been rigorously developed to
meet the needs of clinicians, patients, and carers in improving effective
and useful carer involvement. The interventions aim to shift the status
of informal carers from an underserved, vulnerable and ill-equipped
population to being confident, informed and supported partners in
cancer care.
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98 Assessing the gaps in experience and
knowledge of Australian Primary Health Care
Professionals (GPs), in treating and caring for the
increasing number of Australian neuroendocrine
tumour (NET) patients
Simone Leyden1,2, Meredith Cummins1, KateWakelin1
1The Unicorn Foundation, Blairgowrie, VIC, Australia
2International Neuroendocrine Cancer Alliance (INCA), Boston,
Massachusetts
Aim: Conservatively, the incidence of patients diagnosed with NETs
annually is 7/100 000; however, the prevalence of patients living with
NETs is higher (30-40/100 000) making it the second most common
gastrointestinal malignancy after colorectal cancer. Patients are living
longer, however, with impaired quality of life. Management of debil-
itating symptoms such as diarrhoea, fatigue, anxiety and flushing is
complex and heterogeneous. With >60% having metastatic disease at
diagnosis, transition to community delivery of SSAs, average travel of
300 km to NET COEs leading to reliance on GPs, we wanted to eval-
uate their needs in education, in the diagnosis and ongoing treatment
and care of NET patients.
Method: FromNovember 2018-August 2019, the Unicorn Foundation
encouraged NET patients to nominate their treating GP to participate
in a21-questiononlineor paper survey.Questions ranged fromdiagno-
sis and initial symptoms, interactions with NET specialists, educational
needs and education delivery preferences.
Results: A total of 77 GPs have been nominated, with a return rate
of 46% (35). A total of 72% reported that patients had consulted
them prior to diagnosis; however, only 5% suspected a NET. Present-
ing symptoms included abdominal pain, weight loss, fatigue, diarrhoea,
flushing and nausea. CT and ultrasound were the most common inves-
tigations,with colorectal-surgeonandgastroenterologist referralmost
frequent, followed bymedical-oncologist. A total of 84% of GPs stated
their patients had been presented to aMDT,with 75%ofGPs receiving
reports after consultations.
Education needs identified clinical-presentation, medical-
management, pathophysiology/epidemiology, hormonal syndromes,
somatostatin analogue therapy, symptom management, psychosocial,
nutrition and supportive care as rating highly. Delivery preferences
included online e-modules/webinars, conference workshops and
face-to-face sessions.
Conclusions: With only 5% of GPs suspecting a NET diagnosis, the
results of this vital survey will provide the foundations for much
needed education modules to be made available to GPs. A pilot of this
programwill begin late 2019.
1. 2018/2019 Unicorn Foundation GP survey Dasari A, et al. JAMA
Oncol. 2017; https://doi.org/10.1001/jamaoncol.2017.0589.
99 Development and pilot testing of a
low-literacy decision aid about reproductive
choices for younger womenwith breast cancer
Michelle Peate1,2, Nipuni Ratnayake Gamage1,2, Alice
Hucker1,2, Sian Smith3, Kate Stern2,4, Lesley Stafford2, Laura
Chin-Lenn2,5, Kerry Shanahan5, Sabine Braat1, Martha
Hickey1,2; the aLLIAnCE Collaborative Group1
1University of Melbourne, Parkville, VIC, Australia
2RoyalWomen’s Hospital, Parkville, VIC, Australia
3University of NSW, Randwick, NSW, Australia
4Melbourne IVF, Melbourne, VIC, Australia
5Royal Melbourne Hospital, Parkville, VIC, Australia
About 50% of women lack the skills and capacity to access, under-
stand and use health information effectively. Of concern are young
women with breast cancer who are facing potential treatment-
induced infertility with low health literacy (LHL). These women need
access to high-quality and accessible information in order to make
informed oncofertility decisions. Current decision support in fertility
preservation is not appropriate for LHL groups.
Aim: To develop an online LHL oncofertility decision aid (DA) for
younger women with breast cancer and pilot test it among 30 Aus-
tralian women previously diagnosedwith breast cancer.
Method: The DA was developed using LHL principles. Women who
werepremenopausal (18-40years) at diagnosis (6monthsup to5years
ago) of early stage breast cancer were recruited from the Royal Mel-
bourneHospital, theRoyalWomen’sHospital and throughBreastCan-
cer Network Australia. Participants were asked to complete survey 1,
review the DA and complete survey 2.
Results: Twenty-six women enrolled and completed survey 1; 23 com-
pleted survey 2. Mean age was 37 years, mean age at diagnosis
was 34 years, and 27% had LHL. Most (92%) had planned on hav-
ing children or were unsure at diagnosis. Most (92%) recalled hav-
ing an oncofertility discussion. All participants thought the DA was
clear, good at giving information, useful, very easy to read, would have
been helpful at the time of diagnosis, and 91% would recommend it
to others. Knowledge scores significantly increased pre/post DA by a
mean of three points (95% CI, 2.2-3.7; P < .05). No significant differ-
enceswere seen in knowledge improvementbetweenhigh/low literacy
groups.
Conclusion: The DA was well received and significantly increased
knowledge in women across low and high literacy groups. These data
suggest that the DA is an equitable way to provide oncofertility sup-
port across health literacy levels; however, a further evaluation is
needed.
100 A goodmanufacturing practice training
experience at the Princess Alexandra Hospital,
Brisbane
Marissa I. Ryan1, Joan E. Semmler1, Christine V. Carrington1,2
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1Pharmacy Department, Princess Alexandra Hospital, Brisbane, QLD,
Australia
2School of Pharmacy, University of Queensland, Brisbane, QLD, Australia
Background: The Sterile Production Centre (SPC) at the Princess
Alexandra Hospital (PAH) is one of the few hospital-based production
facilities in Queensland.Manufacturing parenteral cancermedicines is
personalised and requires high precision – doses are manufactured at
the individual patient level, dependent upon patient parameters and
protocol. TheClinicalOncology Society of Australia (COSA)Guidelines
for the Safe Prescribing, Dispensing and Administration of Systemic
Cancer Therapy1 clearly outline the requirement for pharmacy staff
knowledge, competence and adherence to relevant standards in order
toprovide safe andquality aseptic compoundingofmedicinal products,
such as chemotherapy. Furthermore, the Pharmacy Board of Australia
requires pharmacy staff to undertake Continuing Professional Devel-
opment (CPD) activities as part of becoming competent in complex
compounding.2
Description: A perceived GoodManufacturing Practice (GMP) knowl-
edge and competence gap in the PAH’s Cancer Pharmacy team was
identified. CPD opportunities for formal GMP training are limited due
to the specialised nature of the service.
Action: Training provider SeerPharma delivered a bespoke eight-
moduleGMPcourse over 2days to22pharmacists andpharmacy tech-
nicians with varying levels of experience. Course modules included:
operating and managing a clean room, environmental monitoring, and
aseptic principles. Modules incorporated tests, exercises and discus-
sions to assess understanding of course objectives.
Evaluation: Attendees completed a survey consisting of 10 statements
measured against a 6-point Likert scale. Results indicate increased
knowledge across all module outcomes. For the majority of attendees,
actual knowledge before the training was less than their perceived
knowledge.
Implications: The benefits of the GMP training course included
increasedGMPknowledge and competence, diversificationof skillmix,
and the creation of an SPCaudit tool tomeasure compliancewithGMP
standards. Above all, the training contributed towards governance and
expected enhanced quality and safety in the personalised delivery of
sterile production services at PAH.
1. Carrington C, Brown-West L, Cameron K,DiakosC, Griffiths T,
Kelly A, et al. COSA guidelines for the safe prescribing, dispensing
and administration of systemic cancer therapy. Sydney: Cancer
Council Australia. Available from: https://wiki.cancer.org.au/aus
tralia/COSA:Cancer_chemotherapy_medication_safety_guidelines
[cited 2019May 10]
2. Pharmacy Board of Australia. Guidelines on compounding of
medicines. 2017 Aug. Melbourne: Pharmacy Board of Australia.
Available from: https://www.pharmacyboard.gov.au/Codes-Guide
lines.aspx [cited 2019 Feb 13].
101 Advanced cancer patient preferences
for return ofmolecular profiling results
Megan Best1,2,3, Phyllis Butow1,2, Ilona Juraskova1, Jacqueline
Savard4, BettinaMeiser5, David Goldstein5, Mandy Ballinger6,
Chris Jacobs7, Nicci Bartley1, Grace Davies1, David Thomas6,
Barbara Biesecker8, Kathy Tucker5, Timothy E. Schlub1,
Ainsley Newson1
1Univeristy of Sydney, Camperdown, NSW, Australia
2The Psycho-oncology Cooperative Research Group, Univeristy of Sydney,
Sydney, NSW, Australia
3Sydney Health Ethics, Sydney, NSW, Australia
4Deakin University, Geelong, VIC, Australia
5UNSW, Sydney, NSW, Australia
6Garvan Institute of Medical Research, Sydney, NSW, Australia
7University of Technology, Sydney, NSW, Australia
8RTI International, Washington, DC
Aim: Research evidence ismixed regarding cancer patient preferences
for receiving tumourmolecular profiling (MP) results. This study aimed
to discern preferences for return of MP results in patients who have
recently agreed to undergo genomic testing.
Methods: We conducted a mixed-methods study to explore can-
cer patients’ views on which MP results they would like to receive.
The planned accrual target was reached with 1299 advanced cancer
patients undergoing MP and completing questionnaires at the time of
consent. A subset of patients (n = 20) participated in semi-structured
interviews which underwent thematic analysis.
Results: Response rate was 92%. Most (96%) participants wanted
to receive MP results that could guide further treatment for their
advanced cancer. Sixty-four per cent wanted to access MP results
which would not inform treatment, and 60% wanted to learn about
germline findings. Participants with children (Exp(B) = 2.28; 95% CI,
1.09-4.76; P < .05) or with a first degree relative diagnosed with can-
cer (Exp(B)=2.37; 95%CI, 1.17-4.80;P< .05)weremore likely towant
to be informed about gene variants that ‘can guide treatment’. In terms
of being informed about gene variants that ‘cannot guide treatment’,
rural/remote patients were more likely than urban patients to want
these results (Exp(B)= 0.45; 95%CI, 0.28-0.72; P< .01).
Twomain themes were identified in the interview transcripts: (a) ‘Can-
cer is the focus’, which conveyed the priority of identifying therapies
and fear of non-findings, and (b) ‘Trust in clinicians’, where participants
relied on their clinicians tomanage the process.
Conclusions: Themajority of advanced cancer patients undergoingMP
prioritised results which would lead to treatment options and trusted
their oncologists tohelp themnavigate the results returnprocess.Con-
cerns were related to receipt of non-findings.
102 Who should access germline genome
sequencing? Amixedmethods study of patient
views
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Megan Best1,2, Phyllis Butow1,2, Chris Jacobs3, Jacqueline
Savard4, Barbara Biesecker5, Mandy Ballinger6, Nicci Bartley1,
Grace Davies1, Christine E. Napier6, Amelia E. Smit1, David
Thomas6, Ainsley J. Newson1
1Univeristy of Sydney, Camperdown, NSW, Australia
2The Psycho-oncology Cooperative Research Group, Univeristy of Sydney,
Sydney, NSW, Australia
3University of Technology, Sydney, NSW, Australia
4Deakin University, Geelong, VIC, Australia
5RTI International, Washington, DC
6Garvan Institute of Medical Research, Sydney, NSW, Australia
Aim: Implementation of any new medical test, including germline
genome sequencing (GS) to inform cancer risk, should take place only
when a test is effective, ethically justifiable and acceptable to a popula-
tion. Little empirical evidence exists on patient views regarding GS for
cancer risk.
Methods: Participants with a likely genetic basis for their cancer and
their blood relatives were recruited to undergo GS and invited to com-
plete questionnaires at the time of testing. A subset also participated
in qualitative interviews about their views regarding access to GS to
detect cancer risk, which were analysed by thematic analysis.
Results: The planned accrual target was reachedwith 536 participants
(response rate of 92%). Forty participants were interviewed before
saturation was reached, with no refusals. Probands and relatives had
similar views on access to GS. Significantly more participants thought
that if available, GS should be offered to their ‘relatives’ (91%) com-
pared with GS being offered to ‘everyone’ (66%) (a difference of 25%;
95% CI, 20-31%; P < .001). Similarly, more participants thought that
‘anyone who requests it’ should have the GS (91%) than ‘everyone’
(66%) (a difference of 25%; 95% CI, 21-31%; P < .001). Males were
less likely than females to think that relatives should have access to
GS (Exp(B) = 0.43; 95% CI, 0.19-0.96; P = .039). Rationales for these
views elicited during interviews reflected maximising the sound use of
resources. Challenges to introducing community screening via GS to
limit cancer burden were raised, including the current limits of science
and individual ability to copewith uncertain results.
Conclusions: Participants undergoingGS supported cancer risk testing
for thosewith a family history of cancer but were concerned about the
challenges of designing and implementing a population-based GS can-
cer screening program.
103 Key findings from the ColoREctal
Well-Being (CREW) study, a 5-year longitudinal
study of people living with and beyond colorectal
cancer
Claire L. Foster1, Sally J.Wheelwright1, Lynn Calman1,
Samantha C. Sodergren1, Amanda Cummings1, Jane D.
Winter1, Amy E. Din1, Deborah R. Fenlon2, PeterW. Smith1;
Members of the Study Advisory Committee1
1University of Southampton, Southampton, Hampshire, UK
2University of Swansea, Swansea, UK
Aim: People living with and beyond colorectal cancer (CRC) form the
largest group of cancer survivors that includes men and women but
knowledge about recovery from CRC in terms of health and well-
being is limited. The ColoREctal Well-Being (CREW) study is the first
study toprospectively recruit a representative sample ofCRCpatients,
carry out the first comprehensive assessment pre-treatment and fol-
low up longitudinally over 5 years to explore the impact of treatment
on health andwell-being.
Methods: CRC patients from 29 UK cancer centres received ques-
tionnaires at baseline (pre-surgery), 3, 9, 15, 24, 36, 48 and 60
months. Quality of life (QOL), self-efficacy, mental health, social sup-
port, affect, socio-demographics, clinical and treatment characteristics
were assessed. Data were analysed using trajectory analysis and mul-
tivariable regressions (linear and logistic).
Results: A representative cohort of 872 non metastatic CRC patients
participated. Around 30% had poor psychosocial outcomes and this
persisted to 5 years. Baseline psychosocial factors (particularly self-
efficacy and depression) were more important than disease stage and
location of tumour in determining those most likely to have health and
well-being problems over the next 5 years. Risk factors for poor out-
comes throughout the follow-up were depression, low self-efficacy, a
lack of perceived social support, comorbidities that limit an individual’s
typical daily activities and unmet needs.
Conclusions: CREW provides robust evidence that psychosocial fac-
tors, such as self-efficacy, are important predictors for longer term
well-being and health outcomes of CRC patients. We call for early
assessment and intervention, including assessment of depression
and confidence to manage illness-related problems and limiting co-
morbidities, from diagnosis onwards. Early assessment would identify
thosemost likely to need support and has the potential to reduce need
and improve outcomes throughout treatment and beyond.
104 Reducing cancermalnutrition –What is
happening in Victoria?
Belinda Steer, Jane Stewart, Jenelle Loeliger
Peter MacCallum Cancer Centre, Victoria, VIC, Australia
Aim: Cancer malnutrition prevalence has been reported in Victoria
biennially since 2012. The aim of the 2018 cancer malnutrition point
prevalence study (PPS) was to determine the prevalence of malnutri-
tion for adult inpatients and ambulatory patients receiving chemother-
apy and/or radiotherapy.
Methods: A PPS of adult patients with cancer was conducted at multi-
ple Victorian health services between July and August 2018. TheMal-
nutrition Screening Tool and ICD-10-AMmalnutrition definition were
used to determine the risk and presence of malnutrition, respectively.
Results: A total of 19 sites recruited 1462 oncology patients into the
study (n = 319 inpatients, 22%). Four hundred sixty (31%) patients
were at risk of malnutrition, with an overall malnutrition prevalence
of 15% (n = 220). This is a reduction in malnutrition prevalence in 2
years from 23% reported in the 2016 PPS and an overall reduction
94 ORAL ABSTRACTS
of 16% over 8 years. Inpatients had a higher prevalence compared to
ambulatory patients (29% vs 11%) and upper gastrointestinal (UGI)
and lung cancer tumour streams had the highest prevalence (39% and
21%, respectively). Of those patients that were identified as malnour-
ished, only 65%were receiving dietetic care at the time of the study.
Conclusions: The 2018 cancer malnutrition PPS indicates that the
state-wide cancermalnutrition prevalence rate in Victorian health ser-
vices has reduced in both the inpatient and ambulatory settings over
the previous 2 years. Improvements are still needed in the UGI, lung
and colorectal tumour streams where malnutrition prevalence is mod-
erate, but patient volume is high. These results will continue to inform
both local and state-wide approaches to address the burden of cancer
malnutrition.
105 SQiD: Can a single question help clinicians
identify delirium in hospitalised cancer patients?
Megan B. Sands1,2, Swapnil Sharma1,2, Sanja Lujic3, Lindsay J.
Carpenter4, AndrewHartshawn6,5, Jessica T. Lee6,5, Megan E.
Congdon7, AngusM. Buchanan8, Meera Agar9, Janette L.
Vardy6,5
1The Prince ofWales Hospital, Randwick, NSW, Australia
2POWClinical School, University of New SouthWales, Kensington, NSW,
Australia
3Centre for Big Data in Health, University of New SouthWales, Kensington,
NSW, Australia
4Psychological Medicine Centre, Oxford University Hospitals NHS
Foundation Trust, Oxford, UK
5SydneyMedical School, University of Sydney, Darlington, NSW, Australia
6Concord Cancer Centre, Concord Repatriation General Hospital, Sydney,
NSW, Australia
7Prince ofWales Hospital, Randwick, NSW, Australia
8EmergencyMedicine, Hunter New EnglandMedical Service, Gosford,
NSW, Australia
9Cardiovascular and Chronic Care, University of Technology, Sydney, NSW,
Australia
Delirium has poor patient outcomes, more so where diagnosis is
delayed or missed. Detection tools aid delirium identification but are
not always used. We tested the SQiD (Single Question in Delirium)
against psychiatrist diagnosis.
Methods: Patients admitted to either of two comprehensive cancer
centres, in Sydney, Australia, were prospectively screened. Admissions
of 24 h or less, or for chemo or radiotherapy only, were excluded. The
SQiD ‘Doyou feel that [patient’s name] hasbeenmore confused lately?’
posed to the, relative, carer or friendwas tested against clinical diagno-
sis by a consultant psychiatrist (PD) based on Diagnostic and Statistic
Manual criteria. The primary endpoint was negative predictive value
(NPV) of the SQiD versus PD; secondary analysis comprised NPV of
SQiD versus NPV of the short Confusion AssessmentMethod (CAM).
Results: Between May 2012 and July 2015, the SQiD plus CAM was
applied to 122 patients; 73 had SQiD plus psychiatrist interview.
Median agewas 68 years, 46%were femalewithmedian length of hos-
pital stayof 12days (interquartile range5-18days).Major cancer types
were lung (19%), breast (12%) and prostate (11%). A total of 70% of
participants had stage 4 cancer. A total of 9% had cerebral metastasis.
Agreementwas similar between the SQiD (NPV=74%; 95%CI, 67-81;
kappa = 0.32) and CAM (NPV = 72%; 95% CI, 67-77; kappa = 0.32),
comparedwith psychiatrist interview. The CAM identified only a small
number of delirious cases but allwere truepositives.Of the16patients
with hypoactive delirium, six were identified on SQiD, the CAM identi-
fied one. The SQiD had higher sensitivity than CAM (44% [95%CI, 41-
80] vs 26% [95%CI, 10-48]).
Conclusion: The SQiD, administered byward clinical staff, was feasible
and demonstrated favourable psychometric properties. The SQiD has
potential to set a new standard of care as a delirium detection tool for
hospitalised cancer patients.
106 Do cancer survivors change their diet after
cancer diagnosis?
Sim Yee (Cindy) Tan1,2,3, Lauren J. McGrath2, Hoi Y.Wong3,
Jane Turner1,4, Kim Kerin-Ayres1,5, Haryana Dhillon4, Ashanya
Malalasekera1,6, Janette Vardy1,4,6
1Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia
2The University of Sydney, Sydney, NSW, Australia
3Nutrition and Dietetics Department, Concord Hospital, Concord, NSW,
Australia
4Centre for Medical Psychology and Evidence-based Decision-making,
University of Sydney, Sydney, NSW, Australia
5Nursing Services, Concord Hospital, Concord, NSW, Australia
6SydneyMedical School, University of Sydney, Concord, NSW, Australia
Lifestyle factors such as healthy diet and regular exercise may reduce
risk of cancer and/or cancer recurrence. We aimed to investigate
dietary changesmadeby cancer survivors including vegetable and fruit
intake since cancer diagnosis.
Method: Datawere collected prospectively from cancer survivorswho
had completed potentially curative cancer treatment and attended
Sydney Cancer Survivorship Centre (SCSC) clinic between September
2013 and July 2019. Survivors were asked to complete a food ques-
tionnaire including questions about dietary changes since diagnosis
and a 3-day food dairy. A dietitian assessed patients’ fruit and veg-
etable intake based on their food dairy.
Results: A total of 572 survivors consented: 68% were female, mean
age 57 (range 18-90) years. Main cancer types were breast (41%),
colorectal (31%) and lymphoma (17%). More than half (n = 299/518)
reported making dietary changes. Based on 298 descriptions, the
most common dietary changes were increased vegetable intake
(35%), reduced/avoiding red meat (23%), increased fruit intake (19%),
reduced/avoiding sugar or foods high in sugar (18%), reduced alco-
hol intake (13%) and reduced high-fat food products (13%). Less than
10% of survivors chose to avoid dairy, reduce/avoid seafood, decrease
coffee intake and/or start ‘juicing’. An average of two dietary changes
were made, with some making up to seven dietary changes. Adher-
ence to special diets was reported by 8% of survivors, including inter-
mittent fasting, low carbohydrate diet and vegan. Only a small pro-
portion of survivors, 53 of 280 (19%) and 110 of 282 (39%), met the
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recommended serves for vegetable and fruit intake, respectively. Some
alcohol intake was reported by 233 of 487 (48%) survivors.
Conclusion: The majority of survivors modified their diet after cancer
diagnosis; some modifications appear to be beneficial, whereas others
were extreme and not evidence based. Future studies are needed to
investigate the best approach to providing dietary information to sup-
port survivors tomake appropriate dietary changes.
1. https://www.wcrf.org/dietandcancer
107 Cancer epidemiology across age
spectrums (incidence, prevalence, burden and
issues of disease)
David Roder
University of South Australia, Adelaide, SA, Australia
Over the 30 years from 1985 to 2015, numbers of cancer-diagnoses
in Australia increased about 2.5-fold and numbers of cancer deaths
increased about 1.7-fold. Corresponding increases for older Aus-
tralians aged 75+ years were higher at about 3.1-fold for cancer diag-
noses and 2.6-fold for cancer deaths. As a result, case loads have
included progressively higher proportions of older people. This is illus-
trated by the increased percentage of cases in the 75+ age rangewhich
increased from 24% in 1985 to 30% in 2015 for cancer diagnoses and
from 33% to 52% for cancer deaths. These trends indicate the scale of
increase in case load on cancer services over the past 30 years, which
has beenmuch greater among older than younger cases.
Little respite is anticipated. Comparedwith the percentage increase in
population size projected in Australia over the next 30 years, a 51%
higher percentage increase in cancer diagnoses and a 71% higher per-
centage increase in cancer deaths are projected, largely due to change
in agedistribution. Cancer case complexitywill increasewith increased
concentration of cancers in older Australians due to increased preva-
lence of age-related frailty and co-morbidity and age-related reduc-
tions in treatment effectiveness. Also due to ageing, a higher propor-
tion of cases will experience a loss of living independence.
There will need to be an evidence-based response that includes
stronger RCT evidence for treatment planning for older patients and
broader health service data for monitoring clinical and health-system
performance. Evidence-based planning and monitoring of limited
resource availability will be paramount. The implications of increased
cancer load on capacity of clinical services are significant andwill need
to be factored into health-service planning. For holistic care, commu-
nity services including home support will need to be strengthened if as
expected, more people with cancer andmore facing death from cancer
will be living alone.
108 Beyond age and gender –What about
race?
LisaWhop
Menzies School of Health Research, Brisbane, QLD, Australia
Around the world, the changing face of oncology is being driven
by scientific inquiry helping to deliver personalised medicine and
care. Despite cancer mortality decreasing in the last decade for non-
Indigenous Australians, cancer mortality has increased for Indige-
nous Australians. Understanding the multifactorial reasons for these
diverging mortality trajectories requires examining the epidemiologi-
cal understanding of age, gender and cancer type, but also demands
close examination and dismantling of our understanding of race and
racism and how it is operationalised in the Australian health care sys-
tem. Understanding culturally safe care is critical in delivering person-
alised care at the population level for Indigenous Australians and will
allow us the paradigm shift so urgently required.
109 The emergence of youth cancer services as
a uniquemodel of care
Michael Osborn
Royal Adelaide Hospital, Adelaide, SA, Australia
Akey driver in establishing adolescent and young adult (AYA) oncology
as a unique discipline was the observation that conventional health-
care models often struggled to adequately address the complex medi-
cal, psychological, and social issues experienced by patients aged 15 to
25 years. Over the past decade, considerable progress has been made
in Australia and other developed countries to develop novel models
of care to deal with the unmet needs of young people with cancer.
The principles underpinning these models include patient and family-
focused care informed by an understanding of normal AYA develop-
ment, enhancing existing adult or paediatric cancer services to meet
the needs of AYA, and promoting collaboration between paediatric and
adult oncologists. Commonelements of AYA cancer care include estab-
lishing an AYA multidisciplinary team that integrates medical and psy-
chosocial care, efforts to centralize complex care, providing access and
equity for all AYA, promoting clinical trials, and helping facilitate tran-
sition to healthy survivorship. Internationally, a number of successful
organizational approacheshaveevolved,witha consistent themebeing
that local program development depends on resources, infrastructure,
and assessment of unmet needs within the region. In Australia, there
is now a network of five Youth Cancer Services across the country.
Funded by the federal and state governments and CanTeen Australia,
these YouthCancer Services have enabled themajority of 15 –25-year
old Australians with cancer to access AYA-specific multidisciplinary
care. In addition to providing tailored psychosocial support, these ser-
vices have aimed to optimise access to oncofertility services, enrol-
ment on clinical trials, and co-ordination of the complex care needs of
young people during active treatment and the transition to survivor-
ship. The development of national networks has also provided oppor-
tunities for shared learning and approaches to evaluation.
110 Older cancer patients: The evolution of
geriatric oncology and palliative care
Jane Phillips
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University of Technology Sydney, Broadway, NSW, Australia
A combination of population ageing, the increasing number of older
people diagnosed with cancer and living with other comorbidities and
the complexity of cancer treatments is challenging healthcare sys-
tems and clinicians to consider new models of care. There is an urgent
need for greater collaboration between oncology, geriatrics, primary
and palliative care providers to ensure that the needs of this pop-
ulation are adequately addressed. This presentation will provide an
overview of the current evidence supporting the integration of geri-
atric medicine principles and cancer-focused geriatric assessment to
enhance thedelivery of best evidence cancer care for older adults,with
palliative care needs. It will explore the evidence supporting the inter-
facebetweenpalliativemedicine, geriatrics, oncology andprimary care
and the tools and resources that contributes to better care outcomes
for this population.
111 Why should I bother? The clinical benefits
of germline genetic testing for a cancer patient
Nicola Poplawski
Royal Adelaide Hospital, Adelaide, SA, Australia
Tumour genetic testing identifies the unique combination of somatic
mutations within a cancer clone. This tumour profiling provides clin-
icians with knowledge about the metabolic and molecular pathways
to target when making treatment decisions, improving the care of
individual patients. Germline genetic testing, on the other hand, can
improve the clinical care of not only the individual cancer patient but
also their genetic relatives. This talkwill focus on the utility of germline
genetic testing for patients and their families (why to test), how to
effectively target testing to the patients who are most likely to ben-
efit from testing (who to test), gene panel selection (what to test)
and the key discussion points when obtaining informed consent (how
to test).
112 I did it – Nowwhat? Benefits and
limitations of NGS testing
Karin S. Kassahn, Lesley Rawlings
SA Pathology, Adelaide, SA, Australia
Next-generation sequencing (NGS) has greatly reduced the cost of
genetic testing. As a result, more cancer patients now have access to
testing and this has improved clinical care. Nevertheless, the tech-
nology is still evolving and so are the applications and uptake of NGS
testing in various settings. Aswith any new technology, there is a steep
learning curve for both, the laboratory and the clinical services that
use the results of testing. This talk will present a number of clinical
cases that illustrate the power and limitations of NGS testing for
cancer patients. Using clinical case studies, we will discuss mosaicism,
ethnicity and variants of uncertain clinical significance, virtual gene
panels and their design. We will give examples of why a genetic test
result can be different from what was expected and how testing may
change practise.
113 Closing the loop –Managing the patient
and the family
Debra Trott
CALHN (Central Adelaide Local Health Network) RAH site, Adelaide, SA,
Australia
Genetic testing and the identification of disease causing (pathogenic)
mutations is enabling individualised cancer risk advice to be given
to individuals and their genetic relatives. This talk will include a
number of clinical cases to illustrate a number of real world issues
including:
• Disclosure of results
• Residual cancer risk calculation
• Family risk notification and cascade/predictive genetic testing
• The importance of family communication formaximising the clinical
utility of genetic testing for inherited cancer predisposition
114 Recent advances in psychosexual
interventions for prostate cancer
AmandaHutchinson
Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, SA,
Australia
The psychological burden associated with prostate cancer and its
treatment is increasingly recognised by clinicians, patients and their
families. Men with prostate cancer are reported to have a higher
risk of anxiety, depression and suicide than their peers. Thus, routine
screening for distress, anxiety and depression is an important part
of clinical care. The extent to which screening can improve outcomes
for men with prostate cancer is dependent on the provision of quality
evidence-based interventions that are responsive to their needs. In
this presentation, recent evidence for psychosocial interventions
will be considered from published reviews to pilot studies. Attention
will be given to the intervention types, modes of delivery (online vs
face-to-face) and settings of effective interventions.
115 Management of supportive care issues
associatedwith systemic treatment of prostate
cancer
Alexandre Chan
National University of Singapore, Singapore, Singapore
Worldwide, prostate cancer is the second most commonly diag-
nosed of all cancers in men. Systemic treatments such as hormonal
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therapy, chemotherapy and immunotherapy are frequently prescribed
to patients diagnosed with prostate cancer. Despite excellent treat-
ment outcomes associated with these treatment modalities, these
treatments are often associatedwith amyriadof long-termside effects
that could impact the health status of prostate cancer survivors.
In this talk, we will discuss the management of common late toxi-
cities that are associated with systemic prostate cancer treatment,
which include bone, cardiac, metabolic and cognitive side effects, as
well as the implications on care coordination for a prostate cancer
survivor.
116 Continence challenges faced by prostate
cancer survivors
Kerry Santoro
Southern Adelaide Local Health Network, Bedford Park, SA, Australia
Prostate cancer is the most commonly diagnosed cancer in Australian
men and it is estimated that in 2019 there will be 19 508 new cases
of prostate cancer diagnosed in Australia. The risk of being diagnosed
with prostate cancer increases with age, peaking at age groups 65-69
and 70-74. From 1986 to 2015, the 5-year survival from prostate
cancer improved from 59% to 95% indicating men are living longer
following a prostate cancer diagnosis (Australian Institute of Health
andWelfare, 2019).
This presentation will look at prostate cancer as a disease, treatment
options and side effects, with a focus on the impact of urinary incon-
tinence post prostate cancer treatment. Living with incontinence is
a major source of emotional stress, which can affect a man’s social
interactions and his sense of self-worth. It can be very debilitating,
soul destroying and financially draining. It is vital that men are well
counselled before prostate cancer treatment regarding side effects
and their possible impact on quality of life.
Managing incontinence followingprostate cancer treatmentwithmed-
ication or behavioural techniques in conjunctionwith pelvic floor exer-
cises can provide some benefit, but some men may have to look to
surgical intervention in an attempt to improve their urinary control.
Again, careful counselling and sound clinical judgmentmust be applied
whendetermining anappropriate approach tomanagingurinary incon-
tinence following treatment for prostate cancer.
118 Risk-stratifiedmelanoma prevention
and screening
Anne E. Cust
Sydney School of Public Health &Melanoma Institute Australia, The
University of Sydney, Sydney, NSW, Australia
Despite Australia’s highmelanoma incidence rate, there is currently no
population melanoma screening program and no systematic approach
to melanoma prevention and early detection. International clinical
practice guidelines vary considerably in screening and surveillance
recommendations for high-risk individuals. The US Preventive Ser-
vices Task Force has recommended that future research on skin can-
cer screening should focus on evaluating the effectiveness of targeted
screening in those considered to be at higher risk, and risk stratifica-
tion is likely to be an important component of future melanoma pre-
vention and screening services in Australia. This talk will present the
latest evidence on melanoma risk assessment, tailored approaches to
prevention, screening and surveillance, and the benefits and potential
challenges of this precision approach.
119 Prostate cancer screening: Confusion,
controversy and enlightenment
Michael O’Callaghan1,2,3
1Flinders University, Adelaide, SA, Australia
2University of Adelaide, Adelaide, SA, Australia
3Urology, Flinders Medical Centre, Bedford Park, SA, Australia
Prostate Cancer: Prostate cancer is the most common cancer among
Australian men. It is estimated that in 2019 there will be 19 000 new
cases in Australia and 3500 deaths from the disease. Newly diagnosed
patients have a 95% relative survival at 5 years with early stage diag-
nosis being beneficial.
Screening: PSA testing for prostate cancerwas introduced toAustralia
in the late 1980s, resulting in increased incidence (86/100 000 males
in 1988 to 184/100 000 in 1994). These new cases were typically low-
grade disease and a decline in mortality was observed (44/100 000 in
1993, 35/100 000 in 1999). Approximately 80% of men treated for
prostate cancer will experience negative effects such as urinary incon-
tinence or erectile dysfunction.
Practice Recommendations: In Australia, RACGP guidelines do not
recommend routine PSA screening. NHMRC guidelines (2016) rec-
ommend that the risks and benefits of PSA screening are discussed
with men who can then make an informed decision; but do not rec-
ommend a population screening program. The UK national screen-
ing committee (2016) recommended against a systematic screening
program and the US preventive services taskforce (2018) recom-
mended that information about the benefits and harms of PSA testing
is provided to patients. The European Association of Urology (2019)
advocates for structured PSA screening using individualised screening
intervals.
Evidence Limitations: The evidence basis for PSA screening comes
from five randomised controlled trials. All trials have been conducted
outside of Australia and some show low compliance rates and high
contamination. A further obstacle to interpreting these trials is time.
Prostate cancer has a long natural history, with mortality outcomes
typically occurring after 15+ years. As follow-up time increases, the
benefits of screening grow, while treatment options and triaging tools
improve.
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Conclusions: Current evidence supports a benefit for PSA testing, par-
ticularly in the context of individualised screening intervals.
120 Cancer screening – A policy perspective
Sanchia Aranda
Cancer Council Australia, Sydney, NSW, Australia
Australia currently has three national cancer screening programs in
breast, cervical and bowel cancer. There are also new opportuni-
ties and challenges as interest in risk stratified screening intensifies
in breast cancer, following on from some level of risk stratification
already embedded in the cervical screening renewal. Policy issues also
arise from the bowel screening program related to both low invest-
ment in public education about participation and in the context of de
facto and expensive use of colonoscopy. Calls for targeted screening
in lung and liver cancer for high-risk individuals intensify and further
challengepopulation approaches. The emergenceof blood tests for cir-
culating tumour cells and thepotential of these tests tobedirectlymar-
keted to consumerswill also set new challenges for policy and practice.
These challenges occur in the context of lower than desired participa-
tion in existing screening programs. This paper will explore the policy
implications of these emerging issues in screening and will consider
the role researchers and non-government organisations play in build-
ing the evidence base and creating the arguments for changes to exist-
ing programs and the funding of new programs. This policy debate sits
against a backdrop of low investment in cancer prevention and early
intervention compared to investment in treatments for late-stage dis-
ease in a health system struggling for economic sustainability.
121 Challenges in demonstrating the value
of cancer screening
Jonathan Karnon
Flinders University, Bedford Park, SA, Australia
Evaluations of cancer screening programs tend to focus on the early
detection of cancer, but assessing the value of cancer screening
requires the estimation of the consequences of early detection. Such
consequences include improved health outcomes and reduced down-
stream costs, but also potentially increased costs due to the over treat-
ment of precancerous lesions that would not have affected patients
within their remaining lifetime. It is generally not feasible to conduct
clinical trials that are able to detect such long-term consequences and
so decision analytic modelling methods are commonly used to pre-
dict expected costs and patient outcomes. Such models also allow the
comparison of the costs and effects of alternative potential screening
programs to a no screening scenario.
This talk will introduce the types of data and modelling methods used
to assess the value of cancer screening, using applied cancer screening
models to illustrate the methods and model outputs and their use to
inform funding decisions.
122 Dosemodifications for taxane
chemotherapy induced peripheral neuropathy: A
survey of Australianmedical oncologists
Wanyuan Cui1, Julia Shingleton2, Aisling Kelly2, Liesel Byrne2,
Lisa King2, Phillipa Smith2, Craig R. Lewis4,3, Brian N. Stein5,
Jeremy Shapiro6, Chris Karapetis7,8, RachelWong1,9
1Medical Oncology, Eastern Health, Box Hill, VIC, Australia
2Cancer Institute NSW, Everleigh, NSW, Australia
3University of New SouthWales, Randwick, NSW, Australia
4Medical Oncology, Prince ofWales Hospital, Randwick, NSW, Australia
5Medical Oncology, Adelaide Cancer Centre, Kurralta Park, SA, Australia
6Medical Oncology, Cabrini Haematology and Oncology Centre, Malvern,
VIC, Australia
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Aim: Chemotherapy-induced peripheral neuropathy (CIPN) is a recog-
nised adverse effect of taxane chemotherapy that affects long-term
quality of life. Evidence for dose modification of antineoplastic ther-
apy for CIPN is limited. eviQ is an online resource providing cancer
treatment protocols with dose modification guidelines formulated by
expert opinion and evidence-based review. These guidelines recom-
mend omitting taxanes for G3 CIPN, 25% dose reduction for the first
incidence of G2 CIPN and 50% dose reduction if G2 CIPN persists.We
sought to evaluate how rigidly Australian medical oncologists adhered
to eviQ recommended dosemodifications for taxane-related CIPN.
Methods: An online survey was distributed to over 400 MOGA and
eviQ medical oncology reference committee members. Toxicity grad-
ing was based on CTCAE version 5.0.
Results: A total of 66% of 153 respondents (response rate 35%)
followed the eviQ CIPN recommendations. A total of 14% of respon-
dents would stop or dose reduce taxane chemotherapy when patients
experienced G1 CIPN, 89% with G2 and 100% with G3. Reasons for
not following the eviQ recommendations included: dose modification
according to the individual clinical situation (23%), too aggressive
(22%) and too conservative (8%).
Overall 92% of respondents would continue the current taxane dose
on first occurrence of G1CIPN. Fewer clinicians continued the current
dose on the second (63%), third (42%) or fourth recurrence (42%). At
first occurrence of G2 CIPN, 27% would continue the current taxane
dose, 65% would dose reduce and 8% would cease. On second recur-
rence, only 11% would continue the current dose, and 5% on the third
and fourth recurrences.
Conclusions: This survey demonstrated that clinicians readily dose
modified taxane chemotherapy for CIPN and the majority of respon-
dents followed the eviQ recommendations. The eviQ recommenda-
tions were not changed. Notable deviations from the eviQ guidelines
included dose reduction for G1CIPN and no dose reduction at the first
occurrence of G2 CIPN.
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123 BEACONCRC: A randomized, 3-Arm,
phase 3 study of Encorafenib (ENCO) and
Cetuximab (CETUX) with or without Binimetinib
(BINI) versus choice of either Irinotecan or
FOLFIRI plus Cetuximab in BRAFV600E-mutant
metastatic colorectal cancer
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BRAF V600E mutations are identified in ≤15% of metastatic colorec-
tal cancer (mCRC) patients and confer a poor prognosis. In patient’s
refractory to initial therapy, ORR to standard chemotherapy and
biologic combinations are generally<10%, with median PFS and OS of
∼2 and 4-6months, respectively.
The BEACONCRC Study (NCT02928224) was amulticentre, random-
ized, open-label, 3-arm, phase 3 study evaluating ENCO + CETUX
+/− BINI (triplet or doublet combination) versus investigator’s choice
of Irinotecan or FOLFIRI + CETUX (control) in patients with BRAF
V600E-mutant mCRCwho had failed one or two prior regimens in the
metastatic setting. Primary endpoints were OS and ORR (blinded cen-
tral review) for the triplet versus control arm; secondary endpoints
included OS for the doublet versus control arm, as well as PFS, dura-
tion of response and safety.
A total of 665 patientswere randomly assigned to receive: triplet com-
bination (n= 224), doublet combination (n= 220) or control regimen
(n= 221). Median OS was 9.0 months (95% CI, 8.0-11.4) for the triplet
versus 5.4 months (95% CI, 4.8-6.6) for control regimens (HR: 0.52;
95%CI, 0.39-0.70; P< .0001). ConfirmedORR (blinded central review)
was 26% (95% CI, 18-35%) for the triplet versus 2% (95% CI, <1% to
7%) for control (P< .0001). MedianOS for the doublet was 8.4months
(95% CI, 7.5-11.0) (HR vs control, 0.60; 95% CI, 0.45-0.79; P = .0003).
Adverse events (AEs) were consistent with prior trials with each com-
bination. AEs ≥grade 3 occurred in 58%, 50% and 61% of patients in
the triplet, doublet and control arms, respectively.
ENCO + BINI + CETUX improved OS and ORR in patients with
BRAF V600E-mutant mCRC compared with current standard of care
chemotherapy and had a safety profile consistent with the known
safety profile of each agent. This targeted therapy regimen should be
a new standard of care for this patient population.
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Aim: Concerns regarding neurocognitive function (NCF) after whole
brain radiotherapy (WBRT) exist. This trial compared WBRT ver-
sus observation (OBS) following local treatment in patients with one
to three melanoma brain metastases. Here, we present the NCF
results.
Methods: Objective NCF was evaluated in English speakers at base-
line, then two-monthly. Primary outcome was change in delayed recall
at 4 months on the Hopkins Verbal Learning Test-Revised (HVLT-R).
Other NCF tests were also performed. A mixed linear model calcu-
lated the effect of intervention on relative raw scores, adjusted for
baseline score and time. Cognitive failure was determined by Reli-
able Change Index; global cognitive impairment was defined as Global
Deficit Score >0.5. Analysis was by intention-to-treat, with nominal
two-sided significance level 5%.
Results: A total of 207 patients were randomised (100WBRT and 107
OBS) from 31 sites in three countries. NCF testing was completed
by 73 WBRT and 70 OBS patients at baseline. Patients had similar
characteristics.
OBS group had greater relative improvement in HVLT-R from base-
line at every time point. At 4 months, delayed recall declined 2.7%
frombaseline inWBRTbut improvedby20.9% inOBS; overall adjusted
average intervention effect 23.6% (95% CI, 9.0-38.2%; P = .0018). Sig-
nificant effects were seen between groups at 4 months in HVLT-total
recall and delayed recognition; the overall adjusted average interven-
tion effects were 8.3% (95%CI, 0.4-16.1%; P= .0397) and 25.0% (95%
CI, 14.3-35.7%; P < .0001), respectively. There were no significant dif-
ferences in time to cognitive failure (log-rank P = .44) or proportions
with global cognitive impairment at 4months (OBS32%vsWBRT53%;
P = .11). Cognitive decline in T-scores, baseline to 4 months, of 1 SD in
at least oneNCF test occurred in 24 of 38 (63%)WBRT versus 11 of 25
(44%)OBS (P= .13).
Conclusion: Cognitive impairment was common in both groups but
greater memory decline occurred in patients receivingWBRT.
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Aim: The role of adjuvant WBRT in MBMs is controversial. This ran-
domised trial compares WBRT with Obs after local treatment of 1-3
MBMs.
Methods: The primary endpoint is distant intracranial failure (DIF)
within 12 months of randomisation. The a priori neurocognitive func-
tion (NCF) endpoint is Hopkins Verbal Learning Test-Revised (HVLT-R)
delayed recall at 4 months and is reported separately. Secondary end-
points include local failure (LF), overall survival (OS) and global quality
of life (QoL). Analyses were conducted on intention-to-treat basis with
nominal two-sided significance level 5%. Drug therapy was allowed.
Effective drugs became available during trial and their impact was
analysed.
Results: Of 586 eligible patients (pts), 215 consented from 31 sites in
three countries (Australia, the United Kingdom and Norway) between
2009 and 2017. Eight (0.04%) who withdrew or had no data collected
were excluded. A total of 107 randomised to Obs and 100 to WBRT.
Mean age was 62 years, 67% were males, 61% were with single MBM
of mean size 2 cm and 67% had extracranial disease at randomisation.
The two armswere well matched.
ORAL ABSTRACTS 101
Within 12 months, 54 (50.5%) Obs pts had DIF compared with 42
(42.0%) WBRT pts (OR = 0.71; 95% CI, 0.41-1.23; P = .222). There
was no difference in LF (P = .100) or OS (log-rank P = .861). A total of
53% (Obs) and 59% (WBRT) pts were alive at 12 months. There was
no significant between-group difference in mean intervention effect
on global QoL (P= .083). Pts who received T-cell checkpoint inhibitors
and/or mitogen-activated protein kinases (MAPK) pathway inhibitors
andWBRT before or within 12 months of randomisation had DIF rate
29%comparedwithObs andno systemic therapyhad44%, butwasnot
significant (P= .228).
Conclusion: This level one evidence shows WBRT does not improve
outcomes in MBMs. This practice-changing trial justifies the recent
move away from WBRT that occurred during the course of the
trial.
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Aim: Reliable and safe central venous access is needed to facilitate
chemotherapy for many cancer patients. However, central venous
catheter-associated thrombosis (CVCT) is a common complication that
can cause significant morbidity and mortality. There is a paucity of pri-
mary research examining the nature of CVCT inAustralian cancer pop-
ulations or exploring its management. Better understanding of factors
predisposing to CVCTmay allow prophylactic interventions to be bet-
ter targeted to high-risk populations and influence decisions regarding
choice of venous access device.
Methods: This multi-centre retrospective cohort study investi-
gated factors associated with CVCT in cancer patients undergoing
chemotherapy, using unadjusted and multivariate analyses. The
management of CVCTwas also described.
Results: A total of 402 cases of central line insertion were included,
corresponding to 317 patients and 166 972 catheter days. Catheter
associated deep venous thrombosis occurred in 20 patients (5.0%)
and isolated superficial venous thrombosis occurred in four patients
(1.0%). Factors associated with CVCT in univariate analysis included
the proceduralist (P = .04), catheter type (P = .009), catheter site
(P = .02), BMI (P = .03) and antithrombotic use (P = .04). On multi-
variate analysis, peripherally inserted central catheters (hazard ratio
[HR] 4.39; 95% CI, 1.80-10.70, P < .001) and body mass index
≥25.0 kg/m2 (HR = 3.32; 95% CI, 1.23-8.94; P = .02) remained sig-
nificantly associated with thrombosis. CVCT was managed with line
removal (19/24 cases) and anticoagulation, including direct oral anti-
coagulants (DOACs) in five patients.
Conclusions: This is the largest Australian study investigating CVCT in
cancer patients to the authors’ knowledge. Peripherally inserted cen-
tral catheters and increased body mass index were associated with
an independently increased risk of CVCT and this was often man-
aged with catheter removal. Further research into the use of DOACs
for CVCT prophylaxis or management would be of benefit and is
particularly topical in light of recent developments in DOAC use in
malignancy.
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Aim: LEN is a multi-kinase VEGFR inhibitor approved for use in com-
bination with everolimus to treat advanced RCC following VEGF-
targeted therapy. PEMBRO is an anti-PD-1 antibody. We report
results of an interim analysis of the RCC cohort of a phase 2 trial of
LEN+PEMBRO, in patients who progressed with prior ICI therapy.
Methods: This is a per-protocol interim analysis of an open-label study
for patients with mccRCC, ≥1 prior therapy, RECIST disease progres-
sion on/following an ICI regimen (confirmed ≥4 weeks later), measur-
able disease, and ECOGPS≤1. Patients received LEN20mg/day orally
QD plus PEMBRO 200 mg intravenously Q3W until toxicity or dis-
ease progression. Tumour assessmentswere performed every 6weeks
(until week 24), then every 9weeks.
Results: At data cutoff (29 March 2019), the first 33 enrolled patients
were followed for ≥12 weeks for response evaluation, and 24 (73%)
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patients were still on study treatment. The ORR was 51.5%, the DCR
was93.9%, andmost patients had tumour shrinkage.Median follow-up
time for PFS was 4.2 months. Patient characteristics are summarized
(Table). ORR (investigator by irRECIST) was 51.5% (95%CI, 33.5-69.2)
andmedian PFSwasNE. Themost common treatment-related adverse
events were fatigue (49%), dysphonia (36%) and diarrhea (33%). Three
(9%) patients discontinued treatment due to adverse events.
Conclusions: For patients with mccRCC who progressed during/
following ICI therapy, LEN+PEMBRO demonstrated promising antitu-
mor activity. No new safety signals were detected. The study will con-
tinue to full cohort expansion.
Patient Characteristics, n (%) LEN+PEMBRO (n= 33)
Prior anticancer regimens
1 prior regimen 14 (42)
>1 prior regimen 19 (58)
Prior VEGF-targeted therapy 26 (78.8)
Prior ICI therapy 33 (100)
PD-1/PD-L1monotherapy 14 (42.4)
With VEGF agents 9 (27.7)
Nivolumab+ Ipilimumab 7 (21.2)
With other agents 2 (6.1)
PD-L1 positive 12 (36.4)*
*30.3%were negative and 33.3%were not available.
